| Date | Title | | | 05/22/13 | Amgen Announces Voting Results of Annual Meeting of Stockholders| THOUSAND OAKS, Calif., May 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 87.80 percent of outstanding shares were represented at the meeting.
The director nominees David Baltimore, Frank J. Biondi, Jr., Robert A. Bradway, Francois de Carbonnel, Vance D. Coffman, Robert A. Eckert, Rebecca M. Henderson, Frank C. Herringer, Tyler Jacks, Gilbert S. Omenn, Judith C. Pel... |
|  | | 05/16/13 | Amgen To Present At The UBS Global Life Sciences Conference| THOUSAND OAKS, Calif., May 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013, at the Sheraton New York Times Square in New York City, beginning at 10:00 a.m. Eastern Daylight Time. Joseph P. Miletich, M.D., Ph.D., senior vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under I... |
| | | 05/15/13 | New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer| Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response
THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers ... |
| | | 05/15/13 | Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting| THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago.
"The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said Sean E. Harper, M.D., executive vice president of Researc... |
| | | 05/09/13 | Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China| Goal Is to Bring Amgen's Vectibix® (Panitumumab) to Chinese Patients
THOUSAND OAKS, Calif. and ZHEJIANG, China, May 9, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to quickly and efficiently deliver Vectibix to patients in China.
The j... |
| | | 05/07/13 | Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer| Study Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting
THOUSAND OAKS, Calif., May 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix® (panitumumab) versus Erbitux® (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint of non-inferiority for overall survival. The estimated ove... |
| | | 05/01/13 | Four Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California| Amgen's Breakaway from Cancer to Celebrate Cancer Survivors at Every Stage of the Eighth Annual Professional Cycling Race
THOUSAND OAKS, Calif., May 1, 2013 /PRNewswire/ -- Amgen today announced that four individuals who are an inspiration and have made a difference for others affected by cancer have been selected as Breakaway from Cancer® Champions. They will be honored as part of Amgen's Breakaway from Cancer initiative at the eighth consecutive edition of the Amgen Tour of California, Am... |
| | | 04/23/13 | Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96| First Quarter 2013 GAAP EPS Were $1.88
2013 Adjusted EPS Expected to be Above the Midpoint of the Range of $7.05-$7.35; 2013 Revenue Guidance Range of $17.8-$18.2 Billion Unchanged
THOUSAND OAKS, Calif., April 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2013. Key results for the quarter include:
Total revenues increased 5 percent to $4,238 million, with 6 percent product sales growth driven by Enbrel® (etanercept), XGEVA® ... |
| | | 04/18/13 | Amgen Announces Webcast of 2013 First Quarter Financial Results| THOUSAND OAKS, Calif., April 18, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 23, 2013, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Daylight Time. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
... |
| | | 03/19/13 | Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma|
THOUSAND OAKS, Calif., March 19, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF).
The study met its primary endpoint of durable response rate (DRR), defined as the rate of complete or partial respons... |
| | | 03/06/13 | Amgen Announces 2013 Second Quarter Dividend|
THOUSAND OAKS, Calif., March 6, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the second quarter of 2013. The dividend will be paid on June 7, 2013, to all stockholders of record as of the close of business on May 16, 2013.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new... |
| | | 03/01/13 | Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference|
THOUSAND OAKS, Calif., March 1, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 33rd Annual Health Care Conference on Wednesday, March 6, 2013, at the Boston Marriott Copley Place, Boston, Mass., beginning at 9:20 a.m. EST. Arvind Sood, vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast ... |
| | | 02/22/13 | Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients|
THOUSAND OAKS, Calif., Feb. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) notes that an analysis by the Congressional Budget Office released this week shows that, contrary to the implications of past media reports, keeping oral-only drugs in Medicare Part D would actually achieve significant savings over time for both taxpayers and the Medicare program.
As noted by the Government Accountability Office (GAO), it is important that the Centers for Medicare and Medicaid Services (CMS) take the... |
| | | 02/08/13 | Amgen Announces Call For Nominations For 2013 Breakaway From Cancer® Champions| Four Inspirational Individuals Making a Positive Impact for Those Affected by Cancer to be Honored at the Amgen Tour of California
THOUSAND OAKS, Calif., Feb. 8, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the call for nominations for Breakaway from Cancer® Champions. For the last five years, Amgen has recognized outstanding individuals making a difference for cancer patients and their loved ones in communities across California through the Breakaway from Cancer initiative. Br... |
| | | 02/07/13 | Amgen Outlines Long-Term Strategy| Amgen Emphasizes Pipeline, International Expansion and Biosimilars as Growth Drivers
Pivotal Data from Eight Late-Stage Programs Anticipated Between 2013 and 2016
NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City.
Robert A. Bradway, chairman and chief executive officer at Amgen, opened the meeting by affirming the company's core strategy will continue ... |
| | | 01/31/13 | Amgen To Webcast 2013 Business Review Meeting On February 7|
THOUSAND OAKS, Calif., Jan. 31, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will hold its Business Review Meeting on Thursday, Feb. 7, 2013, at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City, beginning at 8 a.m. Eastern Standard Time. In the meeting, Robert A. Bradway, chairman and chief executive officer, Sean E. Harper, M.D., executive vice president, Research and Development, Anthony C. Hooper, executive vice president, Global Commercial Operations, an... |
| | | 01/26/13 | Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta® (pegfilgrastim) In Patients With Colorectal Cancer| Study Shows Neulasta Reduced the Incidence of Febrile Neutropenia in Patients With Colorectal Cancer Receiving FOLFOX or FOLFIRI and Bevacizumab
THOUSAND OAKS, Calif., Jan. 26, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta® (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal ca... |
| | | 01/25/13 | Amgen Backs States' Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety| Biologics and Biosimilars are Complex Drugs, and Their Presence in the Marketplace Requires Appropriate Public Policy at the Federal and State Levels
THOUSAND OAKS, Calif., Jan. 25, 2013 /PRNewswire/ -- In conjunction with our oncology biosimilars partner Actavis' announcement earlier today of our four oncology biosimilars products, Amgen (NASDAQ:AMGN) today stated that it supports state biosimilars initiatives that focus on sound science and patient safety. As a biotech company developing ... |
| | | 01/23/13 | Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51| Full Year 2012 GAAP EPS Were $5.52
2013 Total Revenues and Adjusted EPS Expected to be in the Range of $17.8-$18.2 Billion and $6.85-$7.15, Respectively
THOUSAND OAKS, Calif., Jan. 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2012. Key results include:
For the full year, total revenues increased 11 percent to $17,265 million, with 9 percent product sales growth driven by strong performance across the portfolio... |
| | | 01/18/13 | Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results|
THOUSAND OAKS, Calif., Jan. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2012 financial results on Wednesday, Jan. 23, 2013, after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Standard Time. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior m... |
| | | 01/16/13 | Amgen Announces Top-Line Results Of Phase 3 Aranesp® (darbepoetin alfa) RED-HF® Trial|
THOUSAND OAKS, Calif., Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 Aranesp® (darbepoetin alfa) RED-HF® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial. The trial was initiated in 2006, and a total of 2,278 patients with symptomatic systolic heart failure and anemia (hemoglobin levels ranging from 9.0-12.0 g/dL) were randomized to receive either treatment with Aranesp to achieve a target hemoglobin of at least 13.0 g/dL... |
| | | 01/16/13 | Amgen To Build State-Of-The-Art Manufacturing Facility In Singapore|
THOUSAND OAKS, Calif., Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore. Over the next several years, Amgen anticipates investing approximately $200 million to build an innovative new facility, which will initially focus on expanding Amgen's manufacturing capability for monoclonal antibodies. The facility will be capable of manufacturing both clinical and commercial products.
"Amgen... |
| | | 01/03/13 | Amgen To Present At The 31st Annual J.P. Morgan Global Healthcare Conference|
THOUSAND OAKS, Calif., Jan. 3, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 31st Annual J.P. Morgan Global Healthcare Conference at 9:00 a.m. Pacific Standard Time on Tuesday, Jan. 8, 2013, at the Westin St. Francis in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast... |
| | | 12/19/12 | Amgen Finalizes Agreement Resolving Previously Announced Federal Investigations| $762 Million Agreement Covered by 3rd Quarter 2011 Charge
THOUSAND OAKS, Calif., Dec. 19, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it has finalized a settlement agreement with the U.S. government, 49 states and the District of Columbia related to previously disclosed investigations.
Amgen will pay approximately $612 million to resolve its civil liability related to certain promotional practices related to the drugs Aranesp® (darbepoetin alfa), EPOGEN® (epo... |
| | | 12/13/12 | Amgen Announces Appointment of Robert A. Eckert to Board of Directors|
THOUSAND OAKS, Calif., Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Robert A. Eckert, former chief executive officer at Mattel, Inc., to its Board of Directors. Mr. Eckert will serve on the Audit and Corporate Responsibility and Compliance Committees of the Board. Following the appointment of Mr. Eckert and the previously announced retirement of Kevin W. Sharer from the Board on Dec. 31, 2012, the Board on Jan. 1, 2013, will be comprised of 14 directo... |
| | | 12/13/12 | Amgen Names Robert A. Bradway Chairman of the Board Of Directors| Current Director Vance D. Coffman Named Lead Independent Director
THOUSAND OAKS, Calif., Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced appointments to its Board of Directors. Robert A. Bradway, chief executive officer, has been appointed chairman of the Board, and Vance D. Coffman, an Amgen director since 2007, has been appointed lead independent director, both effective on Jan. 1, 2013. As previously announced, Kevin W. Sharer is retiring from the Board,... |
| | | 12/13/12 | Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization|
THOUSAND OAKS, Calif., Dec. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the first quarter of 2013. The dividend will be paid on March 7, 2013, to all stockholders of record as of the close of business on Feb. 13, 2013. This represents an approximate 31 percent increase from that paid in each of the previous four quarters. Amgen's Board of Directors also approved an increase in share repurchase authorization ... |
| | | 12/10/12 | Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics| deCODE Genetics Will Provide Amgen With an Industry-Leading Ability to Identify and Validate Disease Targets in Human Populations
THOUSAND OAKS, Calif. and REYKJAVIK, Iceland, Dec. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and deCODE Genetics today announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics, a global leader in human genetics, headquartered in Reykjavik, Iceland. The all-cash transaction values deCODE Genetics at $4... |
| | | 12/05/12 | Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting|
THOUSAND OAKS, Calif., Dec. 5, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies at the 54th Annual Meeting of the American Society of Hematology (ASH) from Dec. 8-11, 2012, in Atlanta. These include updated results from a Phase 2 trial evaluating blinatumomab in B-precursor acute lymphoblastic leukemia (ALL) and data evaluating long-term use of Nplate® (romiplostim) in pediatric chronic immune thrombocytopenia (ITP).
"The research we... |
| | | 11/20/12 | Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference|
THOUSAND OAKS, Calif., Nov. 20, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 24th Annual Piper Jaffray Healthcare Conference on Wednesday, Nov. 28, 2012, at the New York Palace hotel in New York City, beginning at 11:30 a.m. Eastern Standard Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers,... |
| | | 11/12/12 | Amgen and Pfizer Highlight Data to be Presented at American College of Rheumatology Meeting|
THOUSAND OAKS, Calif. and NEW YORK, Nov. 12, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) today announced that results from several Enbrel® (etanercept) studies will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) 2012 Annual Meeting in Washington, D.C. from Nov. 10-14, 2012.
"Moderate to severe rheumatoid arthritis (RA) places a significant burden on patients, and we are pleased that ENBREL rema... |
| | | 11/06/12 | The Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol| LAPLACE-TIMI 57 Showed AMG 145 Reduced LDL Cholesterol up to 66 Percent in Patients Currently Taking Statins
MENDEL Showed AMG 145 Reduced LDL Cholesterol up to 53 Percent in Patients Not Taking Statins
Data Presented Simultaneously at American Heart Association Scientific Sessions 2012
THOUSAND OAKS, Calif., Nov. 6, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patie... |
| | | 11/05/12 | Circulation Publishes Results From RUTHERFORD Study Which Showed AMG 145 Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia| AMG 145 Combination Therapy With Statins Reduced LDL Cholesterol up to 56 Percent
Genetic Condition Creates Risk of Aggressive and Premature Cardiovascular Disease
Data Presented Simultaneously at American Heart Association Scientific Sessions 2012
THOUSAND OAKS, Calif., Nov. 5, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that treatment with AMG 145 in combination with statin therapy, with or without ezetimibe, resulted in a reduction in low density lipoprotein cholestero... |
| | | 11/05/12 | Journal of the American Medical Association Publishes AMG 145 Phase 2 GAUSS Study Showing Significant Reductions In LDL Cholesterol In Statin-Intolerant Patients| AMG 145 Reduced LDL Cholesterol by up to 51 Percent in a Difficult-to-Treat Population
Data Simultaneously Presented at American Heart Association Scientific Sessions 2012
THOUSAND OAKS, Calif., Nov. 5, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the AMG 145 Phase 2 GAUSS study, in patients with high cholesterol who cannot tolerate statins. Reductions of up to 51 percent were observed in low density lipoprotein cholesterol (LDL-C), or "bad" cholesterol,... |
| | | 11/03/12 | Phase 3 Sensipar®/Mimpara® EVOLVE(TM) Trial Published In The New England Journal Of Medicine| Study Results Simultaneously Presented at American Society of Nephrology's Kidney Week
THOUSAND OAKS, Calif., Nov. 3, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced results of the Phase 3 EVOLVE(TM) (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated treatment with Sensipar®/Mimpara® (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) an... |
| | | 11/02/12 | Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012|
THOUSAND OAKS, Calif., Nov. 2, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol (LDL-C), or "bad" cholesterol from the blood, at the upcoming American Heart Association (AHA) Scientific Sessions 2012.
Selected abstracts of interest that will be presented at the meeting include:
... |
| | | 11/01/12 | Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2012|
THOUSAND OAKS, Calif., Nov. 1, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2012 on Tuesday, Nov. 6, at 7:00 p.m. Pacific Standard Time. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.
Live audio ... |
| | | 10/23/12 | Amgen's Third Quarter 2012 Revenues Increased 10 Percent To $4.3 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $1.67| 2012 Total Revenues and Adjusted EPS Guidance Ranges Increased to $17.2-$17.3 Billion and $6.50-$6.60
Third Quarter 2012 GAAP EPS Were $1.41
THOUSAND OAKS, Calif., Oct. 23, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2012. Key results for the quarter include:
Total revenues increased 10 percent to $4,319 million, with 8 percent product sales growth driven by strong performance across the portfolio.
Adjusted EPS grew 19 pe... |
| | | 10/18/12 | Amgen Announces Webcast of 2012 Third Quarter Financial Results|
THOUSAND OAKS, Calif., Oct. 18, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, Oct. 23, 2012, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:15 p.m. Pacific Daylight Time. Participating in the call from Amgen will be Robert A. Bradway, president & CEO, and other members of Amgen's senior management team.
Live audio of ... |
| | | 10/14/12 | Amgen Presents Several Sub-Analyses At ASBMR From The Ongoing Open-Label Extension Study Of The Pivotal Phase 3 Prolia Fracture Trial| Prolia Open-Label Extension Trial Showed Continued Increases in Bone Mineral Density and Low Fracture Incidence Over Six Years
THOUSAND OAKS, Calif., Oct. 14, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has presented data from several Prolia® (denosumab) studies, including data from the open-label extension study of the pivotal Phase 3 fracture trial, which showed continued increases in bone mineral density (BMD) and low fracture incidence over six years. These data, an... |
| | | 10/12/12 | Amgen Appoints Cynthia Patton Senior Vice President And Chief Compliance Officer|
THOUSAND OAKS, Calif., Oct. 12, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Cynthia M. Patton to senior vice president and chief compliance officer, effective Oct. 22. In this role, Patton will report to Robert A. Bradway, president and chief executive officer, and will be responsible for Amgen's worldwide compliance and business ethics organization. She succeeds Anna Richo, who has resigned from the company effective Oct. 31 to join another global biopharmace... |
| | | 10/11/12 | Amgen Announces 2012 Fourth Quarter Dividend|
THOUSAND OAKS, Calif., Oct. 11, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that on Oct. 10, 2012, its Board of Directors declared a $0.36 per share dividend for the fourth quarter of 2012. The dividend will be paid on Dec. 7, 2012, to all stockholders of record as of the close of business on Nov. 15, 2012.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to re... |
| | | 09/20/12 | FDA Approves New Indication For Prolia® (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture|
THOUSAND OAKS, Calif., Sept. 20, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia® (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture. Prolia, the first FDA-approved RANK Ligand inhibitor, is a subcutaneous injection administered by a health care professional every six months.
"While osteoporosis and osteoporosis-related fractures are more commonly as... |
| | | 09/10/12 | Amgen Names Ray Jordan Senior Vice President, Corporate Affairs|
THOUSAND OAKS, Calif., Sept. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Ray Jordan to the new position of senior vice president, Corporate Affairs, effective October 1.
Jordan will report directly to Robert A. Bradway, president and chief executive officer, and will be responsible for strategic communications across Amgen, including internal and external communications, issues management and philanthropy.
Since 2003 Jordan has served as communications le... |
| | | 09/10/12 | Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference|
THOUSAND OAKS, Calif., Sept. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 13, 2012, in London, beginning at 9:50 a.m. Greenwich Mean Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, develops, manufactur... |
| | | 09/07/12 | Amgen To Present At The Morgan Stanley Global Healthcare Conference|
THOUSAND OAKS, Calif., Sept. 7, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 12, 2012 at the Grand Hyatt in New York City, beginning at 2:10 p.m. Eastern Daylight Time. Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen... |
| | | 08/31/12 | Amgen To Present At The Baird Healthcare Conference|
THOUSAND OAKS, Calif., Aug. 31, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 6, 2012, at The New York Palace Hotel in New York City, beginning at 1:24 p.m. Eastern Daylight Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, develops, manufact... |
| | | 08/08/12 | Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer|
THOUSAND OAKS, Calif., Aug. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial. Based on the review of a pre-planned interim analysis, the DMC concluded that the addition of ganitumab to gemcitabine is unlikely to demonstrate a statistically signific... |
| | | 07/26/12 | Amgen's Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83| 2012 Total Revenues and Adjusted EPS Guidance Ranges Increased to $16.9-$17.2 Billion and $6.20-$6.35
Second Quarter 2012 GAAP EPS Increased 29 Percent to $1.61
THOUSAND OAKS, Calif., July 26, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2012. Key results for the quarter include:
Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfoli... |
| | | 07/23/12 | Amgen Announces Webcast of 2012 Second Quarter Financial Results|
THOUSAND OAKS, Calif., July 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, July 26, 2012, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific time. Participating in the call from Amgen will be Robert A. Bradway, president & chief executive officer, and other members of Amgen's senior management team.
L... |
| | | 07/19/12 | Amgen Announces 2012 Third Quarter Dividend|
THOUSAND OAKS, Calif., July 19, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the third quarter of 2012. The dividend will be paid on Sept. 7, 2012, to all stockholders of record as of the close of business on Aug. 16, 2012.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the ne... |
| | | 07/05/12 | Amgen Completes Acquisition of KAI Pharmaceuticals|
THOUSAND OAKS, Calif., July 5, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the completion of the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco. The acquisition was initially announced April 10, 2012 and includes KAI's lead product candidate KAI-4169, which is a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. KAI has previously reported... |
| | | 06/25/12 | Actress Maura Tierney And Amgen Launch The Chemotherapy: Myths or Facts (TM) Campaign| Tierney Shares Her Personal Cancer Experience to Help Patients Debunk Common Misconceptions Associated with Chemotherapy
THOUSAND OAKS, Calif., June 25, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched Chemotherapy: Myths or Facts(TM), an awareness campaign for cancer patients and their caregivers featuring Emmy®-nominated actress and breast cancer survivor Maura Tierney. In 2009, Tierney was diagnosed with and treated for an aggressive form of breast cancer. Almost three years af... |
| | | 06/12/12 | Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals| Acquisition Will Build on Amgen's Existing Business and Provide a Platform for Growth in Turkey and the Surrounding Region
THOUSAND OAKS, Calif., June 12, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the completion of the acquisition of more than 99 percent of the shares of Mustafa Nevzat Pharmaceuticals, a privately held Turkish company. The all-cash transaction significantly expands Amgen's presence in Turkey and the surrounding region, which includes several fast-growing, pr... |
| | | 06/11/12 | 20th Annual Amgen Award For Science Teaching Excellence Honors Nine Outstanding Teachers| Award Demonstrates Amgen's Commitment to the Next Generation of Innovators and the Teachers who Inspire Them
THOUSAND OAKS, Calif., June 11, 2012 /PRNewswire/ -- Amgen is pleased to announce the nine science teachers in the United States, Canada and Puerto Rico who are this year's recipients of the Amgen Award for Science Teaching Excellence (AASTE). Now in its 20th year, the award recognizes extraordinary teachers at the kindergarten through 12th grade level who have an outstanding abil... |
| | | 06/08/12 | Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE(TM) Trial|
THOUSAND OAKS, Calif., June 8, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 EVOLVE(TM) (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar®/Mimpara® (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis. The primary endpoint of the study was time to th... |
| | | 05/23/12 | Amgen Announces Voting Results of Annual Meeting of Stockholders| Kevin W. Sharer Retires -- Board of Directors Elects Robert A. Bradway as CEO
THOUSAND OAKS, Calif., May 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held at the Four Seasons Hotel, Westlake Village, Calif. Approximately 87 percent of outstanding shares were represented at the meeting. The director nominees David Baltimore, Robert A. Bradway, Frank J. Biondi, Jr., Vance D. Coffman, Francois de Carbonnel, Rebe... |
| | | 05/16/12 | Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia| Greater than 70 Percent of Patients in the Study Achieved Complete Response
Median Survival 9.0 Months, with a Median Follow-up of 10.7 Months
THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the... |
| | | 05/16/12 | Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer| Data Links MET Protein Expression to Rilotumumab Clinical Response
Rilotumumab Moving into Phase 3 Study in Advanced Gastric Cancer
THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102). This analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric o... |
| | | 05/11/12 | Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars| Company Urges FDA to Put Patients First As Regulators Implement Biosimilar Pathway
THOUSAND OAKS, Calif., May 11, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Joseph P. Miletich, M.D., Ph.D., senior vice president of Research and Development at Amgen will testify at the United States (U.S.) Food and Drug Administration (FDA) stakeholder hearing on biosimilars. Miletich will urge members of the FDA panel charged with implementing a pathway for biosimilars to establish approv... |
| | | 05/09/12 | Cancer Support Community Launches National Program to Assist Patients With Cancer, Make Informed Decisions About Care| Personalized Program Supported by the Amgen Foundation Designed to Improve Doctor-Patient Dialogue
WASHINGTON and THOUSAND OAKS, Calif., May 9, 2012 /PRNewswire/ -- The Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options™, a program designed to bridge the communications gap between physicians and patients and inspire patient confidence in making treatment decisions. Following a successful pilot funded by the Centers for Disease Control (C... |
| | | 05/04/12 | Amgen to Present at the Baird Growth Stock Conference| THOUSAND OAKS, Calif., May 4, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN) will present at the Baird Growth Stock conference on Wednesday, May 9, 2012, at the Four Seasons Hotel, Chicago, Ill., beginning at 8:20 a.m. Central Daylight Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, develops, manufacture... |
| | | 05/03/12 | Amgen to Present at the Deutsche Bank 37th Annual Healthcare Conference| THOUSAND OAKS, Calif., May 3, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN) will present at the Deutsche Bank 37th Annual Healthcare Conference on Tuesday, May 8, 2012, at the InterContinental Hotel, Boston, Mass., beginning at 9:20 a.m. Eastern Daylight Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, de... |
| | | 05/03/12 | CURE Magazine Announces Winner of the 2012 Extraordinary Healer Award for Oncology Nursing | Heartfelt essays from patients honor three extraordinary oncology nurses at a reception featuring Golden Globe® and Tony®-award winning actress and breast cancer survivor, Diahann Carroll
NEW ORLEANS (May 3, 2012) - CURE magazine announced the winner of the 2012 Extraordinary Healer Award for Oncology Nursing during a special award ceremony at the Oncology Nursing Society's (ONS) 37th Annual Congress. The award, now in its sixth year and made possible with financial support from Amgen Oncology... |
| | | 05/01/12 | Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California| Amgen's Breakaway from Cancer to Celebrate Cancer Survivors at Every Stage of the Seventh Annual Professional Cycling Race
THOUSAND OAKS, Calif., May 1, 2012 /PRNewswire via COMTEX/ --Amgen today announced that four individuals who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer® Champions. They will be honored at the seventh consecutive edition of the Amgen Tour of California as part of Amgen's Breakaway from Cancer initia... |
| | | 04/26/12 | Amgen Receives Complete Response Letter From FDA for XGEVA® sBLA for Prevention of Bone Metastases| THOUSAND OAKS, Calif., April 26, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.
The Complete Response Letter states that FDA cannot approve the application in its present form. The FDA determined that ... |
| | | 04/25/12 | Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company| Acquisition Will Build on Amgen's Existing Business and Provide a Platform for Growth in Turkey and This Strategically Important Region
THOUSAND OAKS, Calif. and ISTANBUL, April 25, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN), the world's largest biotechnology company, and Mustafa Nevzat Pharmaceuticals (MN) today announced an agreement under which Amgen will acquire 95.6 percent of shares in MN, a privately held Turkish pharmaceutical company, for an amount that values MN at US $700 m... |
| | | 04/24/12 | Amgen's First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61| First Quarter 2012 GAAP EPS Increased 23 Percent to $1.48
THOUSAND OAKS, Calif., April 24, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN) reported total revenue increased 9 percent during the first quarter of 2012 to $4,048 million versus $3,706 million in the first quarter of 2011.
Adjusted earnings per share (EPS) were $1.61 for the first quarter of 2012, an increase of 20 percent compared to $1.34 for the first quarter of 2011. Adjusted net income increased 2 percent to $1,287 million... |
| | | 04/23/12 | A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)| THOUSAND OAKS, Calif., April 23, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away.
Recruited by Bill Bowes, one of Amgen's founders, Rathmann possessed the kind of passion and charisma that helped build the company and attract world-class scientific talent. Regarded as one of the founding fathers of biotechnology, George had the vision to see how biotechnology could t... |
| | | 04/19/12 | Amgen Announces Webcast of 2012 First Quarter Financial Results| THOUSAND OAKS, Calif., April 19, 2012 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 24, 2012, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and CEO, and other members of Amgen's senior management team.
Live audio of the conf... |
| | | 04/10/12 | Amgen to Acquire Privately Held KAI Pharmaceuticals| Acquisition Includes KAI-4169 Program, Which Delivered Compelling Phase 2a Clinical Results for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease who are on Dialysis
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco. KAI's lead produc... |
| | | 04/04/12 | UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis| First Patient Randomized Marks Start of Phase 3 Program to Evaluate Safety and Efficacy of CDP7851/AMG 785 in Women With Postmenopausal Osteoporosis
BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.
"We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 pr... |
| | | 04/02/12 | Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio| Collaboration Comprises Five Monoclonal Antibodies
Brodalumab (AMG 827) Phase 3 Trial Planned in 2012
THOUSAND OAKS, Calif. and LONDON, April 2, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).
The companies believe all the molecules have novel profiles and offer the potent... |
| | | 03/28/12 | Amgen Announces Phase 2 Study Results for Brodalumab in Moderate to Severe Plaque Psoriasis Published in the New England Journal of Medicine| Brodalumab Moving Into Phase 3 for Moderate to Severe Psoriasis
THOUSAND OAKS, Calif., March 28, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab (formerly AMG 827) in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine. The 12-week, dose-ranging study achieved its primary endpoint with the mean percentage improvement in psoriasis area and severi... |
| | | 03/25/12 | Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b Study| Robust AMG 145 Phase 2 Program Expected to Deliver Results in 2012
THOUSAND OAKS, Calif., March 25, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent ver... |
| | | 03/15/12 | Amgen Announces 2012 Second Quarter Dividend|
THOUSAND OAKS, Calif., March 15, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the second quarter of 2012. The dividend will be paid on June 7, 2012, to all stockholders of record as of the close of business on May 16, 2012.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to ... |
| | | 03/07/12 | Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc.|
THOUSAND OAKS, Calif., March 7, 2012 /PRNewswire/ -- Amgen Inc. ("Amgen") (NASDAQ:AMGN) announced today the expiration of the subsequent offering period of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub," to acquire all outstanding shares of common stock of Micromet, Inc. ("Micromet") (NASDAQ:MITI) for $11.00 per share in cash. The subsequent offering period expired at 12:00 midnight, New York City time, at the end of Tuesday, March 6, 2012.
The depositary for... |
| | | 03/06/12 | Schwartz Center Receives $500,000 Grant from the Amgen Foundation| Funds Support Expanded Efforts to Make Compassionate, Patient-Centered Care a National Healthcare Priority
BOSTON and THOUSAND OAKS, Calif., March 6, 2012 /PRNewswire/ -- The Schwartz Center for Compassionate Healthcare, a Boston-based nonprofit dedicated to strengthening the relationship between patients and their healthcare providers, today announced it has received a $500,000 grant from the Amgen Foundation. This grant will go toward the planned expansion of Schwartz Center Rounds® and t... |
| | | 03/02/12 | Amgen Announces Initial Results of Tender Offer for Outstanding Shares of Micromet, Inc. and Commencement of Subsequent Offering Period|
THOUSAND OAKS, Calif., March 2, 2012 /PRNewswire/ -- Amgen ("Amgen") (NASDAQ: AMGN) announced today that all conditions to the closing of the tender offer (the "Offer") by a wholly owned subsidiary, "Merger Sub", to acquire all outstanding shares of common stock of Micromet, Inc. ("Micromet") (NASDAQ: MITI) for $11.00 per share in cash have been satisfied.
The depositary for the Offer has advised Amgen that, as of the expiration of the Offer at 12:00 midnight, New York Cit... |
| | | 02/29/12 | Amgen to Present at the Cowen and Company 32nd Annual Healthcare Conference|
THOUSAND OAKS, Calif., Feb. 29, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 32nd Annual Healthcare Conference on Monday, March 5, 2012 at the Boston Marriott Copley Place, Boston, Mass., beginning at approximately 2:50 p.m. Eastern Standard Time. Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under In... |
| | | 02/28/12 | Amgen and European Schoolnet Launch New Professional Development Initiative for Life Science Teachers| Program Will Help Increase Student Interest and Achievements in Science in France, Germany, Ireland and Poland
ZUG, Switzerland and BRUSSELS, Belgium (Feb. 28, 2012) – Today, the Amgen Foundation and European Schoolnet launched the “Amgen Science Teacher Training Initiative” in France, Germany, Ireland and Poland.
The Amgen Science Teacher Training Initiative provides professional development for secondary school science teachers to help them incorporate hands-on enquiry-based ... |
| | | 02/23/12 | Amgen to Present at the Citi 2012 Global Healthcare Conference|
THOUSAND OAKS, Calif., Feb. 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Citi 2012 Global Healthcare Conference on Tuesday, Feb. 28, 2012, at the Waldorf Astoria in New York City, beginning at 4:30 p.m. Eastern Standard Time. Arvind Sood, vice president, Investor Relations will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, develops, manufactures and ... |
| | | 02/21/12 | CURE Magazine Teams up with Amgen Oncology and Breakaway from Cancer® to Launch 2012 Extraordinary Healer Award for Oncology Nursing| DALLAS & THOUSAND OAKS, Calif. --(Business Wire)-- For the sixth consecutive year, CURE magazine is calling on cancer patients, survivors, and caregivers from across the country to submit essays for the 2012 Extraordinary Healer Award for Oncology Nursing. The contest, made possible with financial support from Amgen Oncology and Breakaway from Cancer®, invites patients and their families to submit a 400 to1,000 word essay describing the compassion, expertise, and helpfulness a special oncolo... |
| | | 02/15/12 | Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet|
THOUSAND OAKS, Calif., Feb. 15, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Micromet, Inc. (NASDAQ: MITI) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR), in connection with Amgen's tender offer for Micromet, was terminated early on Feb. 14, 2012 by the U.S. Federal Trade Commission. The waiting period was scheduled to expire on Feb. 17, 2012.
As previously announced on Jan. 26, 2012, Amgen and Micromet enter... |
| | | 02/14/12 | Amgen Names Michael Severino, M.D., Senior Vice President, Global Development and Corporate Chief Medical Officer|
THOUSAND OAKS, Calif., Feb. 14, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Michael Severino, M.D., has been named senior vice president, Global Development and Corporate Chief Medical Officer, effective immediately. Severino, 46, formerly vice president, Global Development at Amgen, will replace Sean Harper, M.D. Harper, 49, was appointed Amgen's executive vice president, Research and Development.
"Since joining Amgen in 2004, Mike has demonstrated leadershi... |
| | | 02/13/12 | Amgen to Present at the Leerink Swann Global Healthcare Conference|
THOUSAND OAKS, Calif., Feb. 13, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Swann Global Healthcare Conference at 9:30 a.m. Eastern Standard Time on Thursday, Feb. 16, 2012, at the Waldorf Astoria Hotel in New York City. Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
Abou... |
| | | 02/08/12 | Amgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee Meeting|
THOUSAND OAKS, Calif., Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today's meeting of the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC).
Amgen will discuss results of the pivotal Phase 3 '147 tr... |
| | | 01/26/12 | Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33| Full Year 2011 GAAP EPS Decreased 16 Percent to $4.04 Due to a One-Time Charge
2012 Total Revenue and Adjusted EPS Expected to be in the Range of $16.1-$16.5 Billion and $5.90-$6.15, Respectively
THOUSAND OAKS, Calif., Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010. For the full year 2011, total revenue increased 4 percent to $15,582 mill... |
| | | 01/26/12 | Amgen to Acquire Micromet| Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies
Micromet's Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types
All-Cash Transaction Values Micromet at $1.16 Billion
THOUSAND OAKS, Calif., and ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under wh... |
| | | 01/24/12 | Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results|
THOUSAND OAKS, Calif., Jan. 24, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2011 financial results on Thursday, Jan. 26, 2012 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Standard Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior managem... |
| | | 01/04/12 | Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference|
THOUSAND OAKS, Calif., Jan. 4, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 30th Annual J.P. Morgan Global Healthcare Conference at 10:00 a.m. Pacific Time on Monday, Jan. 9, 2012, at the Westin St. Francis in San Francisco, Calif. Robert A. Bradway, president and chief operating officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About ... |
| | | 12/29/11 | FDA to Review Potential New Use of XGEVA® (Denosumab) at Oncologic Drugs Advisory Committee Meeting|
THOUSAND OAKS, Calif., Dec. 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.
The ODAC will review results from clinical stud... |
| | | 12/19/11 | Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars|
THOUSAND OAKS, Calif. and PARSIPPANY, N.J., Dec. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Watson Pharmaceuticals, Inc. (NYSE:WPI) announced today that they will collaborate to develop and commercialize, on a worldwide basis, several oncology antibody biosimilar medicines. This collaboration reflects the shared belief that the development and commercialization of biosimilar products will not follow a pure brand or generic model, and will require significant expertise, i... |
| | | 12/15/11 | Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012| Roger Perlmutter to Retire as EVP of Research and Development with Sean Harper to Assume the Role on February 13, 2012
THOUSAND OAKS, Calif., Dec. 15, 2011 /PRNewswire/ -- Kevin W. Sharer, chairman and chief executive officer of Amgen (NASDAQ:AMGN) since 2000, has announced his plan to retire from the Company at the end of 2012, following 20 years of service to Amgen. To facilitate an orderly transition process, Sharer will step down as CEO effective May 23, 2012, and r... |
| | | 12/15/11 | Amgen Announces 2012 First Quarter Dividend|
THOUSAND OAKS, Calif., Dec. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the first quarter of 2012. This represents an approximate 29 percent increase from that paid in the previous two quarters. The dividend will be paid on March 7, 2012 to all stockholders of record as of the close of business on Feb. 15, 2012.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative... |
| | | 12/14/11 | Amgen Announces Final Results of Its Tender Offer|
THOUSAND OAKS, Calif., Dec. 14, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011.
Amgen has accepted for purchase 83,333,333 shares of its common stock at a price of $60.00 per share, for an aggregate cost of approximately $5 billion, excluding fees and expenses relating to the tender offer. These shares represe... |
| | | 12/13/11 | Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)| Additional Key Nplate Data Also Presented at American Society of Hematology Annual Meeting
THOUSAND OAKS, Calif., Dec. 13, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that data from several key Nplate® (romiplostim) studies were presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 10-13, 2011, in San Diego. Of note, final results from the international, Phase 3, open-label, single-arm '209 study evaluating the safe... |
| | | 12/09/11 | Amgen to Present at the 22nd Annual Oppenheimer Healthcare Conference|
THOUSAND OAKS, Calif., Dec. 9, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the Oppenheimer Healthcare Conference on Wednesday, Dec. 14, 2011, at the Waldorf Astoria Hotel in New York City, beginning at 1:35 p.m. Eastern Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, develops, manufactures ... |
| | | 12/08/11 | Amgen Announces Preliminary Results of Its Tender Offer|
THOUSAND OAKS, Calif., Dec. 8, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, on Wednesday, Dec. 7, 2011.
Based on the preliminary count by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 98,062,630 shares of Amgen's common stock were properly tendered and not properly withdrawn at or ... |
| | | 12/06/11 | Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy| Prescribing Physicians, Patients and Institutions no Longer Required to Enroll in Nplate® NEXUS Program
THOUSAND OAKS, Calif., Dec. 6, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has modified the requirements of the Nplate® (romiplostim) Risk Evaluation and Mitigation Strategy (REMS) Program. Prescribing physicians, patients and institutions are no longer required to enroll in the safety monitoring program, called the Nplate® NEXUS (N... |
| | | 11/22/11 | Enbrel® (etanercept) Patent Issued| THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN) today issued the following statement:
Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept). This patent is owned by Hoffman-La Roche Inc. ("Roche") and exclusively licensed to Amgen. Immunex Corporation (acquired by Amgen in 2002) originally licensed this patent application from Roche in 1999, and in 2004, Amgen paid Roche a one-time payment and obtained an exclusi... |
| | | 11/15/11 | The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer| XGEVA Prevented or Delayed the Onset of Bone Metastases in Patients With Prostate Cancer
THOUSAND OAKS, Calif., Nov. 15, 2011 /PRNewswire via COMTEX/ --
Amgen (NASDAQ: AMGN) announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA® (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer (CRPC). Published in The Lancet, the study found XGEVA significantly prolonged bon... |
| | | 11/15/11 | Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union| THOUSAND OAKS, Calif., Nov. 15, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix® (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excludi... |
| | | 11/14/11 | Amgen Statement on European Investor Visit| THOUSAND OAKS, Calif., Nov. 14, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ:AMGN) today issued the following statement:
Amgen will be meeting with investors in Europe this week with a view to raise $1-1.5 billion in Euro and Sterling denominated debt to support its share repurchase program, as well as for general corporate purposes. The timing of this potential offering will be subject to market conditions.
The debt will not be or have not been registered under the Securities Act of 19... |
| | | 11/07/11 | Amgen Announces Plan to Launch Tender Offer and Launch of Senior Notes Offering| THOUSAND OAKS, Calif., Nov. 7, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced its plan to launch a modified Dutch auction tender offer to purchase up to $5 billion of its common stock, par value $0.0001 per share ("Common Stock"). Amgen also announced a public offering of its senior notes, the proceeds of which will be used to fund the tender offer and for general corporate purposes.
"This tender offer reflects Amgen's confidence in the future outlook of our business a... |
| | | 11/05/11 | Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease| Amgen and Pfizer Announce Results From the Largest Completed Clinical Trial of a Biologic Therapy in Adults with Moderately Active RA
THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low diseas... |
| | | 11/05/11 | Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial| THOUSAND OAKS, Calif., Nov. 5, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced positive data from the first three years of the open-label extension study of the pivotal Phase 3 fracture trial showing that six years of Prolia® (denosumab) treatment in postmenopausal women with osteoporosis was associated with continued increase in bone mineral density (BMD) and consistent reduction in markers of bone turnover. These results will be presented on Nov. 8, 2011, at the 2011 Americ... |
| | | 10/24/11 | Amgen's Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40|
2011 Total Revenue and Adjusted EPS Guidance Ranges Increased to $15.4-$15.6 Billion and $5.15-$5.30
Amgen's Board of Directors Increased Stock Repurchase Authorization to $10 Billion
Third Quarter 2011 GAAP EPS Were $0.50 as a Result of a Legal Settlement Reserve
THOUSAND OAKS, Calif., Oct. 24, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the third quarter of 2011 to $3,944 million versus $3,816 million in the third quarter of 2010. ... |
| | | 10/19/11 | Amgen Announces Webcast of 2011 Third Quarter Financial Results| THOUSAND OAKS, Calif., Oct. 19, 2011 /PRNewswire via COMTEX/ -- Amgen (NASDAQ: AMGN) today announced that it will report its third quarter financial results on Monday, Oct. 24, 2011 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.
Live ... |
| | | 10/19/11 | Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations| THOUSAND OAKS, Calif., Oct. 19, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced the appointment of Anthony (Tony) Hooper, executive vice president, Global Commercial Operations, effective October 26th. In this role, Hooper will report to Robert A. Bradway, president and chief operating officer, and will be responsible for the Company's Global Commercial Operations.
Hooper, 56, joins Amgen after sixteen years at Bristol-Myers Squibb Company (BMS) where he was most recentl... |
| | | 10/13/11 | Amgen Appoints Robert A. Bradway to the Company's Board of Directors| THOUSAND OAKS, Calif., Oct. 13, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) announced today that its Board of Directors has appointed Robert A. Bradway to the Company's Board. Bradway, 48, is Amgen's president and chief operating officer. The addition of Bradway brings the number of Amgen board members to 13.
Bradway joined Amgen in 2006 as vice president, Operations Strategy and served as executive vice president and chief financial officer from April 2007 to May 2010. Prior to join... |
| | | 10/13/11 | Amgen Announces 2011 Fourth Quarter Dividend| THOUSAND OAKS, Calif., Oct. 13, 2011 /PRNewswire via COMTEX/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.28 per share dividend for the fourth quarter of 2011. The dividend will be paid on Dec. 8, 2011 to all stockholders of record as of the close of business on Nov. 17, 2011.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize ... |
| | | 09/23/11 | Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress| THOUSAND OAKS, Calif., Sept. 23, 2011 /PRNewswire via COMTEX/ -- Amgen (NASDAQ: AMGN) announced today that data from XGEVA® (denosumab) and Vectibix® (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.
"The data being presented at the 2011 European Multidisciplinary Cancer Congress reflect Amgen's ongoing commitment to advancing the understanding of cancer and developing novel therapies to treat it," said ... |
| | | 09/19/11 | FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy| Prolia is the First-and-Only Medicine Approved for Cancer Treatment-Induced Bone Loss
THOUSAND OAKS, Calif., Sept. 19, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fractu... |
| | | 09/17/11 | Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment| THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in bone mineral density (BMD), an important determinant of bone strength, and a persistent reduction in markers of bone turnover. The data were presented at the annual meeting of the American Society for Bone and Mi... |
| | | 09/15/11 | Amgen to Present at the UBS Global Life Sciences Conference| THOUSAND OAKS, Calif., Sept. 15, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, Sept. 20, 2011, at the Grand Hyatt in New York City, beginning at 8:30 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.... |
| | | 09/15/11 | Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits| THOUSAND OAKS, Calif., Sept. 15, 2011 /PRNewswire via COMTEX/ --Each year, thousands of Amgen staff generously devote their personal time, energy and talents to a variety of charitable organizations. To recognize these exceptional efforts, the Amgen Foundation today announced the 11 recipients of the 2011 Amgen Excellence in Volunteering Awards.
The Awards recognize staff in the United States (U.S.) and Puerto Rico who are making a difference in the communities where Amgen has a presence. T... |
| | | 09/12/11 | Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference| THOUSAND OAKS, Calif., Sept. 12, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 15, 2011 in London, beginning at 11:20 a.m. Greenwich Mean Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
(Logo: http://photos.prnewswire.com/prnh/20... |
| | | 09/08/11 | Amgen to Present at the Morgan Stanley Global Healthcare Conference| THOUSAND OAKS, Calif., Sept. 8, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) will present at the Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 13, 2011 at the Grand Hyatt in New York City, beginning at 9:10 a.m. Eastern Time. Jim Daly, senior vice president of North America Commercial Operations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discove... |
| | | 09/06/11 | Amgen to Present at the Baird Healthcare Conference| THOUSAND OAKS, Calif., Sept. 6, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 8, 2011, at The New York Palace Hotel in New York City, beginning at 10:00 a.m. Eastern Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, develops, manufact... |
| | | 09/02/11 | Amgen to Present at the Stifel Nicolaus Healthcare Conference| THOUSAND OAKS, Calif., Sept. 2, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) will present at the Stifel Nicolaus Healthcare Conference on Wednesday, Sept. 7, 2011 at the Four Seasons Hotel, Boston, Mass., beginning at 8:35 a.m. Eastern Time. Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, develops, manufac... |
| | | 08/25/11 | Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign| Campaign Educates and Encourages Women With Postmenopausal Osteoporosis at Increased Risk for Fractures to Take Action to Help Strengthen Their Bones
THOUSAND OAKS, Calif., Aug. 25, 2011 /PRNewswire via COMTEX/ --
Emmy® and Tony® award-winning actress Blythe Danner and Amgen (NASDAQ:AMGN) today launch Act 2 Reduce Fractures(TM), an educational campaign for women with postmenopausal osteoporosis at increased risk for fractures. Earlier this year, Danner was diagnosed with postmenopausal osteop... |
| | | 08/22/11 | Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application| THOUSAND OAKS, Calif., Aug. 22, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) will target a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2012 for the supplemental Biologics License Application (sBLA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. Bone is one of the most common places for cancer to spread.... |
| | | 08/18/11 | Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting| THOUSAND OAKS, Calif., Aug. 18, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.
"The breadth of data being presented at this... |
| | | 07/29/11 | Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion|
Second Quarter 2011 Product Sales Increased 8 Percent to $3.9 Billion
Second Quarter 2011 Adjusted and GAAP Earnings Per Share (EPS) Were $1.37 and $1.25, Respectively
Amgen Announced its First Quarterly Cash Dividend of $0.28 Per Share
2011 Total Revenue and Adjusted EPS Guidance Updated to Upper End of $15.1 Billion to $15.5 Billion and $5.00 to $5.20, Respectively
THOUSAND OAKS, Calif., July 29, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) reported total revenue increased 4 perce... |
| | | 07/25/11 | Amgen Announces Webcast of 2011 Second Quarter Financial Results| THOUSAND OAKS, Calif., July 25, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that it will report its second quarter financial results on Friday, July 29, 2011 before the opening of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 8 a.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.
Liv... |
| | | 07/15/11 | Amgen Resolves G-CSF Patent Litigation With Teva|
Teva Admits Neutroval(TM) Infringes Amgen's Valid and Enforceable Patents
Court Enters Permanent Injunction
THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) announced today that the United States (U.S.) District Court in Pennsylvania has entered final judgment and a permanent injunction against Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA prohibiting them from infringing Amgen's patents relating to human G-CSF (granulocyte colony-stimula... |
| | | 07/15/11 | XGEVA® (Denosumab) Granted Marketing Authorization in the European Union| Additional Year of Market Exclusivity Granted Based on Significant Clinical Benefit XGEVA Provides Over Existing Therapies
THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid... |
| | | 07/05/11 | Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss| Thousand Oaks, Calif. and BRUSSELS, July 5, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today that they are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space shuttle Atlantis, on the final NASA shuttle mission, Space Shuttle Flight STS-135, scheduled to launch July 8, 2011.
The loss of bone... |
| | | 06/27/11 | Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone| THOUSAND OAKS, Calif., June 27, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or delay the spread of cancer to the bone.
The sBLA submissio... |
| | | 06/24/11 | Notice to Investors Regarding 2011 and 2015 Guidance| THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire via COMTEX/ --Today, Amgen (NASDAQ: AMGN) issued the following notice to investors:
Amgen reaffirms its guidance for 2011 and 2015.
Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other ... |
| | | 06/24/11 | Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease|
Modified Labeling Provides Different Treatment Guidance for Patients on Dialysis and Not on Dialysis
Changes to Prescribing Information Include Modification to the Boxed Warning
THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved modified language in the prescribing information for the use of erythropoiesis-stimulating agents (ESAs), including Aranesp® (darbepoetin alfa) and EPOGEN® ... |
| | | 06/24/11 | Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy| THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Vectibix® (panitumumab) be approved for use in the European Union (EU) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding ir... |
| | | 06/21/11 | Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence| THOUSAND OAKS, Calif., June 21, 2011 /PRNewswire via COMTEX/ --
Amgen (NASDAQ: AMGN) today announced the 34 science teachers in the United States, Canada and Puerto Rico who are this year's recipients of the 19th annual Amgen Award for Science Teaching Excellence. The award recognizes extraordinary science teachers at the kindergarten through 12th grade level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student learning in co... |
| | | 05/25/11 | Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel(R) (etanercept) for Patients with Chronic Inflammatory Conditions|
New Interim Results from the PRESERVE Study Evaluate ENBREL Therapy in Patients with Moderately Active Rheumatoid Arthritis
Analysis of Ankylosing Spondylitis Trials Suggests Nocturnal Back Pain is Predictive of Fatigue, and ENBREL was Shown to Reduce These Symptoms
PRISTINE Trial Data Explore Effects of ENBREL on Cardiometabolic Biomarkers in Subjects with Moderate-to-Severe Plaque Psoriasis
THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire via COMTEX/ -- Amgen (NASDAQ: AMGN) a... |
| | | 05/20/11 | Amgen Announces Voting Results Of Annual Meeting of Stockholders| SEATTLE, May 20, 2011 /PRNewswire via COMTEX/ -- Amgen (NASDAQ: AMGN), today announced results of voting at the Company's Annual Meeting of Stockholders, held at The Fairmont Olympic Hotel in Seattle, Wash. Approximately 86.32 percent of outstanding shares were represented at the meeting.
The director nominees David Baltimore, Frank J. Biondi, Jr., Francois de Carbonnel, Vance D. Coffman, Rebecca M. Henderson, Frank C. Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, USN (Retired... |
| | | 05/20/11 | Amgen Receives CHMP Positive Opinion for XGEVA(TM) (Denosumab) in the European Union| Positive Opinion Based on Largest Clinical Program Ever Conducted in Patients with Bone Metastases
THOUSAND OAKS, Calif., May 20, 2011 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of XGEVA(TM) (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord co... |
| | | 05/18/11 | Amgen Oncology Data to be Presented at ASCO Annual Meeting| THOUSAND OAKS, Calif., May 18, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago. These studies include data from the XGEVA® (denosumab), Vectibix® (panitumumab), ganitumab (AMG 479) and AMG 386 programs.
"Amgen researchers around the globe are passionate about developing new and innovative therapies fo... |
| | | 05/17/11 | Phase 3 Data Demonstrate XGEVA(TM) (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer|
Study Meets Primary Endpoint by Significantly Improving Bone Metastasis-Free Survival for More Than Four Months
Up to 90 Percent of Men with Advanced Prostate Cancer Will Develop Bone Metastases
THOUSAND OAKS, Calif., May 17, 2011 /PRNewswire via COMTEX/ --
Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA(TM) (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resist... |
| | | 05/13/11 | Amgen to Webcast Investor Meeting at Upcoming American Urological Association Conference| THOUSAND OAKS, Calif., May 13, 2011 /PRNewswire via COMTEX/ -- Amgen (NASDAQ: AMGN) will webcast its investor meeting at the upcoming American Urological Association (AUA) Conference on Tuesday, May 17 at 12:00 p.m. Eastern Time. Members of Amgen's scientific and management team and a clinical investigator will participate at the meeting to discuss data being presented at AUA.
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members ... |
| | | 05/11/11 | Patrick Dempsey Teams up With Breakaway from Cancer(R) to Help Connect Cancer Patients to Free Resources| THOUSAND OAKS, Calif., May 11, 2011 /PRNewswire via COMTEX/ --
Patrick Dempsey is speaking out to help connect cancer patients to the free resources available to them via Amgen's Breakaway from Cancer(R) initiative.
"Cancer entered my life in 1997 when my mother was first diagnosed with ovarian cancer," explained Dempsey. "I remember the feelings well - it was overwhelming. My family was trying to come to terms with the fear and shock of the diagnosis, while also working to sort through vas... |
| | | 05/10/11 | Five Californians Selected as Breakaway from Cancer(R) Champions to be Honored During Amgen Tour of California| Amgen's Breakaway from Cancer to Honor and Celebrate Cancer Survivors at Every Stage of the Sixth Annual Race
THOUSAND OAKS, Calif., May 10, 2011 /PRNewswire via COMTEX/ --
Amgen today announced that five inspirational cancer survivors who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer Champions as part of Amgen's Breakaway from Cancer initiative.
The five Breakaway from Cancer Champions were selected following a publi... |
| | | 04/28/11 | Amgen to Present at the Deutsche Bank 36th Annual Healthcare Conference| THOUSAND OAKS, Calif., April 28, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the Deutsche Bank 36th Annual Healthcare Conference on Tuesday, May 3, 2011 at the InterContinental, Boston, Mass., beginning at 9:20 a.m. Eastern Time. Senior Vice President of North America Commercial Operations Jim Daly will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, dev... |
| | | 04/21/11 | Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans|
Company Provides Guidance For 2015
Announces Quarterly Dividend Policy
NEW YORK, April 21, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today outlined the Company's strategy, capital allocation plans and provided financial guidance for 2015 during a meeting with investors in New York.
Kevin Sharer, chairman & CEO opened the meeting by outlining key elements of the Company's strategy:
Bring medicines to market that advance treatment of serious illness;
Make ... |
| | | 04/21/11 | Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)| Top-line Results Met Primary Endpoint
THOUSAND OAKS, Calif. and BRUSSELS, April 21, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).
This Phase 2 study met its primary endpoint, demonstrating significant inc... |
| | | 04/20/11 | Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion|
First Quarter 2011 Adjusted Earnings Per Share Increased 3 Percent To $1.34
First Quarter 2011 GAAP Earnings Per Share Increased 2 Percent To $1.20
THOUSAND OAKS, Calif., April 20, 2011 /PRNewswire via COMTEX/ --
Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS) of $1.34 for the first quarter of 2011, an increase of 3 percent compared to $1.30 for the first quarter of 2010. Adjusted net income decreased 2 percent to $1,258 million in the first quarter of 2011 compared to $1,... |
| | | 04/14/11 | Amgen to Webcast 2011 Business Review Meeting on April 21| THOUSAND OAKS, Calif., April 14, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that it will hold its Business Review Meeting on Thursday, April 21, 2011 at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City, beginning at 8 a.m. Eastern Time. In the meeting, Kevin Sharer, chairman and CEO, Robert A. Bradway, president and COO, Roger M. Perlmutter, M.D., Ph.D., executive vice president, Research and Development, and Jonathan M. Peacock, executive vice president an... |
| | | 04/13/11 | Amgen Announces Webcast of 2011 First Quarter Financial Results| THOUSAND OAKS, Calif., April 13, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN) today announced that it plans to report its first quarter financial results on Wednesday, April 20, 2011 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.
... |
| | | 04/08/11 | Amgen Establishes Commercial Operations in Brazil| Amgen Acquires Privately Held Brazilian Pharmaceutical Company Bergamo and Agrees to Reacquire Rights to Certain Amgen Products in Brazil from Hypermarcas
THOUSAND OAKS, Calif., April 8, 2011 /PRNewswire via COMTEX/ --Amgen (NASDAQ: AMGN), the world's largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately-held Brazilian pharmaceutical company. Amgen has also agreed to reacquire rights in Brazil to its product... |
| | | 03/30/11 | Amgen to Appeal CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe| THOUSAND OAKS, Calif., March 30, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP)for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).
Amgen believes that Vectibix in combination with chemotherapy provides an i... |
| | | 03/30/11 | Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients| THOUSAND OAKS, Calif., CAMBRIDGE, Mass. and OSAKA, Japan, March 30, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN), Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer (NSCLC). The trial did not meet its primary objective of dem... |
| | | 03/23/11 | Prolia(R) (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial| THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia(R) (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year-over-year increases in lumbar spine and total hip bone mineral density (BMD), a key measurement of bone strength. The overall adverse event profile was similar for the fourth and fifth ... |
| | | 03/23/11 | Treatment With Prolia(R) (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate| New 2-Year Open-Label Study Shows More Than 90 Percent of Patients Preferred Prolia Injection Every Six Months Over Weekly Oral Alendronate
THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia(R) (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosi... |
| | | 03/18/11 | Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer| THOUSAND OAKS, Calif., March 18, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today issued the following statement:
Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen's application to extend the marketing authorization in Europe for Vectibix(R) (panitumumab) to include combination with chemotherapy for the treatment of patients with wild-type KRAS metastatic colorecta... |
| | | 03/14/11 | Amgen Donates $1 Million to Help Japanese Disaster Victims| THOUSAND OAKS, Calif., March 14, 2011 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) today announced that the company will donate $1 million to Japanese disaster relief efforts. Amgen and the Amgen Foundation will distribute the funds to both Direct Relief International and International Medical Corps to bring basic needs and vital health services to those affected in Japan.
Amgen has a long history in Japan with our partnership with Kirin Holdings and its pharmaceutical affiliate Kyowa Ha... |
| | | 03/04/11 | Amgen Completes Acquisition of BioVex| Acquisition Includes a Therapeutic in Phase 3 Clinical Trials for the Treatment of Advanced Melanoma and Head and Neck Cancer
THOUSAND OAKS, Calif., March 4, 2011 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN), today announced the completion of the acquisition of BioVex Group, Inc., a privately held biotechnology company based in Woburn, Mass., with additional operations in Abingdon, UK. The acquisition includes OncoVEX(GM-CSF), a novel investigational oncolytic vaccine in Phase 3 clinical ... |
| | | 03/03/11 | Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference| THOUSAND OAKS, Calif., March 3, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the Cowen and Company 31st Annual Healthcare Conference on Tuesday, March 8, 2011 at the Boston Marriott Copley Place, Boston, Mass., beginning at 8:45 a.m. Eastern Time. James Daly, Amgen's Senior Vice President of North American Commercial Operations, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
Abo... |
| | | 03/03/11 | Breakaway From Cancer(R) Launches Newly-Enhanced Website Offering Comprehensive, Tailored Support for Cancer Patients| Innovative Cancer Resource Navigator Tool Facilitates Easy Search of Leading Online Cancer Resources; Patients Able to Share and Read Inspirational Stories from Across the Nation THOUSAND OAKS, Calif., March 3, 2011 /PRNewswire via COMTEX/ --
As part of its ongoing mission to serve cancer patients, Amgen's Breakaway from Cancer(R) initiative announced the launch of its enhanced website that provides cancer patients, survivors, and caregivers a 'one-stop shop' of essential resources spanning can... |
| | | 03/02/11 | World-Class Professional Golfer Phil Mickelson Launches 'On Course with Phil' for People with Certain Inflammatory Joint and Skin Conditions| TWO LEADING PATIENT ADVOCATE GROUPS COLLABORATE TO URGE EARLY DIAGNOSIS AND TREATMENT
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., March 2, 2011 /PRNewswire via COMTEX/ --World-class professional golfer and psoriatic arthritis patient Phil Mickelson today launches "On Course with Phil," a disease education program for people with certain chronic inflammatory joint and skin conditions, in partnership with Amgen (Nasdaq: AMGN) and Pfizer, Inc. (NYSE: PFE). This program seeks to inspire patients... |
| | | 03/01/11 | NBPTS and Amgen Foundation Join to Bolster Science Education| $1.5 Million Grant Will Provide Support For Teachers Seeking National Board Certification
THOUSAND OAKS, Calif. and ARLINGTON, Va., March 1, 2011 /PRNewswire via COMTEX/ --The National Board for Professional Teaching Standards (NBPTS) and the Amgen Foundation today announced a grant to improve highly-effective science teaching and learning in schools across the country. The Amgen Foundation is committing $1.5 million over three years to support science teachers who choose to obtain National B... |
| | | 02/24/11 | Results Published in The Lancet Demonstrate Superiority of XGEVA(TM) (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer| Bone Is One of the Most Common Sites for Metastases Affecting up to 75 Percent of Patients with Advanced Prostate Cancer
THOUSAND OAKS, Calif., Feb. 24, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA(TM) (denosumab) to Zometa(R) (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases. The study, published i... |
| | | 02/24/11 | Amgen to Present at the Citi 2011 Global Healthcare Conference| THOUSAND OAKS, Calif., Feb. 24, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will participate in the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011, at the Hilton Club New York in New York City, beginning at 11:30 a.m. Eastern Time. Rolf Hoffmann, senior vice president, International Commercial Operations and Arvind Sood, vice president, Investor Relations will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's w... |
| | | 02/22/11 | The Journal of Clinical Oncology Publishes Phase 3 XGEVA(TM) (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma| THOUSAND OAKS, Calif., Feb. 22, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors (not including breast and prostate cancer) or multiple myeloma, which compared XGEVA(TM) (denosumab) to Zometa(R) (zoledronic acid) in preventing skeletal-related events (SREs). The study, which appeared today in the Journal of Clinical Oncology, found that XGEVA was non-i... |
| | | 02/04/11 | Enbrel(R) (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis| THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel(R) (etanercept) significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology (AAD) meeting in New Orleans, La.
"At least half of people with plaque pso... |
| | | 01/24/11 | Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass| Acquisition Includes a Therapeutic in Phase 3 Clinical Trials for the Treatment of Advanced Melanoma and Head and Neck Cancer
THOUSAND OAKS, Calif. and WOBURN, Mass., Jan. 24, 2011 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) and BioVex Group, Inc. today announced that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, Inc., a privately held, venture-funded, biotechnology company headquartered in Woburn, Mass. BioVex is ... |
| | | 01/24/11 | Amgen's Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21|
Fourth Quarter 2010 Revenue Increased 1 Percent to $3.8 Billion; Full Year 2010 Revenue Increased 3 Percent to $15.1 Billion
Fourth Quarter 2010 GAAP Earnings Per Share Increased 17 Percent to $1.08; Full Year 2010 GAAP Earnings Per Share Increased 6 Percent to $4.79
2011 Total Revenue Expected to be in the Range of $15.1 Billion to $15.5 Billion
2011 Adjusted Earnings Per Share Expected to be in the Range of $5.00 to $5.20
THOUSAND OAKS, Calif., Jan. 24, 2011 /PRNewswire via COMTEX/ --Amg... |
| | | 01/24/11 | Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results| THOUSAND OAKS, Calif., Jan. 24, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 24, 2011 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management te... |
| | | 01/18/11 | Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility| Boehringer Ingelheim to Strengthen Global Biopharma Presence and Amgen to Maintain Strong Presence in San Francisco Bay Area Biotech Hub
THOUSAND OAKS, Calif. and INGELHEIM, Germany, Jan. 18, 2011 /PRNewswire via COMTEX/ --Amgen Inc. (Nasdaq: AMGN) and Boehringer Ingelheim today announced they have signed an agreement under which Boehringer Ingelheim will acquire Amgen's rights in and substantially all assets at Amgen's Fremont California development and manufacturing facility.
The trans... |
| | | 01/07/11 | Sensipar(R) Patents Upheld By District Court| Injunction Prohibits Teva and Barr from Marketing Generic Versions of Amgen's Sensipar Through 2018 Patent Expiry
THOUSAND OAKS, Calif., Jan. 7, 2011 /PRNewswire via COMTEX/ --A U.S. District Court in Delaware today granted an injunction preventing Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals Industries Ltd., and Barr Laboratories, Inc. from commercializing generic versions of Amgen's (Nasdaq: AMGN) Sensipar(R) (cinacalcet) until expiration of the drug's U.S. patents. The latest Sensi... |
| | | 01/06/11 | Amgen to Present at the 29th Annual JP Morgan Healthcare Conference| THOUSAND OAKS, Calif., Jan. 6, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the 29th Annual JP Morgan Global Healthcare Conference at 8:00 a.m. Pacific Time on Tuesday, Jan. 11, 2011, at the Westin St. Francis in San Francisco, Calif. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
About Amgen
Amgen discovers, develops, manuf... |
| | | 01/06/11 | Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases| THOUSAND OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) and Xencor, Inc. announced today that they will collaborate to develop XmAb(R)5871, an Fc- engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.
Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a pre-defined Pha... |
| | | 12/16/10 | Teach For America and the Amgen Foundation Renew Partnership to Improve Math and Science Education in Urban and Rural Schools| $1.8 Million Grant Will Enable Teach For America to Recruit and Train More Math and Science Graduates to Join the Teaching Corps
THOUSAND OAKS, Calif. and NEW YORK, Dec. 16, 2010 /PRNewswire via COMTEX/ --Teach For America and the Amgen Foundation today announced the renewal of their partnership to advance math and science education in America's underserved public schools. Under this partnership, the Amgen Foundation pledged $1.8 million to increase the number of outstanding math and science ... |
| | | 12/13/10 | XGEVA(TM) (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer|
Pivotal Phase 3 '147 Study Meets Primary Endpoint
First Bone-Targeted Therapy to Delay the Onset of Bone Metastases in Patients with Prostate Cancer
THOUSAND OAKS, Calif., Dec. 13, 3010, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. The trial, known as the '147 study, demonstrated that XGEVA significantly improved median bone metast... |
| | | 12/10/10 | Amgen Presents New XGEVA(TM) (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS|
XGEVA Long Term Extension Data Demonstrate XGEVA Delayed Skeletal-Related Events by Five Months Compared to Zometa(R)
Additional Data Shows Advanced Breast Cancer Patients Treated with XGEVA Experienced Less Disruption of Daily Functioning from Pain and Improvements in Health-Related Quality of Life
THOUSAND OAKS, Calif., Dec. 10, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced results from new analyses comparing XGEVA(TM) (denosumab), the first new treatment for advanced... |
| | | 12/08/10 | Amgen to Present at Deutsche Bank's 2010 BioFEST| THOUSAND OAKS, Calif., Dec. 8, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will participate in Deutsche Bank's 2010 BioFEST on Wednesday, Dec. 15, 2010, at the Four Seasons in Boston, beginning at 10:00 a.m. Eastern Time. Roy Baynes, M.D., Ph.D., vice president of Global Development and Arvind Sood, vice president, Investor Relations will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.
... |
| | | 12/08/10 | Three Innovative Ideas Receive $10,000 Prizes in Patients | Choices | Empowerment Competition| THOUSAND OAKS, Calif. and WASHINGTON, Dec. 8, 2010 /PRNewswire via COMTEX/ --The Amgen Foundation and Ashoka's Changemakers today announced three winners for the Patients | Choices | Empowerment competition. Each winner will receive a $10,000 cash prize and was selected by the public for their innovative solutions that empower and elevate patients' voices to improve health outcomes.
Out of 10 finalists, the entries receiving the most votes in the Changemakers.com competition are:
... |
| | | 12/05/10 | Amgen's Nplate(R) Maintains Platelet Counts for More Than Five Years in Adults With Chronic ITP| Final Results From Largest And Longest Study To Date Evaluating Exposure To A Platelet Producer Presented At ASH
ORLANDO, Fla., Dec. 5, 2010 /PRNewswire via COMTEX/ --Amgen Inc. (Nasdaq: AMGN) today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of Nplate(R) (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in ... |
| | | 12/02/10 | Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting| Final Results From The Largest And Longest Study Of Nplate(R) For The Treatment Of Adult Chronic ITP To Be Presented
Amgen Expands Amgen FIRST STEP(TM) Program Co-Pay Coupon Benefits To Help Patients With Out-of-Pocket Costs For Neulasta(R) And Nplate(R)
THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that it will present data from several key Nplate(R) (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society o... |
| | | 11/18/10 | FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors| First Bone Targeted Therapy for Cancer Patients to Be Approved in Nearly a Decade
Approval Based on Largest Clinical Program Ever Conducted in Patients with Bone Metastases
THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire via COMTEX/ --
Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved XGEVA(TM) (denosumab), the first and only RANK Ligand inhibitorfor the prevention of skeletal-related events (SREs) in patients with bone metastases from s... |
| | | 11/17/10 | Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition| Voting Starts Today
THOUSAND OAKS, Calif. and WASHINGTON, Nov. 17, 2010 /PRNewswire via COMTEX/ --The Amgen Foundation and Ashoka's Changemakers today announced ten finalists in the Patients | Choices | Empowerment competition and launched public online voting in search of the best innovative solutions that empower patients, elevate patients' voices, and improve health outcomes.
The ten finalists were selected by a panel of five distinguished judges from 277 entries received from 40 coun... |
| | | 11/16/10 | Call for Applications: The Amgen Award for Science Teaching Excellence| 34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates
THOUSAND OAKS, Calif., Nov. 16, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in st... |
| | | 11/11/10 | Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits| THOUSAND OAKS, Calif., Nov. 11, 2010 /PRNewswire via COMTEX/ --Amgen today announced the 11 recipients of the Amgen Excellence in Volunteering Awards. Launched this year by the Amgen Foundation, the Awards recognize staff in the United States (U.S.) and Puerto Rico who are making a difference in the communities where the company has a presence. The Amgen Foundation will award $5,000 to each nonprofit organization featured in the winning staff members' applications.
"At Amgen, we are committ... |
| | | 11/10/10 | Study Published in New England Journal of Medicine Shows Nplate(R) Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP| THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire via COMTEX/ --Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from the first open-label study to compare Nplate(R) (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were r... |
| | | 11/10/10 | Amgen Scholars Undergraduate Summer Research Program Begins Phase 2| Eight-Year, $34 Million Program, in Partnership with 13 Top Universities, Will Reach Nearly 2,500 Undergraduates
THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire via COMTEX/ --Today, Amgen Scholars, the signature initiative of the Amgen Foundation, moves into its second phase of what has become a $34 million program to advance science learning and inspire the next generation of scientists.
To view the multimedia assets associated with this release, please click: http://multivu.prnewswire... |
| | | 11/09/10 | Amgen to Present at 19th Annual Credit Suisse Healthcare Conference| THOUSAND OAKS, Calif., Nov. 9, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will participate in the 19th Annual Credit Suisse Healthcare Conference on Friday, Nov. 12, 2010, at the Biltmore Hotel in Phoenix, Ariz., beginning at 8:30 a.m. Mountain Time. Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's website, www.amgen.com, ... |
| | | 11/08/10 | Published Results Show Denosumab Superior to Zometa(R) in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer| Bone is One of the Most Common Sites for Distant Metastases Affecting up to 75 percent of Patients with Advanced Breast Cance
THOUSAND OAKS, Calif., Nov. 8, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa(R) (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases. An SRE consists of any of the follo... |
| | | 11/06/10 | Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership| Collaboration Aims to Empower Patients with Psoriatic Arthritis and Rheumatoid Arthritis to Seek Care
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., Nov. 6, 2010 /PRNewswire via COMTEX/ --Amgen Inc. (Nasdaq: AMGN), Pfizer Inc. (NYSE: PFE) and world-class professional golfer Phil Mickelson, have entered into a partnership to share Phil's experience with his diagnosis of psoriatic arthritis and treatment with Enbrel(R) (etanercept), and to encourage patients with similar symptoms to visit their ... |
| | | 11/05/10 | Prolia(TM) (denosumab) Receives Best New Drug Honor at Scrip Awards| THOUSAND OAKS, Calif., Nov. 5, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) is pleased to announce that it has won the Best New Drug awardfor Prolia(TM) (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that bre... |
| | | 11/03/10 | Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LA's Promise| LOS ANGELES and THOUSAND OAKS, Calif., Nov. 3, 2010 /PRNewswire/ -- The Amgen Foundation will grant $4.5 million over the next three years to MLA Partner Schools (MLA) to invest in "LA's Promise" – an endeavor to prepare thousands of children from one South Los Angeles community for college and a healthier, more successful life.
"The goal is t... |
| | | 11/01/10 | Amgen to Provide Testimony at FDA Hearing on Biosimilars| Company Urges FDA to Put Patients First As Regulators Implement Biosimilar Pathway
THOUSAND OAKS, Calif., Nov. 1, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) Senior Vice President of Research and Development Joe Miletich, M.D., Ph.D., will urge members of a U.S. Food and Drug Administration (FDA) panel charged with implementing a pathway for biosimilars to establish approval standards that ensure patient safety and follow a science-based approach.
"Put patients first and sound po... |
| | | 10/25/10 | Amgen's Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year| Third Quarter 2010 Adjusted Earnings Per Share Decreased 9 Percent to $1.36
Third Quarter 2010 GAAP Earnings Per Share Decreased 6 Percent to $1.28
2010 Revenue and Adjusted EPS Guidance Reaffirmed
THOUSAND OAKS, Calif., Oct 25, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009.
Adjusted net income decreased 14 percent to $1,313 million for the third quarter ... |
| | | 10/20/10 | Breakaway From Cancer(R) Launches 'Striking the Balance' Podcast Series to Inspire Action and Change Across the Cancer Continuum| THOUSAND OAKS, Calif., Oct 20, 2010 /PRNewswire via COMTEX/ --Amgen announced today the launch of the Breakaway from Cancer(R) initiative's "Striking the Balance" podcast series. The series presents the best moments from a dynamic, first-of-its-kind roundtable event held with Amgen's four nonprofit Breakaway from Cancer partner organizations at the 2010 American Society of Clinical Oncology (ASCO) annual meeting.
The podcast series aims to highlight potential areas for improvement throughou... |
| | | 10/20/10 | Amgen Announces Webcast of 2010 Third Quarter Financial Results| THOUSAND OAKS, Calif., Oct 20, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Monday, Oct. 25, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.
Live audio... |
| | | 10/18/10 | Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today| THOUSAND OAKS, Calif., Oct 18, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).
"This advisory committee meeting is a va... |
| | | 10/14/10 | Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting| THOUSAND OAKS, Calif., Oct 14, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that results from several Prolia(TM) (denosumab) studies, as well as analyses of the growing global burden of osteoporosis, will be presented at the 2010 American Society for Bone and Mineral Research (ASBMR) annual meeting in Toronto, Ontario from Oct. 15-19, 2010.
"The continued need to reduce fractures caused by postmenopausal osteoporosis is reinforced by data that will be presented at thi... |
| | | 10/10/10 | Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa(R)| Additional Analyses Highlight the Significant Impact of Bone Complications on Pain and Consumption of Health Resources
Abstract Numbers: 1249P, 1248P, 1101P
THOUSAND OAKS, Calif., Oct 10, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq:AMGN) today announced results from two integrated analyses of head-to-head pivotal Phase 3 trials comparing denosumab to Zometa(R) (zoledronic acid), the current standard of care in the prevention of skeletal related events (SREs) in patients with advanced malign... |
| | | 10/09/10 | Updated AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer| THOUSAND OAKS, Calif., Oct 09, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The updated results, now including data on overall survival, are being presented in a poster discussion at the 35th European Society for Medical Oncology (ESMO) Congress being held in Milan, Italy. (Abstract Number: 975PD)
"Treatment advances in... |
| | | 10/05/10 | Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress| THOUSAND OAKS, Calif., Oct 05, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.
"Cancer is a complex disease which requires innovative therapeutic approaches. Amgen is exploring numerous biologic pathways to develop novel therapies to treat cancer and lessen the side effects... |
| | | 10/04/10 | Two Pivotal Vectibix(R) Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology| Data Shows Vectibix Combined with Chemotherapy Improved Progression-Free Survival in Patients with Wild-type KRAS mCRC
THOUSAND OAKS, Calif., Oct 04, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix(R) (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the J... |
| | | 09/24/10 | Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN(R) and PROCRIT(R) (Epoetin alfa)| THOUSAND OAKS, Calif., Sept 24, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) announced today that certain lots of EPOGEN(R) and PROCRIT(R) (Epoetin alfa) vials are being voluntarily recalled from specialty distributors, wholesalers, pharmacies and healthcare providers as a precaution. The product that is being recalled may contain extremely thin glass flakes (lamellae) that are barely visible in most cases. The lamellae result from the interaction of the formulation with glass vials over ... |
| | | 09/22/10 | Amgen and Pfizer Introduce 'Psophisticated Style: A Guide to Everyday Style and Psoriasis(TM)' Hosted by Tim Gunn| Online Style Resource Designed Specifically for People with Psoriasis
NEW YORK, Sept 22, 2010 /PRNewswire via COMTEX/ --Amgen and Pfizer today announced the launch of "Psophisticated Style: A Guide to Everyday Style and Psoriasis(TM)," an online resource, providing a wealth of style advice specifically for people with psoriasis. Hosted by Tim Gunn, mentor to the designers on TV's "Project Runway" and chief creative officer of Liz Claiborne, Inc. and dermatologist Susan C. Taylor, M.D., the s... |
| | | 09/20/10 | Amgen to Present at the UBS Global Life Sciences Conference| THOUSAND OAKS, Calif., Sept 20, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will participate in the UBS Global Life Sciences Conference on Wednesday, Sept. 22, 2010, at the Grand Hyatt in New York City, beginning at 9:00 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's website, www.amgen.com,... |
| | | 09/14/10 | Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference| THOUSAND OAKS, Calif., Sept 14, 2010 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 16, 2010, in London, beginning at 9:50 a.m. Greenwich Mean Time. Amgen executives Rolf Hoffmann, senior vice president, International Commercial Operations; Willard Dere, M.D., senior vice president, International Chief Medical Officer; and Arvind Sood, vice president, Investor Relations, will participate in th... |
| | | 09/13/10 | Amgen to Present at the Baird Healthcare Conference| THOUSAND OAKS, Calif., Sept 13, 2010 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) will participate in the Baird Healthcare Conference on Wednesday, Sept. 15, 2010, at the St. Regis New York in New York City, beginning at 12:15 p.m. Eastern Time. Roy Baynes, M.D., Ph.D., vice president of Global Development, for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's website, www.amgen.com, under Investors.
... |
| | | 08/11/10 | Amgen Announces Top-Line Results of Phase 3 Head and Neck Cancer Trial| THOUSAND OAKS, Calif., Aug 11, 2010 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) today announced top-line results from a randomized Phase 3 trial evaluating Vectibix(R) (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone [m... |
| | | 07/29/10 | Amgen's Second Quarter 2010 Adjusted Earnings Per Share Increased 7 Percent to $1.38|
Second Quarter 2010 Revenue Increased 2 Percent to $3.8 Billion
Second Quarter 2010 GAAP Earnings Per Share Unchanged at $1.25
Adjusting for the Impact of a Weaker Euro, 2010 Total Revenue Guidance Revised to Slightly Below $15.1 Billion
2010 Adjusted Earnings Per Share Guidance Unchanged at Towards Lower End of $5.05-$5.25
THOUSAND OAKS, Calif., July 29, 2010 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.38 for the second quarter of 201... |
| | | 07/28/10 | 2010 Addressing Psoriasis(TM) Contest Winners Attend a Style Consultation with Tim Gunn in New York City| Five Winners with Moderate to Severe Plaque Psoriasis Receive Individualized Advice to Help Achieve Their Best Personal Style
NEW YORK, July 28, 2010 /PRNewswire via COMTEX/ --Amgen and Pfizer today announced the five winners of the 2010 Addressing Psoriasis(TM) contest, which recognizes people with moderate to severe plaque psoriasis who want to feel more confident in their everyday style. The winners have traveled to New York City where they will receive a one-on-one consultation with Tim G... |
| | | 07/26/10 | Amgen Announces Webcast of 2010 Second Quarter Financial Results| THOUSAND OAKS, Calif., July 26, 2010 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) today announced that it plans to report its second quarter financial results on Thursday, July 29, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.
Live ... |
| | | 07/22/10 | Amgen Appoints Ronald D. Sugar to the Company's Board of Directors| THOUSAND OAKS, Calif., July 22, 2010 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) today announced that its board of directors has appointed Ronald D. Sugar to the company's board, effective immediately. Dr. Sugar, 61, is chairman emeritus of Northrop Grumman Corp. and served as the company's chairman and chief executive officer from 2003 to 2009. He was president and chief operating officer of Northrop from 2001 to 2003. He has been a director of Chevron Corporation since 2005.
Previousl... |
| | | 07/19/10 | Amgen Scholars' Summer Research Helps Lead to Science Careers| THOUSAND OAKS, Calif., July 19, 2010 /PRNewswire via COMTEX/ --
A Rhodes Scholar, a Labouisse winner, a Hertz Foundation Fellow and co-author of an internationally acclaimed research project - these are just a few examples of what alumni of the Amgen Scholars Program have achieved.
Established in 2006, Amgen Scholars is a $27.5 million international initiative of the Amgen Foundation. The opportunity to work with top academic scientists is a cornerstone of the program, with participating un... |
| | | 07/16/10 | FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal Related Events in Advanced Cancer Patients| FDA Accepts Submission Which Includes Data from Three Pivotal Phase 3 Trials
THOUSAND OAKS, Calif., July 16, 2010 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer. Filed in mid-May with the FDA, the Biologics License Application (BLA) subm... |
| | | 07/15/10 | Amgen Appoints Jonathan M. Peacock Executive Vice President and Chief Financial Officer| THOUSAND OAKS, Calif., July 15, 2010 /PRNewswire via COMTEX/ --
Amgen (Nasdaq: AMGN) today announced the appointment effective Sept. 1 of Jonathan M. Peacock as chief financial officer (CFO). He will be responsible for Amgen's finance and investor relations operations. Peacock will report to Kevin W. Sharer, Amgen's chairman and chief executive officer, and will succeed Michael A. Kelly, who served as acting CFO since May 2010.
Peacock, 52, joins Amgen from Novartis Pharmaceutical AG, where... |
| | | 07/14/10 | Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients for Better Outcomes| THOUSAND OAKS, Calif. and WASHINGTON, July 14, 2010 /PRNewswire via COMTEX/ --The Amgen Foundation is supporting an online competition with Ashoka's Changemakers to find the best solutions that elevate patients' voices to improve health outcomes globally.
The Patients| Choices| Empowerment competition is seeking solutions that tap the medical experience, knowledge, and wisdom of current and past patients, health care practitioners, advocates and other key stakeholders to ensure that patient... |
| | | 06/22/10 | 34 Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence| THOUSAND OAKS, Calif., June 22, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year's recipients of the 18th annual Amgen Award for Science Teaching Excellence. The award recognizes extraordinary teachers in grades K-12 whose dedication to students has had a significant impact on the learning and interest of the future generation of scientists.
Since the program's inception in 1992, Am... |
| | | 06/15/10 | Amgen to Present at the Goldman Sachs Global Healthcare Conference| THOUSAND OAKS, Calif., June 15, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the Goldman Sachs Global Healthcare Conference on Thursday, June 17, 2010 at the Century Plaza Hyatt Regency, Los Angeles, beginning at 9:20 a.m. Pacific Time. Amgen Chairman and CEO Kevin Sharer will present. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's website, www.amgen.com, under Investors.
Information regarding presentation time, webcas... |
| | | 06/07/10 | Amgen to Present at the Jeffries Global Life Sciences Conference| THOUSAND OAKS, Calif., June 7, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the Jeffries Global Life Sciences Conference at 6:00 a.m. Pacific Time on Wednesday, June 9, 2010, at the Grand Hyatt Hotel in New York City. Amgen's Roy Baynes, vice president of Global Development and Arvind Sood, vice president of Investor Relations will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's website, www.amg... |
| | | 06/06/10 | New AMG 386 Data Demonstrate Promising Antitumor Activity in Patients With Recurrent Ovarian Cancer|
AMG 386 Treatment Response Increased With Dose And Exposure
AMG 386 Moving Into Phase 3 For Recurrent Ovarian Cancer
Separately, Two Analyses Provide Evidence Of Biomarker As Predictor Of Tumor Response To Motesanib
THOUSAND OAKS, Calif., June 6, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being ... |
| | | 06/05/10 | Striking the Balance: Community Experts Come Together for High-Level Dialogue on Cancer Care| Advocacy Leaders, Renowned Physicians, and Actor Patrick Dempsey Spur Dialogue and Inspire Action in First-of-Its-Kind Roundtable Event
CHICAGO , June 5 /PRNewswire/ -- Eminent leaders and thinkers in the cancer community came together yesterday at the 2010 American Society of Clinical Oncology (ASCO) annual meeting for a first-of-its-kind roundtable event. The session, sponsored by Amgen and its Breakaway from Cancer (R) initiative, was designed to highlight potential areas for improvement th... |
| | | 06/05/10 | Denosumab Demonstrated Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Prostate Cancer| The Third Of Three Pivotal Head-To-Head Trials Submitted To FDA For Treatment Of Patients With Bone Metastases
THOUSAND OAKS, Calif., June 5, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa(R) (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated den... |
| | | 06/05/10 | New Analyses of Denosumab Pivotal Phase 3 Trials Reinforce Potential Advantages Over Standard of Care|
Integrated Analysis Shows Denosumab Superiority Over Zometa(R) In Delaying Or Preventing Skeletal Related Events In Broad Population With Advanced Cancer
Additional Analyses Demonstrate Denosumab Significantly Delays Onset And Worsening Of Bone Pain Over Zometa
Exploratory Analysis Shows Denosumab Superior To Zometa In Delaying Time To First Skeletal Related Event Or Hypercalcemia Of Malignancy
THOUSAND OAKS, Calif., June 5, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announ... |
| | | 06/04/10 | New AMG 479 Phase 2 Data Show Antitumor Activity in Patients With Metastatic Pancreatic Cancer| AMG 479 Extended Progression-Free Survival And Overall Survival Compared To Gemcitabine Alone
AMG 479 Moving Into Phase 3 For Metastatic Pancreatic Cancer
THOUSAND OAKS, Calif., June 4, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced results from a small, randomized, placebo-controlled Phase 2 study indicating that adding AMG 479 to gemcitabine improved overall survival at six months (primary endpoint) and progression-free survival in patients with metastatic pancreatic ... |
| | | 06/01/10 | FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture| Given As An Injection Every Six Months, Prolia Reduced Risk Of Fracture At The Spine, Hip And Other Sites
THOUSAND OAKS, Calif., June 1, 2010 /PRNewswire via COMTEX/ --Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia(TM) (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or... |
| | | 05/28/10 | Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union|
Given as an Injection Every Six Months, Prolia Reduced the Risk of Fractures in Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fractures
First and Only Approved Treatment in Europe for Bone Loss Due to Hormone Ablation in Men with Prostate Cancer
First Prolia(R) Regulatory Approval
THOUSAND OAKS, Calif., May 28, 2010 /PRNewswire via COMTEX/ --Amgen Inc. (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorization for Prolia(R... |
| | | 05/20/10 | Amgen Highlights Key Clinical Data to Be Presented at American Society of Clinical Oncology Annual Meeting|
First Presentation of Results from a Pivotal, Phase 3 Head-to-Head Denosumab Bone Metastases Advanced Prostate Cancer Trial
First Integrated Analysis from Two Phase 3 Head-to-Head Denosumab Trials in Advanced Cancer Patients (Breast Cancer and Solid Tumors including Multiple Myeloma)
First Presentations of Phase 2 Data from AMG 479 in Pancreatic Cancer and AMG 386 in Ovarian Cancer
THOUSAND OAKS, Calif., May 20, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that resu... |
| | | 05/14/10 | Amgen Submits Denosumab Biologics License Application to FDA for the Reduction of Skeletal Related Events in Cancer Patients| Submission Includes Data from Three Pivotal Phase 3 Trials
THOUSAND OAKS, Calif., May 14, 2010 /PRNewswire via COMTEX/ --Amgen Inc. (Nasdaq: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor. The BLA submission summarizes clinical experience from nearly 6,900 patients across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the three, ... |
| | | 05/12/10 | Amgen Announces Voting Results of Annual Meeting of Stockholders| THOUSAND OAKS, Calif., May 12, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN), today announced results of voting at the company's Annual Meeting of Stockholders, held at the Four Seasons Hotel Westlake Village in Westlake Village, Calif. Approximately 85 percent of outstanding shares were represented at the meeting.
The director nominees David Baltimore, Frank J. Biondi, Jr., Francois de Carbonnel, Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Rebecca M. Henderson, Frank C. Herri... |
| | | 05/11/10 | Amgen's Breakaway From Cancer(R) to Honor Cancer Survivors at Amgen Tour of California| Breakaway From Cancer Champions To Lead Breakaway Mile In Four Cities
THOUSAND OAKS, Calif., May 11, 2010 /PRNewswire via COMTEX/ --Amgen today announced that four inspirational cancer survivors who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer(R) Champions to participate in Breakaway Miles during the 2010 Amgen Tour of California.
Founded by Amgen in 2005 as a complementary component to the title sponsorship of the Amge... |
| | | 05/06/10 | Amgen Scientists Visit Biotechnology Classrooms Across the Country in Support of National Lab Day| Scientists Will Engage with Students Participating in the Amgen-Bruce Wallace Biotechnology Lab Program
THOUSAND OAKS, Calif., May 6, 2010 /PRNewswire via COMTEX/ --Answering the call from President Obama to reinvigorate science and math education by connecting students to hands-on learning experiences, Amgen scientists will visit high schools that include the Amgen-Bruce Wallace Biotechnology Lab Program in their science curriculum. In conjunction with National Lab Day, the visits will give s... |
| | | 04/29/10 | Amgen to Present at the Deutsche Bank 35th Annual Healthcare Conference| THOUSAND OAKS, Calif., April 29, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the Deutsche Bank 35th Annual Healthcare Conference on Tuesday, May 4, 2010 at the InterContinental, Boston, Mass., beginning at 9:20 a.m. Eastern Time. Senior Vice President of North America Commercial Operations Jim Daly will present. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's website, www.amgen.com, under Investors.
Information regardi... |
| | | 04/26/10 | Amgen Appoints Robert A. Bradway President and Chief Operating Officer| THOUSAND OAKS, Calif., April 26, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that the Board of Directors has appointed Robert A. Bradway president and chief operating officer (COO), effective May 11. In this new role, Bradway will report to Kevin Sharer, Amgen's chairman and chief executive officer, and will be responsible for the company's Global Commercial Operations, Manufacturing Operations, Strategy & Corporate Development, Information Technology, Global Governme... |
| | | 04/21/10 | Amgen's First Quarter 2010 Adjusted Earnings Per Share Increased 20 Percent to $1.30| --First Quarter 2010 Revenue Increased 9 Percent to $3.6 Billion
--First Quarter 2010 GAAP Earnings Per Share Increased 20 Percent to $1.18
--Adjusting for Impact of U.S. Health Care Reform, 2010 Total Revenue and Adjusted EPS Expected Towards Lower End of Current Guidance Ranges of $15.1-$15.5 Billion and $5.05-$5.25, Respectively
THOUSAND OAKS, Calif., April 21, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.30 for the first quar... |
| | | 04/19/10 | Amgen Announces Webcast of 2010 First Quarter Financial Results| THOUSAND OAKS, Calif., April 19, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that it plans to report its first quarter financial results on Wednesday, April 21, 2010 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.
Li... |
| | | 04/19/10 | Amgen Preclinical Study Demonstrated Anti-Tumor Activity in Mammary Tumor Model| Study Shows Effect of RANKL Inhibition on Extraskeletal Tumor Development
THOUSAND OAKS, Calif., April 19, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstr... |
| | | 04/18/10 | Analysis of Vectibix(R) Study Using New Gene Technology Helps to Advance Prospects for Personalized Medicine| --Nine Genes Beyond KRAS Investigated As Potential Predictive Biomarkers For Metastatic Colorectal Cancer Therapy --ABSTRACT NUMBER: LBA 8791
THOUSAND OAKS, Calif., April 18, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix(R) (panitumumab) plus best supportive care (BSC) compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigat... |
| | | 04/12/10 | Amgen Highlights Biomarker and Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting| Key RANK Ligand Preclinical Data and Vectibix Biomarker Data Will Be Presented
THOUSAND OAKS, Calif., April 12, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that results from several preclinical studies investigating potential new cancer agents and a comprehensive biomarker analysis will be presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C. from April 17 - 21, 2010.
Results from a biomarker analysis of the piv... |
| | | 03/08/10 | Amgen to Present at the Cowen and Company 30th Annual Healthcare Conference| THOUSAND OAKS, Calif., March 8, 2010 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) will present at the Cowen and Company 30th Annual Healthcare Conference on Wednesday, March 10, 2010 at the Boston Marriott Copley Place, Boston, Mass., beginning at 9:30 a.m. Eastern Time. James Daly, Amgen's Senior Vice President of North American Commercial Operations, will present. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, und... |
| | | 03/03/10 | 'Project Runway's' Tim Gunn Returns to Address Psoriasis(TM) and Empower Patients to be Confident in Their Personal Style| New Contest Sponsored by Amgen and Pfizer Offers Chance for Five People to Win a Style Consultation with Tim Gunn in New York CityNEW YORK, March 3, 2010 /PRNewswire via COMTEX/ -- Amgen and Pfizer have once again partnered with Tim Gunn, television host, fashion consultant and chief creative officer of Liz Claiborne, Inc., to launch the second year of Addressing Psoriasis(TM), the disease awareness program designed to help people with psoriasis get more information about their condition and fee... |
| | | 02/19/10 | FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date| THOUSAND OAKS, Calif., Feb 19, 2010 /PRNewswire via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia(TM) (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.
In October 2009, the FDA'... |
| | | 02/16/10 | Amgen and Centocor Ortho Biotech Products Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA| --Companies To Launch ESA APPRISE Program On March 24, 2010 For Patients With Cancer
--Medication Guide Available For All IndicationsTHOUSAND OAKS, Calif., Feb 16, 2010 /PRNewswire via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Ep... |
| | | 02/08/10 | Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases| --Denosumab Trial Met Primary and All Secondary Endpoints by Significantly Delaying Time to First Skeletal Related Event and Significantly Reducing First-and-Subsequent Skeletal Related Events Compared to Zometa
--Second Phase 3 Advanced Cancer Trial to Demonstrate Denosumab Superiority Versus ZometaTHOUSAND OAKS, Calif., Feb 08, 2010 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic aci... |
| | | 01/25/10 | Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share Increased 8 Percent to $4.91| --Fourth Quarter 2009 Revenue Increased 2 Percent to $3.8 Billion; Full Year 2009 Revenue Decreased 2 Percent to $14.6 Billion
--Fourth Quarter 2009 GAAP Earnings Per Share Increased 6 Percent to $0.92; Full Year 2009 GAAP Earnings Per Share Increased 20 Percent to $4.51
--2010 Total Revenue Expected to be in the Range of $15.1 Billion to $15.5 Billion
--2010 Adjusted Earnings Per Share Expected to be in the Range of $5.05 to $5.25
THOUSAND OAKS, Calif., Jan 25, 2010 /PRNe... |
| | | 01/21/10 | Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium| THOUSAND OAKS, Calif., Jan 21, 2010 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix(R) (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, ... |
| | | 01/20/10 | Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results| THOUSAND OAKS, Calif., Jan 20, 2010 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced that it plans to report its fourth quarter and full year financial results on Monday, Jan. 25, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management te... |
| | | 01/14/10 | Amgen Donates $2 Million, Establishes Earthquake Relief Program| Company, Staff Contributions To Help Haitian VictimsTHOUSAND OAKS, Calif., Jan 14, 2010 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced that the company will donate $2 million to Haiti relief efforts. Amgen staff are being encouraged to be generous and that effort should also generate meaningful additional support.
The Amgen Foundation will deploy its Disaster Relief Program web site for Amgen staff around the globe who wish to contribute their own funds to designated organizat... |
| | | 01/07/10 | Amgen to Present at the 28th Annual JP Morgan Healthcare Conference| THOUSAND OAKS, Calif., Jan 07, 2010 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) will present at the 28th Annual JP Morgan Global Healthcare Conference at 8:00 a.m. Pacific Time on Tuesday, Jan. 12, 2010, at the Westin St. Francis in San Francisco, Calif. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Information regarding present... |
| | | 12/22/09 | Amgen Resolves EPO Patent Dispute With Roche| Roche Admits Infringement And Validity Of Amgen's EPO Patents; Court Enters Permanent Injunction; Amgen Allows Roche's MIRCERA Onto U.S. Market In Mid-2014THOUSAND OAKS, Calif., Dec 22, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen (Nasdaq: AMGN) announced today that the United States (U.S.) District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting Roche from infringing Amgen's patents on recombinant erythropoietin (EPO), thus bringing the five-ye... |
| | | 12/18/09 | Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines| THOUSAND OAKS, Calif., Dec 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen (Nasdaq: AMGN) announced today that Roger M. Perlmutter, M.D., Ph. D., Amgen's executive vice president of Research & Development, has been elected a 2009 Fellow of the American Association for the Advancement of Science (AAAS). Each year the AAAS Council elects members whose "efforts on behalf of the advancement of science or its applications are scientifically or socially distinguished."
Perlmutter is being ho... |
| | | 12/18/09 | Amgen Receives CHMP Positive Opinion for Prolia(TM) (Denosumab) in the European Union| THOUSAND OAKS, Calif., Dec 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at i... |
| | | 12/14/09 | Array BioPharma and Amgen Partner in Type 2 Diabetes| Amgen to Pay $60 Million Up-front with Additional Potential Milestones and RoyaltiesBOULDER, Colo. and THOUSAND OAKS, Calif., Dec 14, 2009 /PRNewswire-FirstCall via COMTEX/ -- Array BioPharma Inc. (Nasdaq: ARRY) and Amgen Inc.(Nasdaq: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array's small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.
U... |
| | | 12/10/09 | NEW STUDY RESULTS PRESENTED AT 2009 SAN ANTONIO BREAST CANCER SYMPOSIUM SHOW IMPORTANCE OF PROTECTING YOUR BONES| Dec 10, 2009 /PRNewswire via COMTEX/ -- An estimated 70 to 80 percent of patients with advanced or stage four
breast cancer develop bone metastases. Bone metastases occurs when the
disease progresses to a patient's bones. When cancer spreads to the bone, it
can make the bones weaker resulting in skeletal complications like fractures.
Results of a new treatment option for the treatment of bone metastases in
patients with advanced breast cancer was recently presented at the 2009 San
Antonio ... |
| | | 12/10/09 | Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care| Denosumab Significantly Reduced Risk Of Developing Multiple Skeletal Related Events By 23 Percent Versus Zometa(R) In Advanced Breast Cancer PatientsSAN ANTONIO, Dec 10, 2009 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced further detailed results from a Phase 3, head-to-head trial of denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer. In this trial denosumab met both primary and secondary endpoints and d... |
| | | 12/07/09 | Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP| Updated Five-Year Long-Term Data in Adults with Chronic ITP Also Presented at ASH Annual Meeting
NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious blee... |
| | | 12/07/09 | Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program|
THOUSAND OAKS, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that its board of directors has authorized repurchases of up to an additional $5 billion in Amgen common stock. The company currently has approximately $1.2 billion remaining under its previous stock repurchase authorization. This new authorization reflects Amgen's confidence in its long-term prospects.
About Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeut... |
| | | 12/06/09 | Nplate(R) Data From MDS Studies Presented at ASH| NEW ORLEANS, Dec. 6 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced results from three studies on the safety and efficacy of Nplate® (romiplostim) in adult patients with myelodysplastic syndromes (MDS). MDS is a pre-leukemic condition in which early blood forming cells in the bone marrow are unable to mature normally, thereby limiting their ability to produce normal mature blood elements, which can lead to low platelet counts. The results of the studies were presented at the ... |
| | | 12/03/09 | New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists| Applications for 2010 Amgen Scholars U.S. and Europe Programs Now Available
THOUSAND OAKS, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Each year, hundreds of undergraduate students from across the United States (U.S.) and Europe participate in the Amgen Scholars Program to gain hands-on laboratory experience under renowned faculty members at the world's leading universities. Now, the Amgen Scholars - past, present and future - will have exclusive access to the online Amgen Scholars Commun... |
| | | 11/30/09 | Amgen Highlights Data to be Presented at ASH| Nplate(R) Data Documents Long-Term Safety and Efficacy for Treatment of Serious Chronic Autoimmune Disorder
THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes ... |
| | | 11/23/09 | Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards|
THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate® (romiplostim), at a Nov. 18 ceremony in London.
The Best Overall Pipeline award was presented to Amgen by Scrip in recognition of the size, quality, novelty and market potential of the company's pipeline, as well as its mix of candidates across development stages. According to the judges, Amgen's pipe... |
| | | 11/16/09 | Amgen to Present at Lazard Capital Healthcare Conference|
THOUSAND OAKS, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Lazard Capital Healthcare Conference on Wednesday, Nov. 18, 2009, at the St. Regis Hotel in New York City, beginning at 9:30 a.m. Eastern Time. Arvind Sood, vice president, Investor Relations at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Information re... |
| | | 11/12/09 | Amgen to Present at 18th Annual Credit Suisse Healthcare Conference|
THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12, 2009, at the Biltmore Hotel in Phoenix, Ariz., beginning at 9:30 a.m. Mountain Time. Robert A. Bradway, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com,... |
| | | 11/05/09 | Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer| Phase 3 Results Reinforce Importance of KRAS Status
THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix (R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. Earlier this year, it was announced that the trial met its primary endpoin... |
| | | 11/04/09 | Call for Applications: The Amgen Award for Science Teaching Excellence| 34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates
THOUSAND OAKS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it now invites applications for its 19th annual Amgen Award for Science Teaching Excellence (AASTE). This award is designed to recognize and honor extraordinary science teachers at the K-12 level who significantly impact their students through exemplary science teaching and who achieve demonstrated results in student le... |
| | | 10/30/09 | Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints| Aranesp(R) (Darbepoetin Alfa) Did Not Reduce the Risk of Mortality, Cardiovascular Morbidity, or End Stage Renal Disease
THOUSAND OAKS, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 di... |
| | | 10/21/09 | Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49| Third Quarter 2009 Revenue Decreased 2 Percent to $3.8 Billion
THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008.
Total revenue decreased 2... |
| | | 10/19/09 | Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)| THOUSAND OAKS, Calif., Oct 19, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis.
The FDA issues Complete Response Letters to request additional information needed to complete the review of applications for product approval.
The Complete Res... |
| | | 10/16/09 | Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting| New Data Contribute to Existing Body of Knowledge About ENBREL
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Oct. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Pfizer (NYSE: PFE), today announced new scientific data about ENBREL being presented at the 2009 American College of Rheumatology (ACR) Scientific Meeting in Philadelphia, Pa., from Oct. 17-21, 2009. These presentations contribute to data generated through 17 years of collective clinical experience.
"The clinical data being p... |
| | | 10/15/09 | Amgen Announces Webcast of 2009 Third Quarter Financial Results|
THOUSAND OAKS, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Wednesday, Oct. 21, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen's senior management team.
... |
| | | 09/24/09 | Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer| THOUSAND OAKS, Calif., Sept 24, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone,... |
| | | 09/22/09 | Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients|
THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. These results were presented today during the Presidential Session at the 2009 ECCO 15 - ESMO 34 European Mul... |
| | | 09/22/09 | Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer|
THOUSAND OAKS, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC. These results were presented at the 2009 ECCO 15 - ESMO 34 Europe... |
| | | 09/21/09 | Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases|
THOUSAND OAKS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Mult... |
| | | 09/17/09 | Amgen to Present at the UBS Global Life Sciences Conference|
THOUSAND OAKS, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the UBS Global Life Sciences Conference on Monday, Sept. 21, 2009, at the Grand Hyatt in New York City, beginning at 8:30 a.m. Eastern Time. Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, un... |
| | | 09/16/09 | Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress| Key Denosumab and Vectibix(R) (Panitumumab) Data to be Presented
THOUSAND OAKS, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.
Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa(R) (zoledronic acid) for the treatment of b... |
| | | 09/16/09 | Amgen Scholars Europe Programme Convenes Undergraduates From 15 Countries for Innovative Science Research|
Symposium Offers Unique Opportunity to Meet Peers and Leading Scientists; Discuss Hands-On Summer Research Projects
CAMBRIDGE, England, September 16 /PRNewswire/ -- This week, 59 undergraduates with diverse cultural and educational backgrounds will meet at the University of Cambridge for the first Amgen Scholars European Symposium with the common goal of discussing their potential as the future generation of leading scientists.
The first Amgen Scholars Europe class represents 35 dif... |
| | | 09/15/09 | Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product|
THOUSAND OAKS, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court's decision that Roche's peg-EPO product, Mircera, infringes four Amgen patents ('868, '698, '933 and '422) relating to recombinant erythropoietin (EPO) and processes for making it. Regarding a fifth patent ('349), the Federal Circuit reversed the holding of non-infringement by the District Court and remande... |
| | | 09/14/09 | Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference|
THOUSAND OAKS, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept. 17, 2009, in London, beginning at 9:50 a.m. Greenwich Mean Time. Amgen executives will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Information regarding presentation time, webcast ava... |
| | | 09/13/09 | Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis| Poor Adherence Can Lead to Higher Fracture Risk, More Frequent Hospital Admissions and Higher Medical Costs
DENVER, Sept. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR).
"These da... |
| | | 09/11/09 | Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference|
THOUSAND OAKS, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, 2009, at the Grand Hyatt hotel in New York City, beginning at 12:00 p.m. Eastern Time. Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Informati... |
| | | 09/10/09 | Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting|
THOUSAND OAKS, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that new data will be presented on the burden of osteoporosis, current osteoporosis treatment challenges and Prolia(TM) (denosumab) at the 2009 American Society for Bone and Mineral Research (ASBMR) annual meeting in Denver from Sept. 11-15, 2009. Prolia currently is being evaluated by regulatory bodies in the United States (U.S.), the European Union, Switzerland, Australia and Canada as a potent... |
| | | 09/10/09 | Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering One's Risk of Infection During Treatment|
LOS ANGELES, Sept. 10 /PRNewswire/ -- Award-winning actresses Edie Falco and Cynthia Nixon appear in a new Stand Up To Cancer(TM) (SU2C) public service campaign to educate cancer patients and their loved ones about the increased risk of infection during cancer treatment and the importance of learning how to manage one's risk.
Often patients are overwhelmed with medical information once they have been diagnosed with cancer. Many do not fully understand the risk of infection during chemotherapy... |
| | | 09/09/09 | Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope|
LEWISTON, Maine and THOUSAND OAKS, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Amgen has signed on as the presenting sponsor of The Dempsey Challenge: A Journey for Hope, a cycling and 5K fundraising event scheduled for October 4 in Lewiston, Maine. The event supports The Patrick Dempsey Center for Cancer Hope & Healing at Central Maine Medical Center.
The sponsorship provides an opportunity to expand Amgen's Breakaway from Cancer((R)) initiative, which aims to increase awareness of the ... |
| | | 09/08/09 | Amgen to Present at the Thomas Weisel Healthcare Conference|
THOUSAND OAKS, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Thomas Weisel Healthcare Conference on Friday, Sept. 11, 2009, at the Four Seasons in Boston, Mass. beginning at 8:35 a.m. Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global Development for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Inform... |
| | | 09/04/09 | Amgen to Present at the Baird Healthcare Conference|
THOUSAND OAKS, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Baird Healthcare Conference on Thursday, Sept. 10, 2009, at the Four Seasons in New York City, beginning at 10:00 a.m. Eastern Time. Roy Baynes, M.D. Ph.D., vice president of Global Development, for Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Informatio... |
| | | 09/02/09 | Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis| Eight Contest Winners Model Custom-Designed Outfits to Show that Moderate to Severe Plaque Psoriasis Does Not Impact Their Personal Style
NEW YORK, Sept. 2 /PRNewswire/ -- Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City. The fashion show recognizes people with moderate to seve... |
| | | 08/25/09 | Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes| No Statistically Significant Difference in Cardiovascular and Renal Composite Endpoints Between Aranesp and Placebo
THOUSAND OAKS, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia wit... |
| | | 08/17/09 | Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer| Second Prospective Phase 3 Vectibix Combination Chemotherapy Trial to Show
Progression-Free Survival Advantage in KRAS Wild-Type Population
THOUSAND OAKS, Calif., Aug. 17 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced positive top-line results from a Phase 3 trial
evaluating Vectibix (panitumumab) in combination with FOLFIRI (an
irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients
with metastatic colorectal cancer (mCRC). The c... |
| | | 08/13/09 | Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting| THOUSAND OAKS, Calif., Aug 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) issued the following statement on the outcome of today's meeting with the U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD) to review the potential use of Prolia(TM) (denosumab) for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate cancer... |
| | | 08/13/09 | Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs| --Committee to Review Denosumab in Women with Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation Therapy for Either Prostate or Breast CancerTHOUSAND OAKS, Calif., Aug 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen Inc. (Nasdaq: AMGN) today will summarize data from the submitted Biologic License Applications (BLAs) for denosumab for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in breast and prostate cancer pat... |
| | | 08/11/09 | Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss| Twice-Yearly Administration of Denosumab Resulted in 68 Percent Reduction in
Risk for a Vertebral Fracture and 40 Percent Reduction in Risk for a Hip
Fracture in Women with Postmenopausal Osteoporosis
Denosumab Administered Twice-Yearly Reduced the Incidence of New Vertebral
Fractures by 62 Percent in Men with Non-Metastatic Prostate Cancer Undergoing
Androgen Deprivation Therapy
THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCal... |
| | | 08/06/09 | Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer| Pivotal Study Meets Primary Endpoint of Progression-Free Survival in Wild-Type
KRAS
Population
Phase 3 Results Reinforce Importance of KRAS Testing
THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that Vectibix (panitumumab), administered in
combination with FOLFOX (an oxaliplatin-based chemotherapy), significantly
prolonged progression-free survival (PFS) compared with FOLFOX alone in the
... |
| | | 08/04/09 | Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers| THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Aug. 4 /PRNewswire-FirstCall/
-- Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE:
WYE), issued a statement in response to the Food and Drug Administration (FDA)
announcement regarding the results of a safety review of Tumor Necrosis Factor
(TNF) blockers [marketed as Remicade (infliximab), Enbrel (etanercept),
Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab)].
This safety review was the ... |
| | | 08/03/09 | Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)| Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary
Endpoint
Denosumab Delayed Time to Skeletal Related Events
THOUSAND OAKS, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced positive top-line results from a pivotal Phase 3
head-to-head trial evaluating denosumab administered subcutaneously versus
Zometa (zoledronic acid) administered as an intravenous (IV) infusion in the
... |
| | | 07/27/09 | Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)| Amgen to Retain Full Rights for Denosumab in the United States and Canada and
for Oncology Indications in Europe
GlaxoSmithKline Will Commercialize Denosumab for PMO and Oncology in Emerging
Markets
THOUSAND OAKS, Calif. and LONDON, July 27 /PRNewswire-FirstCall/ -- Amgen
(Nasdaq: AMGN) and GlaxoSmithKline (GSK) today announced a collaboration in
which the companies will share commercialization of Amgen's monoclona... |
| | | 07/27/09 | Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29| Second Quarter 2009 Revenue Decreased 1 Percent to $3.7 Billion
Second Quarter 2009 GAAP Earnings Per Share Increased 49 Percent to $1.25
2009 Total Revenue Trending Towards Upper End of Current Guidance Range of
$14.4-$14.8 Billion
2009 Adjusted Earnings Per Share Guidance Range of $4.55-$4.75 Raised to
$4.80-$4.95
THOUSAND OAKS, Calif., July 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) r... |
| | | 07/23/09 | Amgen Announces Webcast of 2009 Second Quarter Financial Results| THOUSAND OAKS, Calif., July 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that it plans to report its second quarter financial
results on Monday, July 27, 2009 after the close of the financial markets. The
announcement will be followed by a conference call with the investment
community at 2 p.m. Pacific Time. Participating in the call from Amgen will
be Kevin Sharer, chairman and chief executive officer, and other members of
Amgen's senior management team.
Liv... |
| | | 07/20/09 | Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium| THOUSAND OAKS, Calif., July 20, 2009 /PRNewswire-FirstCall via COMTEX/ -- From July 18-20, more than 260 of the country's brightest undergraduate students met at UCLA for the third annual Amgen Scholars U.S. Symposium designed to bring together program participants and help them apply their science research experiences into future science careers.
The three-day symposium is a key component of the Amgen Scholars Program, a $27.5 million initiative that provides undergraduates the opportunity for... |
| | | 07/17/09 | Amgen Announces KRAS Safety Update to U.S. Prescribing Information for Vectibix(R) (Panitumumab)| Class Labeling Recognizes KRAS as a Predictive Biomarker for anti-EGFr
Antibody Monotherapy in Metastatic Colorectal Cancer
Results from First Pivotal Trials Prospectively Evaluating KRAS Utility in
Combination Therapy Expected In Third Quarter 2009
THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/ -- Amgen Inc.
(Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has
approved revisions to the U.S. prescribing informa... |
| | | 07/09/09 | Amgen Appoints Rebecca M. Henderson to the Company's Board of Directors| THOUSAND OAKS, Calif., July 9 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) announced today that its Board of Directors has appointed Rebecca M.
Henderson, Ph.D., to the Company's Board. Dr. Henderson, 48, has recently
joined the faculty at the Harvard Business School, having been the Eastman
Kodak LFM Professor of Management at the Massachusetts Institute of Technology
(MIT) Sloan School since 1999. She specializes in technology strategy and the
broader strategic problems faced by f... |
| | | 07/07/09 | Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases| Denosumab Significantly Delayed the Time to the First Skeletal Related Event
and Significantly Reduced First and Subsequent Skeletal Related Events
Compared to Zometa
First of Three Pivotal Oncology Trials Comparing Denosumab to Zometa in the
Advanced Cancer Setting Meets Primary and Secondary Endpoints
THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that a pivotal, Phase 3, head-to-head trial eva... |
| | | 07/06/09 | Winners of the Addressing Psoriasis(TM) Contest Selected to Walk the Runway in New York City Fashion Show Hosted by Tim Gunn |
Eight Inspiring People Will Model Custom-Designed Outfits Created by Emerging Talent from the Fashion Institute of Technology
NEW YORK, July 6 /PRNewswire/ -- Amgen and Wyeth today announced the eight winners of the Addressing Psoriasis(TM) contest, which recognizes people with moderate to severe plaque psoriasis who have tried not to allow the condition to inhibit their personal style. The winners will help raise public awareness of the condition by walking the runway in the A... |
| | | 06/22/09 | Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August| Advisory Committee to Review Denosumab Data
THOUSAND OAKS, Calif., June 22 /PRNewswire-FirstCall/ -- Amgen Inc.
(Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration
(FDA) has asked the company to participate in a meeting of the Reproductive
Health Drugs Advisory Committee (RHDAC) on Aug. 13, 2009. The RHDAC will
review data supporting the Biologics License Application (BLA) for denosumab,
a RANK Ligand inhibitor for which Amgen is seeking approval for preventi... |
| | | 06/17/09 | 34 Outstanding Teachers and Schools Receive $10,000 Amgen Award for Science Teaching Excellence|
2009 Awardees Recognized in Amgen Communities Across North America
THOUSAND OAKS, Calif., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ Amgen (Nasdaq: AMGN) today announced the 34 science teachers in the United States (U.S.), Canada and Puerto Rico who are this year's recipients of the Amgen Award for Science Teaching Excellence. The award recognizes teachers in grades K-12 whose dedication to students has had a significant impact on the learning and interest of the futu... |
| | | 06/08/09 | Amgen to Present at the Goldman Sachs Global Healthcare Conference| THOUSAND OAKS, Calif., June 8 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the Goldman Sachs Global Healthcare Conference on
Wednesday, June 10, 2009 at the Grand Hyatt, New York City, N.Y., beginning at
9:00 a.m. Eastern Time. Roger M. Perlmutter, Amgen's Executive Vice President
of Research & Development, will present. Live audio of the presentation will
be available over the Internet and can be accessed from Amgen's Web site,
www.amgen.com, under Investors.
I... |
| | | 06/07/09 | New Study Shows Nplate(R) Significantly Reduces Splenectomy Rate and Treatment Failure in Patients With Chronic ITP| BERLIN, June 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today
released the results of a new study comparing Nplate(R) (romiplostim) to the
medical standard of care (SOC) in non-splenectomised adult patients with
chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious
autoimmune disorder characterised by low platelet counts in the blood
(thrombocytopenia), which can lead to serious bleeding events. The study
results show Nplate significantly reduced the incid... |
| | | 05/27/09 | VIDEO from Medialink and Amgen: New Survey Highlights Growing Concern About Risk of Infection and Emerging Antibiotic Resistance in Cancer Patients| --Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient PopulationTHOUSAND OAKS, Calif., May 27, 2009 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists, and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes, as well as emerging ant... |
| | | 05/27/09 | New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance| --Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient PopulationTHOUSAND OAKS, Calif., May 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes in chemotherapy... |
| | | 05/26/09 | Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452| Cytokinetics Receives Exercise Fee of $50 Million;
Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET
SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26
/PRNewswire-FirstCall/ -- Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen
Inc. (Nasdaq: AMGN) today announced that Amgen has exercised its option to
obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics'
cardiac contractility program. The license includes CK-1827452, a... |
| | | 05/15/09 | Amgen Highlights Data to Be Presented at ASCO| New Vectibix(R) (Panitumumab) Combination Chemotherapy Data
New Data Reinforce Importance of Infection Prevention in Chemotherapy
Patients
Oncology Pipeline Continues to Advance With New Data in Multiple Tumor
Types
THOUSAND OAKS, Calif., May 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced it will present new data from the Company's oncology
portfolio of approved and investigational cancer products at the 2009 American
Society of Clinical Oncology (ASCO)... |
| | | 05/13/09 | Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference| THOUSAND OAKS, Calif., May 13 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the Deutsche Bank 34th Annual Healthcare Conference on
Monday, May 18, 2009 at the InterContinental, Boston, Mass., beginning at 9:20
a.m. Eastern Time. Chairman and Chief Executive Officer Kevin Sharer will
present. Live audio of the presentation will be available over the Internet
and can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Information regarding presentati... |
| | | 05/06/09 | Amgen Announces Voting Results Of Annual Meeting Of Stockholders| THOUSAND OAKS, Calif., May 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN), today announced results of voting at the company's Annual Meeting of
Stockholders, held at The St. Regis Hotel, San Francisco, Calif.
Approximately 87.3 percent of outstanding shares were represented at the
meeting.
The director nominees: David Baltimore, Frank J. Biondi, Jr., Francois de
Carbonnel, Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C.
Herringer, Gilbert S. Omenn, Judith C. Pe... |
| | | 04/30/09 | Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign|
'Coping with Cancer from the Outside In' Program to Launch at the Annual
Oncology Nursing Society Congress
THOUSAND OAKS, Calif., April 30 /PRNewswire-FirstCall/ -- Amgen and
ONSEdge, a subsidiary of the Oncology Nursing Society (ONS), today announced
that they will partner alongside celebrity make-up artist and cancer survivor
Jan Ping to support a new educational campaign, Coping with Cancer From the
Outside In. The initiative is aimed at educating oncology nurses about the
sk... |
| | | 04/30/09 | Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign|
"Coping with Cancer from the Outside In" Program to Launch at the Annual
Oncology Nursing Society Congress
THOUSAND OAKS, Calif., April 30 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) and ONSEdge, a subsidiary of the Oncology Nursing Society (ONS), today
announced that they will partner alongside celebrity make-up artist and cancer
survivor Jan Ping to support a new educational campaign, Coping with Cancer
From the Outside In. The initiative is aimed at educating oncology nurse... |
| | | 04/23/09 | Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08| First Quarter 2009 Revenue Decreased 8 Percent to $3.3 Billion
First Quarter 2009 GAAP Earnings Per Share Decreased 3 Percent to $0.98
2009 Total Revenue Guidance Range Lowered from $14.8 to $15.2 Billion to
$14.4 to $14.8 Billion
2009 Adjusted Earnings Per Share Guidance Range Maintained at $4.55 to
$4.75
THOUSAND OAKS, Calif., April 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) reported adjusted earnings per share (EPS) of $1.08 for the first
quarter of... |
| | | 04/20/09 | Amgen Announces Webcast of 2009 First Quarter Financial Results| THOUSAND OAKS, Calif., April 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that it plans to report its first quarter financial
results on Thursday, April 23, 2009 after the close of the financial markets.
The announcement will be followed by a conference call with the investment
community at 2 p.m. Pacific Time. Participating in the call from Amgen will
be Kevin Sharer, chairman and chief executive officer, and other members of
Amgen's senior management team.
... |
| | | 04/16/09 | Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR| Early Research Suggests that Understanding the Fundamental Mechanism of
Angiogenesis is More Complicated Than Understanding the Function of VEGF - A
Amgen Launches Angiogenesis Website
THOUSAND OAKS, Calif., April 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that results from several preclinical studies
investigating potential new cancer agents will be presented at the 2009
American Association for Cancer Research (AACR) Annual Meeting in Denver
between Ap... |
| | | 03/30/09 | Amgen to Present at the Citigroup Biotech Day| THOUSAND OAKS, Calif.,
March 30
/PRNewswire-FirstCall/ --
Amgen
(Nasdaq:
AMGN) will present at
Citigroup's
4th Annual Biotech Day on
Wednesday, April
1, 2009
at the Citigroup Conference Center,
New York, N.Y.
, beginning at
11:20
a.m. Eastern Time
. Amgen Vice President of Investor Relations Arvind Sood
will present. Live audio of the presentation will be available over the
Internet and can be accessed from
Amgen's
... |
| | | 03/16/09 | Amgen to Present at the Cowen and Company Annual Healthcare Conference| THOUSAND OAKS, Calif., March 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the Cowen and Company Annual Healthcare Conference on
Wednesday, March 18, 2009 at the Boston Marriott Copley Place, Boston, Mass.,
beginning at 9:30 a.m. Eastern Time. James Daly, Amgen's Senior Vice
President of North American Commercial Operations, will present. Live audio of
the presentation will be available over the Internet and can be accessed from
Amgen's Web site, www.amgen.com, un... |
| | | 03/09/09 | Amgen to Present at the Barclays Capital Global Healthcare Conference| THOUSAND OAKS, Calif., March 9 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the Barclays Capital Global Healthcare Conference on
Wednesday, March 11, 2009 at the Loews Miami Beach Hotel, Miami Beach, Fla.,
beginning at 9:00 a.m. Eastern Time. Amgen's Chief Financial Officer Robert
A. Bradway will present. Live audio of the presentation will be available over
the Internet and can be accessed from Amgen's Web site, www.amgen.com, under
Investors.
Information regar... |
| | | 03/04/09 | "Project Runway's" Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate that Patients Shouldn't Let Psoriasis Impact Personal Style| -- Campaign Sponsored by Amgen and Wyeth Offers Chance to Win a Walk on the Runway in New York City Fashion Show
NEW YORK, March 4, 2009 /PRNewswire-FirstCall via COMTEX/ -- Campaign Sponsored by Amgen and Wyeth Offers a Chance to Win a Walk on the Runway in New York City Fashion Show
Amgen and Wyeth today announced that they have partnered with Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") to launch Addressing Psoriasis(TM), an awareness camp... |
| | | 02/18/09 | FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab| THOUSAND OAKS, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Amgen Inc.
(Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration
(FDA) has accepted Amgen's submission and filed a Biologics License
Application (BLA) for denosumab, an investigational RANK Ligand inhibitor.
The indications for which Amgen is seeking FDA approval are treatment and
prevention of postmenopausal osteoporosis (PMO) in women and treatment and
prevention of bone loss in patients undergoing hormone a... |
| | | 02/11/09 | Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial| THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Feb. 11 and OSAKA, Japan (Feb.
12, 2009) /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN), Millennium: The
Takeda Oncology Company, and its parent company Takeda Pharmaceutical Company
Limited (TSE:4052) today announced the Independent Data Monitoring Committee
(DMC) for the MONET1 trial has recommended the trial resume enrollment of
patients with non-squamous non-small cell lung cancer (NSCLC) following a
three-month enrollment suspension. MON... |
| | | 02/06/09 | Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)| First and Only Approved Platelet Producer in Europe Represents New
Treatment Approach for Serious Chronic Autoimmune Disorder
ZUG, Switzerland, Feb. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN)
today announced that the European Commission (EC) has granted marketing
authorisation for Nplate(R) (romiplostim) for the treatment of splenectomised
adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who
are refractory to other treatments (e.g. corticosteroids, im... |
| | | 01/26/09 | Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55| Full Year 2008 Revenue Increased 2 Percent to $15.0 Billion; Fourth
Quarter 2008 Revenue Flat at $3.75 Billion
Full Year 2008 GAAP Earnings Per Share Increased 38 Percent to $3.90;
Fourth Quarter 2008 GAAP Earnings Per Share Increased 20 Percent to $0.91
2009 Total Revenue Expected to be in the Range of $14.8 to $15.2 Billion
2009 Adjusted Earnings Per Share Expected to be in the Range of $4.55 to
$4.75
THOUSAND OAKS, Calif., Jan. 26 /PRNewswire-FirstCall/ -- Amgen (Na... |
| | | 01/22/09 | Amgen's Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services| THOUSAND OAKS, Calif., Jan. 22 /PRNewswire-FirstCall/ -- In an ongoing
effort to raise awareness of the comprehensive continuum of resources
available to cancer patients and their caregivers -- from prevention to
education, patient care to advocacy and financial support --Amgen's Breakaway
from Cancer(TM) initiative has expanded its charitable partners to now include
the National Coalition for Cancer Survivorship, Patient Advocate Foundation,
Prevent Cancer Foundation and The Wellness ... |
| | | 01/20/09 | Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results| THOUSAND OAKS, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) today announced that it plans to report its fourth quarter and full year
financial results on Monday, Jan. 26, 2009 after the close of the financial
markets. The announcement will be followed by a conference call with the
investment community at 2:00 p.m. Pacific Time. Participating in the call
from Amgen will be Kevin Sharer, chairman and chief executive officer, and
other members of Amgen's senior manageme... |
| | | 01/07/09 | Amgen to Present at the 27th Annual JP Morgan Healthcare Conference| THOUSAND OAKS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq:
AMGN) will present at the 27th Annual JP Morgan Global Healthcare Conference
at 9:00 a.m. Pacific Time on Monday, Jan. 12, 2009, at the Westin St. Francis
in San Francisco, Calif. Amgen Chairman and CEO Kevin Sharer will present at
the conference. Live audio of the presentation will be available over the
Internet and can be accessed from Amgen's Web site, www.amgen.com, under
Investors.
(Logo: http://www.ne... |
| | | 12/19/08 | Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer| THOUSAND OAKS, Calif., Dec. 19 /PRNewswire-FirstCall/ -- Amgen Inc.
(Nasdaq: AMGN), today announced submission of a Biologics License Application
(BLA) with the U.S. Food and Drug Administration (FDA) for denosumab, an
investigational RANK Ligand inhibitor. The indications for which Amgen is
seeking FDA approval are treatment and prevention of postmenopausal
osteoporosis (PMO) in women, and treatment and prevention of bone loss in
patients undergoing hormone ablation for either prostat... |
| | | 12/16/08 | Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting| THOUSAND OAKS, Calif., Dec 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- KRAS Biomarker Presents Potential to Personalize Colorectal Cancer Treatment Determining Who Can Benefit from Vectibix(R)
Amgen (Nasdaq: AMGN) today announced they will discuss the clinical utility of the KRAS gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFr) antibody Vectibix(R) (panitumumab) with the U.S. Food and Dru... |
| | | 12/08/08 | Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients| Interim Phase 2 MDS Data Also Presented at ASH Annual MeetingSAN FRANCISCO, Dec 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amgen Inc. (Nasdaq: AMGN)
today released updated results from the ongoing, open-label extension study of
the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult
patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a
chronic and serious autoimmune disorder characterized by lower than expected
platelet counts in the bl... |
| | | 11/21/08 | Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union| First and Only Approved Platelet Producer Represents New Treatment Approach
for Serious Chronic Autoimmune Disorder
THOUSAND OAKS, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Amgen
(Nasdaq: AMGN) today announced that the European Committee for Medicinal
Products for Human Use (CHMP) has issued a positive opinion recommending
marketing authorisation for Nplate(TM) (romiplostim) in the European Union
(EU). The CHMP recommends Nplate for adult chronic immune (idiopathic... |
| | | 11/19/08 | Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer| THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Amgen
(Nasdaq: AMGN) and Millennium: The Takeda Oncology Company, a subsidiary of
Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that
enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in
combination with paclitaxel and carboplatin for the first-line treatment of
advanced non-small cell lung cancer (NSCLC) has been temporarily suspended
following a planned safety data review of 600 patients ... |
| | | 11/10/08 | Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe| Hands-On Science Research Program Expansion Brings the Amgen Foundation's Total Commitment to Amgen Scholars to $27.5 Million
Applications for 2009 Amgen Scholars U.S. Program Now Available
THOUSAND OAKS, Calif. (Nov. 10, 2008) -- Each year, hundreds of students from across the United States (U.S.) participate in the Amgen Scholars Program under renowned faculty members at the country's leading universities. Now, the same opportunity will be extended to undergraduates throughout Europe.... |
| | | 11/07/08 | Amgen Positioned to Deliver Attractive Growth Over Next Five Years| NEW YORK, Nov 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- At an Amgen (Nasdaq: AMGN)
meeting of about 200 securities analysts and investors in New York City today,
several members of its senior management team outlined the Company's growth
strategy, which includes delivering on its pipeline -- including the
experimental bone drug denosumab -- growing in-line products and continuing to
pursue operating efficiencies.
"In 2001, Amgen had two blockbuster products and today we ha... |
| | | 11/03/08 | Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York| THOUSAND OAKS, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Amgen
(Nasdaq: AMGN) today announced that it will hold its Business Review Meeting
on Friday, Nov. 7, 2008 at the Millennium Broadway Hotel, 145 West 44th
Street, New York City, beginning at 8 a.m. Eastern Time. Participating in the
meeting will be Kevin Sharer, chairman and CEO, Roger M. Perlmutter, M.D.,
Ph.D., executive vice president, Research and Development, George Morrow,
executive vice president, Global Commercial Operati... |
| | | 11/03/08 | Call for Applications: The Amgen Award for Science Teaching Excellence| 34 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates
THOUSAND OAKS, Calif., Nov. 3 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today
announced that it now invites applications for its 18th annual Amgen Award for
Science Teaching Excellence (AASTE). This award is designed to recognize and
honor extraordinary science teachers at the K-12 level who significantly
impact their students through exemplary science teaching and who achieve
demonstrated results in student lea... |
| | | 10/27/08 | Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis| SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that
ENBREL is the first biologic with published clinical trial data to show
sustained improvements in multiple measures of efficacy in moderate to severe
rheumatoid arthritis (RA) patients completing up to 10 years of therapy. In
this analysis, the safety profile remained consistent with continuous ENBREL
use for up to 10 years. These new ... |
| | | 10/22/08 | Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23| Third Quarter 2008 Revenue Increased 7 Percent to $3.9 Billion
Third Quarter 2008 GAAP Earnings Per Share were $1.09,
an Increase from Third Quarter 2007
GAAP Earnings Per Share of $0.18
Full Year Revenue Guidance Raised from
$14.6 Billion - $14.9 Billion to $14.9 Billion - $15.2 Billion
Full Year Adjusted EPS Guidance Raised from
$4.25 - $4.45 to $4.45 - $4.55
THOUSAND OAKS, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Amgen
(Nasdaq: AMGN) reported adjusted earnings per s... |
| | | 10/20/08 | Amgen Announces Webcast of 2008 Third Quarter Financial Results| THOUSAND OAKS, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Amgen
(Nasdaq: AMGN) today announced that it plans to report its third quarter
financial results on Wednesday, Oct. 22, 2008 after the close of the financial
markets. The announcement will be followed by a conference call with the
investment community at 1:30 p.m. Pacific Time. Participating in the call
from Amgen will be Kevin Sharer, chairman and CEO, and other members of
Amgen's senior management team.
Live audio of the ... |
| | | 10/10/08 | Amgen Issues Statement on Court of Appeals Ruling That Affirms Preliminary Injunction Against Roche| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--
Today the United States (U.S.) Court of Appeals for the Federal
Circuit issued a ruling that affirms the preliminary injunction
ordered by the U.S. District Court in Boston barring Roche from
selling its pegylated-erythropoietin (peg-EPO) product MIRCERA in the
U.S.
Amgen (NASDAQ:AMGN) issued the following statement regarding
today's ruling by the Court of Appeals:
Amgen is pleased that the Court of Appeals has affirmed the
preliminar... |
| | | 10/03/08 | Amgen Appoints Francois de Carbonnel to the Company's Board of Directors| THOUSAND OAKS, Calif., Oct 03, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) announced today that its Board of Directors has
appointed Francois de Carbonnel to the
Company's Board. Mr. de Carbonnel, 61, is a consultant and corporate
financial advisor. He is also chairman of the board of Thomson S.A.
(Euronext Paris:18453; NYSE:TMS), an international multimedia
corporation. He is also a member of the boards of Pages Jaunes S.A., a
French public compan... |
| | | 10/02/08 | District Court Affirms Patent Infringement Rulings and Finds That Amgen is Entitled to a Permanent Injunction against Roche| Court Also Upholds Validity of Patent Claim in TKT and Aventis Litigation
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) announced today that the United States (U.S.)
District Court in Boston issued its written decision upholding the
prior jury verdict and court rulings regarding the infringement,
validity and enforceability of 10 claims of four of Amgen's
erythropoietin (EPO) patents. The Court also ruled that Amgen is
entitled to a permanent injunction prohibiting Roche ... |
| | | 09/30/08 | Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology| THOUSAND OAKS, Calif., Sep 30, 2008 (BUSINESS WIRE) -- Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of
preliminary results from the Cochrane Collaboration's
independent meta-analysis of patient-level data from previously
conducted, randomized, controlled, clinical studies evaluating
erythropoiesis-stimulating agents (ESAs) in cancer patients. Amgen has
submitted the executive summary to regulatory authorities, including the
U.S. F... |
| | | 09/22/08 | Amgen to Present at UBS Global Life Sciences Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 22, 2008--Amgen
(NASDAQ:AMGN) will participate in the UBS Global Life Sciences
Conference on Tuesday, Sept. 23, 2008, at the Grand Hyatt in New York
City, beginning at 10:30 a.m. Eastern Time. Roger M. Perlmutter, M.D.,
Ph.D., executive vice president, Research and Development for Amgen,
will present at the conference. Live audio of the presentation will be
available over the Internet and can be accessed from Amgen's Web site,
www.amgen.co... |
| | | 09/16/08 | Amgen to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medical Devices Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 16, 2008--Amgen
(NASDAQ:AMGN) will participate in the Merrill Lynch Global
Pharmaceutical, Biotech & Medical Devices Conference on Thursday,
Sept. 18, 2008, at the Merrill Lynch Financial Centre in London,
beginning at 9:50 a.m. United Kingdom Time. Arvind Sood, vice
president, Investor Relations for Amgen, will present at the
conference. Live audio of the presentation will be available over the
Internet and can be accessed from Amgen's We... |
| | | 09/15/08 | Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate| Additional Data From Separate Head-to-Head Trial Showed More Than
75 Percent of Patients Prefer the Administration and Frequency of
Twice-Yearly Subcutaneous Injection Compared to Weekly Oral Pill
MONTREAL--(BUSINESS WIRE)--Sept. 15, 2008--Amgen (NASDAQ:AMGN)
today announced full data results from a non-pivotal Phase 3
head-to-head, double-blind trial comparing bone mineral density (BMD)
gains in postmenopausal women with low bone mass who transitioned from
weekly oral alendronate... |
| | | 09/15/08 | Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen| STOCKHOLM, Sweden & THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept.
15, 2008--Biovitrum AB (publ) (STO:BVT) and Amgen (NASDAQ:AMGN)
announced today that they have entered into an agreement under which
Biovitrum will acquire the marketed biologic therapeutic products
Kepivance(R) (palifermin) and Stemgen(R) (ancestim) from Amgen, and
will also obtain from Amgen a worldwide exclusive license to
Kineret(R) (anakinra) for its current approved indication. The
agreement includes an inventory ... |
| | | 09/11/08 | Amgen to Present Important Clinical Trial Data at Two Key Congresses|
New Denosumab Osteoporosis Data at ASBMR
Denosumab Oncology and Oncology Therapeutics Data at ESMO
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 11, 2008--Amgen
(NASDAQ:AMGN) today announced it will present new data from
osteoporosis studies of its investigational therapy, denosumab, at the
2008 American Society of Bone and Mineral Research (ASBMR) Annual
Meeting that will be held in Montreal, Sept. 12-16, 2008.
Additionally, data from the denosumab oncology program... |
| | | 09/08/08 | Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 8, 2008--Amgen
(NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare
Unplugged Conference on Tuesday, Sept. 9, 2008, at the Grand Hyatt New
York in New York City, beginning at 12:00 p.m. Eastern Time. Kevin
Sharer, chairman and chief executive officer for Amgen, will present
at the conference. Live audio of the presentation will be available
over the Internet and can be accessed from Amgen's Web site,
www.amgen.com, under ... |
| | | 09/04/08 | Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers| THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Sept.
4, 2008--Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug
Administration (FDA) safety announcement regarding opportunistic
fungal infections in patients treated with Tumor Necrosis Factor (TNF)
blockers (marketed as Remicade(R) (infliximab), Enbrel(R)
(etanercept), Humira(R) (adalimumab) and Cimzia(R) (certolizumab
pegol)).
AMGEN AN... |
| | | 08/22/08 | FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP| First and Only Approved Platelet Producer Represents New Treatment Approach for Serious Chronic Autoimmune Disorder Amgen to Launch Nplate(TM) NEXUS Program to Provide Treatment Access and Patient Support ProgramsTHOUSAND OAKS, Calif., Aug 22, 2008 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ: AMGN) today announced that the United States
(U.S.) Food and Drug Administration (FDA) has approved Nplate(TM)
(romiplostim), the first and only platelet producer for the treatment
of thrombocytopenia in splen... |
| | | 07/31/08 | Amgen Licenses Molecule for the Treatment of Chronic and Neuropathic Pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc.| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 31, 2008--Amgen
(NASDAQ: AMGN) today announced that it has licensed a clinical stage
molecule for the treatment of chronic and neuropathic pain to
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson &
Johnson company. The terms of the agreement include a $50 million
upfront payment, the potential for $385 million in success-based
milestones and additional sales based milestones and royalties on
sales.
The agreement provides O... |
| | | 07/30/08 | Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 30, 2008--Amgen
(NASDAQ: AMGN) issued the following statement in response to the
receipt today of the complete response on the revised ESA labeling
from the FDA.
"This label is consistent with our expectations. We will soon be
communicating the revised product labeling for ESAs to both physicians
and patients."
The potential impact of this revised label was factored into our
updated guidance announced July 28, 2008.
CONTAC... |
| | | 07/28/08 | Amgen's Second Quarter 2008 Adjusted Earnings Per Share Increased 2 Percent to $1.14| Second Quarter 2008 Revenue Increased 1 percent to $3.8 Billion
Second Quarter 2008 GAAP Earnings Per Share Decreased 3 percent to $0.87
Full Year Revenue Guidance Raised from $14.2 Billion - $14.6 Billion to $14.6 Billion - $14.9 Billion
Full Year Adjusted EPS Guidance Raised from $4.00 - $4.30 to $4.25 - $4.45
THOUSAND OAKS, Calif., Jul 28, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS),
excluding stock option expense and certain other ex... |
| | | 07/25/08 | Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial| Study Met Primary Endpoint of Reducing New Vertebral Fractures and
Secondary Endpoints of Reducing Time to First Non-Vertebral and Hip
Fractures; Adverse Events Similar to Placebo
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 25, 2008--Amgen
(NASDAQ: AMGN) today announced findings from the pivotal fracture
trial evaluating its RANK Ligand inhibitor, denosumab, in the
treatment of postmenopausal osteoporosis.
In this pivotal, three-year, international, Phase 3 study of
approxim... |
| | | 07/21/08 | 250 Amgen Scholars from 10 Premier Universities Convene for National Summer Symposium to Explore Drug Discovery & Development | Annual Symposium Offered Opportunity to Meet Peers and Leading Scientists; Discuss Hands-On Summer Research Projects
THOUSAND OAKS, Calif. and CAMBRIDGE, Mass. (July 21, 2008) -- From July 19-21, nearly 250 undergraduate students from across the country gathered at the University of California, Los Angeles (UCLA) to share their summer research projects and gain insight into how scientific research can translate into the discovery and development of important drugs for patients.
The experience... |
| | | 07/17/08 | Amgen Announces Webcast of 2008 Second Quarter Financial Results| THOUSAND OAKS, Calif., Jul 17, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced that it plans to report its
second quarter financial results on Monday, July 28, 2008 after the
close of the financial markets. The announcement will be followed by a
conference call with the investment community at 2 p.m. Pacific Time.
Participating in the call from Amgen will be Kevin Sharer, chairman
and chief executive officer, and other members of Amgen's senior
management team.
Live audio of t... |
| | | 07/15/08 | Study Showed Half of Patients Treated with Enbrel(R) (etanercept) Plus Methotrexate Can Achieve DAS Clinical Remission and 80 Percent Had No Progression of Joint Damage in Active Early Rheumatoid Arthritis| Data Demonstrated Benefits of Early Treatment in Patients with
Moderate-to-Severe Rheumatoid Arthritis (RA)
COLLEGEVILLE, Pa. & THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July
15, 2008--Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and
Amgen (NASDAQ:AMGN) today announced the publication of data from the
COMET (COmbination of Methotrexate and ETanercept in Active Early
Rheumatoid Arthritis) trial demonstrating that half of patients
treated with the combination of ENBREL and m... |
| | | 07/14/08 | Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy| Data From First Pivotal Study in Men Met Primary Endpoint of Increases in Bone Mineral Density and Secondary Endpoint of New Vertebral Fracture Reduction THOUSAND OAKS, Calif., Jul 14, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced findings from a three-year
pivotal Phase 3 placebo-controlled trial evaluating denosumab in the
treatment of bone loss in men undergoing androgen deprivation therapy
(ADT) for non-metastatic prostate cancer.
In this study of more than 1,400 men, d... |
| | | 07/11/08 | Amgen and Ortho Biotech Settle Antitrust Suit| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 11, 2008--Amgen
(NASDAQ:AMGN) today announced that it has reached an agreement to
settle its outstanding antitrust litigation with Ortho Biotech
Products L.P. (Ortho Biotech). Ortho Biotech, a subsidiary of Johnson
& Johnson (NYSE: JNJ), had alleged that discounts offered to oncology
clinics on Amgen's Neupogen and Neulasta and Aranesp products violated
antitrust laws.
Under terms of the agreement, Amgen will pay Ortho Biotech $200
mil... |
| | | 07/10/08 | Amgen Commits to PhRMA's Enhanced Code on Interactions with Healthcare Professionals as Part of the Company's 'Clearly Amgen' Initiative| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 10, 2008--Amgen
(NASDAQ: AMGN) today announced its intent to comply with the
Pharmaceutical Research and Manufacturers of America's (PhRMA) revised
"Code on Interactions with U.S. Healthcare Professionals." The
company's announcement of its voluntary support for the Code is the
latest element of Clearly Amgen, the company's ongoing initiative to
provide clear communications about and easy access to Amgen's policies
and practices on ethical ... |
| | | 06/26/08 | New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)| Study Adds to Body of Evidence on KRAS Mutational Status As a
Predictive Biomarker of Vectibix Response
BARCELONA, Spain--(BUSINESS WIRE)--June 26, 2008--Amgen (NASDAQ:
AMGN) today announced updated results from the STEPP (Skin Toxicity
Evaluation Protocol with Panitumumab) trial, the first prospective
study to examine differences between preemptive and reactive skin
treatment for skin toxicities in metastatic colorectal cancer (mCRC)
patients receiving epidermal growth factor rec... |
| | | 06/18/08 | Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting| FDA Advisory Committee Recommends Enbrel(R) (etanercept) for the
Treatment of Children and Adolescents with Chronic Moderate to Severe
Plaque Psoriasis
THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--June
18, 2008--Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division
of Wyeth (NYSE: WYE), today issued the following statement on the
outcome of today's meeting of the U.S. Food and Drug Administration's
(FDA) Dermatologic and Ophthalmologic Drug Advisory Committee (... |
| | | 06/18/08 | Enbrel(R) (etanercept) Application for the Treatment of Pediatric Psoriasis to be Discussed at FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting| ENBREL Reviewed As Potential New Treatment Option for Children and
Adolescents with Chronic Moderate to Severe Plaque Psoriasis Who Have
Tried Another Therapy
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 18, 2008--Amgen
(NASDAQ:AMGN) announced that the supplemental Biologics License
Application (sBLA) for ENBREL for the treatment of pediatric patients
with chronic moderate to severe plaque psoriasis who have tried
another therapy will be discussed today at a meeting of the DODAC.
... |
| | | 06/15/08 | Romiplostim Data Show Potential Long-Term Efficacy and Safety in Adults with Chronic ITP| Results Show Romiplostim Increased and Sustained Platelet Counts
with Extended Treatment
COPENHAGEN, Denmark--(BUSINESS WIRE)--June 15, 2008--Amgen Inc.
(NASDAQ: AMGN) today announced updated results from the ongoing,
open-label extension study on the long-term safety and efficacy of
romiplostim in adult patients with chronic immune thrombocytopenic
purpura (ITP), a chronic and serious autoimmune disorder characterized
by low platelet counts in the blood. The updated results conti... |
| | | 06/09/08 | Amgen SVP of North American Commercial Operations James Daly to Present at the Goldman Sachs Healthcare Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 9, 2008--Amgen
(NASDAQ:AMGN) Senior Vice President of North American Commercial
Operations James Daly will present at the Goldman Sachs Healthcare
Conference on Wednesday, June 11, 2008 beginning at 8:40 a.m. Pacific
Time. Live audio of the presentation will be available over the
Internet and can be accessed from Amgen's Web site, www.amgen.com,
under Investors.
Information regarding presentation time, webcast availability, and
webcast... |
| | | 06/06/08 | Amgen Names Anna Richo Senior Vice President of Worldwide Compliance| THOUSAND OAKS, Calif., Jun 06, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced the appointment of Anna S.
Richo as senior vice president, Worldwide Compliance. Richo will head
the organization responsible for Amgen's corporate compliance and
business ethics programs. She will report to Amgen Chairman and Chief
Executive Officer Kevin Sharer.
Richo, 47, joined Amgen in 2003 and was most recently vice
president, Law, responsible for worldwide management of all corporate
litigati... |
| | | 06/05/08 | 2008 Recipients of Amgen Award for Science Teaching Excellence Announced| 32 Outstanding Science Teachers and Schools Recognized in Amgen
Communities Across the United States, Canada and Puerto Rico
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 5, 2008--Amgen
(NASDAQ:AMGN) today announced the 32 science teachers across the
United States (U.S.), Canada and Puerto Rico who are this year's
recipients of the Amgen Award for Science Teaching Excellence, a
program designed to recognize teachers in the K-12 grade levels in
public and private schools whose dedic... |
| | | 06/04/08 | Amgen and Wyeth Statement on the FDA Early Communication About Tumor Necrosis Factor (TNF) Blockers| THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa., Jun 04, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug
Administration (FDA) Early Communication regarding an ongoing safety
review of Tumor Necrosis Factor (TNF) blockers (marketed as Remicade,
Enbrel, Humira and Cimzia) and the possible association between the
use of these medicines and the development of lymphoma and other
cancers in chi... |
| | | 06/01/08 | Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy| Phase 2 Data Corroborate the Role of the KRAS Biomarker in
Advanced Colorectal Cancer
Abstract Numbers 4064, 4034, 4127
CHICAGO--(BUSINESS WIRE)--June 1, 2008--Amgen (NASDAQ:AMGN) today
announced updated interim pooled, blinded, safety results from two
Phase 3 trials evaluating Vectibix(R) (panitumumab) in combination
with standard chemotherapy in earlier lines of metastatic colorectal
cancer (mCRC). Updated data from these trials, as well as the first
prospective trial evalu... |
| | | 05/31/08 | Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients| Phase 2 Study of Patients Previously Treated with IV
Bisphosphonates Showed Denosumab Reduced Bone Resorption and
Skeletal-Related Events
Comparison of Phase 2 Studies Showed Consistent Reduction of Bone
Resorption with Denosumab in either Bisphosphonate-Naive or -Treated
Patients
Sub-group Analysis of Phase 3 Study Showed Denosumab Increased
Bone Mineral Density Throughout the Skeleton In Women With
Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Treatment
AB... |
| | | 05/31/08 | Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate| Giant Cell Tumor is a Rare Bone Tumor Afflicting Younger Adults For Which Few Treatment Options Exist ABSTRACT NUMBER: 10500CHICAGO, May 31, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced interim results of an
open-label Phase 2 study demonstrating a positive response rate to
administration of denosumab in subjects with recurrent or unresectable
giant cell tumor of bone. The study was presented at the 2008 American
Society of Clinical Oncology (ASCO) annual meeting.
Interim res... |
| | | 05/31/08 | Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline| Early Data from Apoptosis, Angiogenesis and Growth Regulation
Programs Suggest Biologic Activity in a Range of Tumor Types
Abstract Numbers 3570, 2051, 3583 and 3539
CHICAGO--(BUSINESS WIRE)--May 31, 2008--Amgen (NASDAQ:AMGN) today
announced interim results from four of the company's investigational
cancer agents. Data presented from trials with recombinant human (rh)
Apo2L/TRAIL, AMG 479, AMG 102 and motesanib alone, and in combination
with chemotherapy or other targeted agen... |
| | | 05/29/08 | Amgen to Webcast Investor Meeting at Upcoming American Society of Clinical Oncology Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 29, 2008--Amgen
(NASDAQ:AMGN) will webcast its investor meeting at the upcoming
American Society of Clinical Oncology (ASCO) Conference on Sunday,
June 1 at 8 p.m. Central Time. Members of Amgen's scientific and
management team will participate at the meeting. The company plans to
highlight key compounds in its pipeline, including denosumab.
Live audio of the presentation will be available over the Internet
and can be accessed from Amgen... |
| | | 05/28/08 | Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))| Phase 3 Study Showed Bone Mineral Density Gains at All Skeletal
Sites Measured with Denosumab Administration
BARCELONA, Spain--(BUSINESS WIRE)--May 28, 2008--Amgen (NASDAQ:
AMGN) today announced complete results from a head-to-head,
double-blind study comparing the effects of twice-yearly subcutaneous
injections of denosumab versus weekly oral doses of alendronate
(FOSAMAX(R)) on bone mineral density (BMD) in postmenopausal women
with low BMD. The results were presented during a l... |
| | | 05/27/08 | Amgen Announces Webcast to Discuss Results of denosumab Phase 3 Head-to-Head Study versus alendronate at the Upcoming European Symposium on Calcified Tissues Conference| THOUSAND OAKS, Calif., May 27, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced that it will hold a conference
call on Wednesday, May 28, 2008, beginning at 8 a.m. Eastern Time to
discuss the results of the denosumab Phase 3 head-to-head study versus
alendronate (the "141" study) at the upcoming European Symposium on
Calcified Tissues (ECTS) Conference in Barcelona, Spain. Speakers will
include the principal study investigator, Jacques P. Brown, M.D.,
Head, Division of Rheumatol... |
| | | 05/22/08 | Amgen Posts Medical Education and Foundation Grants and Donations as Part of the Company's 'Clearly Amgen' Initiative| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 22, 2008--Amgen
(NASDAQ: AMGN) today posted to the company's Web site grants and
donations made by the Amgen Medical Education department (AmgenMED)
and the Amgen Foundation. The posting is the latest element of Clearly
Amgen, a section of the Company's Web site designed to provide clear
and easy access to Amgen's policies and practices. Grants, donations
and charitable contributions will be updated quarterly along with a
brief description o... |
| | | 05/19/08 | Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study| Patients Transitioned from Alendronate to Denosumab Therapy
Achieved Superior Gains in Bone Mineral Density Versus Those
Continuing on Alendronate Therapy
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 19, 2008--Amgen
(NASDAQ: AMGN) today announced findings from a head-to-head,
double-blind trial comparing the effects of denosumab in
post-menopausal women with low bone mass transitioned from weekly
alendronate (FOSAMAX(R)) versus continued alendronate therapy on bone
mineral density... |
| | | 05/15/08 | Amgen Highlights Data to Be Presented at ASCO| New Data from Denosumab, Vectibix(R) and Mid-Stage Pipeline
Demonstrate Progress of Oncology Portfolio
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 15, 2008--Amgen
(NASDAQ:AMGN) today announced it will present new data from the
Company's oncology portfolio on both approved and investigational
cancer therapies at the 2008 American Society of Clinical Oncology
(ASCO) Annual Meeting that will be held in Chicago from May 30 to June
3, 2008.
"Denosumab, which targets the RANKL path... |
| | | 05/13/08 | Amgen VP of Investor Relations Arvind Sood to Present at the Baird Growth Stock Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 13, 2008--Amgen
(NASDAQ:AMGN) Vice President of Investor Relations Arvind Sood will
present at the RW Baird Growth Stock Conference on Wednesday, May 14,
2008 beginning at 8:55 a.m. Central Time. Live audio of the
presentation will be available over the Internet and can be accessed
from Amgen's Web site, www.amgen.com, under Investors.
Information regarding presentation time, webcast availability, and
webcast links are noted on Amgen's I... |
| | | 05/07/08 | Amgen Announces Voting Results of Annual Meeting of Stockholders| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 7, 2008--Amgen
(NASDAQ:AMGN), today announced results of voting at the company's
Annual Meeting of Stockholders, held at the Four Seasons Hotel
Westlake Village in Westlake Village, Calif. Approximately 86.9
percent of outstanding shares were represented at the meeting.
The director nominees David Baltimore, Frank J. Biondi, Jr., Jerry
D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer,
Gilbert S. Omenn, Judith C. Pelham... |
| | | 05/06/08 | Amgen to Participate in CHMP Oncology Scientific Advisory Group Meeting in May| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 6, 2008--Amgen
(NASDAQ:AMGN) today announced that the European Committee for
Medicinal Products for Human Use (CHMP) has requested Amgen and other
erythropoiesis-stimulating agent (ESA) marketing authorization holders
to participate in a closed meeting of the Scientific Advisory Group on
Oncology (SAG-O) on May 15.
The marketing authorization holders have been asked to provide an
overview on studies that have been initiated or conducted ... |
| | | 05/01/08 | Amgen to Participate in Dermatologic and Ophthalmic Drugs Advisory Committee Meeting in June| Company Is in Discussions with FDA About Enbrel(R) (etanercept) in
Pediatric Psoriasis
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 1, 2008--Amgen
(NASDAQ:AMGN) today announced that the U.S. Food and Drug
Administration (FDA) has asked the Company to participate in a meeting
of the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) on
June 18, 2008. The DODAC will review data supporting the supplemental
Biologic License Application (sBLA) submitted by Amgen for the use of... |
| | | 04/30/08 | Amgen CFO Bob Bradway to Present at the Morgan Stanley Global Healthcare Unplugged Conference| THOUSAND OAKS, Calif., Apr 30, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) Executive Vice President and CFO Bob Bradway
will present at the Morgan Stanley Global Healthcare Unplugged
Conference on Thursday, May 1, 2008 beginning at 10:00 a.m. Eastern
Time. Live audio of the presentation will be available over the
Internet and can be accessed from Amgen's Web site, www.amgen.com,
under Investors.
Information regarding presentation time, webcast availability, and
webcast links are noted on ... |
| | | 04/24/08 | Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12| First Quarter 2008 Revenue Decreased 2 percent to $3.6 Billion
First Quarter 2008 GAAP Earnings Per Share Increased 11 percent to $1.04THOUSAND OAKS, Calif., Apr 24, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS),
excluding stock option expense and certain other expenses, of $1.12
for the first quarter of 2008, an increase of 4 percent compared to
$1.08 for the first quarter of 2007. Adjusted net income, excluding
stock option expense and certain oth... |
| | | 04/16/08 | Amgen Announces Webcast of 2008 First Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 16, 2008--Amgen
(NASDAQ:AMGN) today announced that it plans to report its first
quarter financial results on Thursday, April 24, 2008 after the close
of the financial markets. The announcement will be followed by a
conference call with the investment community at 2 p.m. Pacific Time.
Participating in the call from Amgen will be Kevin Sharer, chairman
and chief executive officer, and other members of Amgen's senior
management team.
Liv... |
| | | 04/15/08 | Amgen Presents Preclinical and Clinical Data from Oncology Programs| Early Data Presented from Investigational Molecules that Target
Apoptosis and Growth Regulation Pathways
Abstract Numbers: 3162, 1326, 3999, 2804, 4001, 3994
SAN DIEGO--(BUSINESS WIRE)--April 15, 2008--Amgen (NASDAQ:AMGN)
today announced data generated by the company's robust oncology
research and development programs in the areas of apoptosis
(programmed cell death) and cell growth regulation. The data,
presented at the American Association for Cancer Research (AACR)
Annua... |
| | | 04/14/08 | Amgen Scientist Visits Los Angeles Classroom During Teach For America Week|
THOUSAND OAKS, Calif. (April 14, 2008) -- For the 13 million children growing up in poverty in this country today, disparities in educational outcomes will limit opportunities in life. This week, Dr. Joseph Miletich, senior vice president of Research and Development at Amgen, will be one of more than 150 distinguished guest teachers in classrooms across the nation participating in Teach For America Week, an annual event that raises awareness about the challenges facing students in low-i... |
| | | 04/13/08 | Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types| AMG 386 Preclinical Data Suggests Greater Reduction in Tumor
Growth when Angiopoietin 1/2 and VEGF Pathways are Both Inhibited
Abstract Numbers: 1113, 4887 and 5764
SAN DIEGO--(BUSINESS WIRE)--April 13, 2008--Amgen (NASDAQ:AMGN),
today announced results from preclinical studies suggesting a
significantly greater reduction in tumor growth when AMG 386, a
recombinant Fc-peptide fusion protein (peptibody) designed to bind
angiopoietins 1 and 2, thereby inhibiting Tie2 depende... |
| | | 04/11/08 | Amgen-Teach for America Summit to Focus on Strategies for Advancing Math and Science Education|
More Than 300 Leading Thinkers, Teach For America Corps Members and Alumni Expected at Second Annual Gathering
PALO ALTO, Calif., April 11, 2008--How will we improve math and science education in our country? What steps can we take to lay an early foundation for student success in these subject areas? How can we incorporate technology into the classroom to increase student achievement?
These are some of the questions on tap for the Amgen-Teach For America Mathematics and Science Su... |
| | | 04/08/08 | Amgen Statement on Romiplostim PDUFA Date| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 8, 2008--Amgen Inc.
(NASDAQ:AMGN) today issued the following statement on the Prescription
Drug User Fee Act (PDUFA) date for romiplostim.
"Amgen has received notification from the U.S. Food and Drug
Administration (FDA) that the action date for FDA's priority review of
Biologics License Application (BLA) for romiplostim for the treatment
of thrombocytopenia in adult patients with chronic immune
thrombocytopenic purpura (ITP) has been ... |
| | | 04/03/08 | Amgen's Oncology Pipeline Data Highlighted at Upcoming Scientific Meeting| Five Investigational Compounds from Robust Ongoing Clinical Trials
Program Target Novel Cancer Pathways
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2008--Amgen
(NASDAQ: AMGN) today announced that results from several preclinical
and clinical trials investigating cancer treatment will be presented
at the American Association for Cancer Research (AACR) Annual Meeting
2008 in San Diego between April 12-16, 2008. Data will be presented on
pipeline compounds: AMG 102, AMG 386, AMG... |
| | | 04/03/08 | National Kidney Foundation Introduces Plan to Track Patients in National Screening Program|
Data Will Inform Efforts to Fight Kidney Disease
Amgen Supports Initiative and Renews Primary Sponsorship of Kidney
Early Evaluation Program (KEEP)
DALLAS--(BUSINESS WIRE)--April 3, 2008--The National Kidney
Foundation and Amgen (NASDAQ:AMGN) today announced a new initiative of
the Kidney Early Evaluation Program (KEEP) that will provide important
data to help communities address the growing prevalence of chronic
kidney disease (CKD). The initiativ... |
| | | 04/02/08 | Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women| Overall Incidence of Adverse Events Similar Between Denosumab and
Placebo Groups
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 2, 2008--Amgen
(NASDAQ: AMGN) today announced the publication of results from its
24-month, 332-patient Phase 3 pivotal study in women with early and
late stage postmenopausal osteoporosis in the Journal of Clinical
Endocrinology and Metabolism.
In this Phase 3 study, twice-yearly subcutaneous injections of
denosumab increased bone mineral density (BM... |
| | | 03/17/08 | Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)| THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--March
17, 2008--Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division
of Wyeth (NYSE: WYE), today announced updates to the U.S. Food and
Drug Administration (FDA)-approved U.S. Prescribing Information (PI)
for Enbrel(R) (etanercept).
The U.S. PI now contains a boxed warning relating to the risk of
infections, including tuberculosis, which is similar to labeling for
other medicines in the tumor necrosis factor (TNF) i... |
| | | 03/14/08 | Amgen to Present at the 28th Annual Cowen Healthcare Conference and the 11th Annual Lehman Brothers Global Healthcare Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 14, 2008--Amgen
(NASDAQ:AMGN) will present at the 28th Annual Cowen Healthcare
Conference on Tuesday, March 18, 2008 at the Boston Marriott Copley
Place, Boston, Mass., beginning at 9:30 a.m. Eastern Time. Amgen will
also present at the 11th Annual Lehman Brothers Global Healthcare
Conference on Wednesday, March 19, 2008, at the Loews Miami Beach
Hotel in Miami, Fla., beginning at 8:00 a.m. Eastern Time. Amgen
Executive Vice President of R... |
| | | 03/13/08 | Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemotherapy at FDA ODAC Meeting| ESAs Provide Important Clinical Benefits to Cancer Patients With
Anemia Due to Chemotherapy; Ongoing and Planned Risk Management Will
Further Reduce Risks
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 13, 2008--Amgen Inc.
(NASDAQ: AMGN) will today present the benefits and risks of
Erythropoiesis-stimulating Agents (ESAs) in cancer patients with
anemia due to concomitantly administered chemotherapy at a meeting
with the U.S. Food and Drug Administration's (FDA) Oncologic Drugs
Adv... |
| | | 03/12/08 | Amgen Statement on Successful Outcome of Romiplostim Panel Meeting| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 12, 2008--Amgen Inc.
(NASDAQ:AMGN) today issued the following statement on the outcome of
the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory
Committee (ODAC) meeting on romiplostim, a investigational
thrombopoietin mimetic peptibody, for the treatment of
thrombocytopenia in adult patients with chronic immune (idiopathic)
thrombocytopenic purpura (ITP).
"We are pleased that the panel today recognized the importance o... |
| | | 03/12/08 | Amgen to Discuss Romiplostim Application at FDA ODAC Meeting| Orphan Drug Romiplostim Reviewed as Potential New Treatment Approach for Serious Bleeding Disorder
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 12, 2008--Amgen Inc.
(NASDAQ: AMGN) will discuss the proposed Biologic License Application
(BLA) for romiplostim, an investigational thrombopoietin mimetic
peptibody, for the treatment of thrombocytopenia in adult patients
with chronic immune (idiopathic) thrombocytopenic purpura (ITP) today
at the Oncologic Drugs Advisory Committee (ODAC)... |
| | | 03/07/08 | Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)| Revised Boxed Warning Applies to Oncology Indication for the Class of Approved ESAsTHOUSAND OAKS, Calif., Mar 07, 2008 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ:AMGN) today announced the U.S. Food and Drug
Administration (FDA) has approved updated safety information,
including an updated boxed warning in the labeling information for the
class of drugs known as erythropoiesis-stimulating agents (ESAs),
including Aranesp(R) (darbepoetin alfa) and EPOGEN(R) (Epoetin alfa).
The updated boxed warnin... |
| | | 03/05/08 | Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody| KW-0761 Studies Underway in Inflammation and Oncology
THOUSAND OAKS, Calif. & TOKYO--(BUSINESS WIRE)--March 5,
2008--Kyowa Hakko Kogyo Co., Ltd (Kyowa Hakko) (TSE: 4151) and Amgen
(NASDAQ: AMGN) today announced an agreement under which Amgen will
receive an exclusive license to develop and commercialize Kyowa
Hakko's humanized monoclonal antibody KW-0761 worldwide, except in
Japan, Korea, China and Taiwan. Kyowa Hakko will retain the
development and commercialization rights in th... |
| | | 03/05/08 | The Colon Cancer Alliance Teams up with Joan Lunden for Amgen Sponsored Workshop Series Designed to Provide Support to Patients and Caregivers| The 2nd Annual Workshop Program is Part of Education Effort Launched During March's Colorectal Cancer Awareness Month
WASHINGTON & THOUSAND OAKS, Calif., Mar 05, 2008 (BUSINESS WIRE) -- The Colon Cancer Alliance (CCA) and Amgen (NASDAQ:AMGN) today
announced that journalist and best-selling author, Joan Lunden, will
partner with the CCA for "Conversations about Colorectal Cancer," a
series of seminars focused on providing support and educational
resources for colorectal cancer patients an... |
| | | 03/05/08 | EU Commission Approves Updated Prescribing Information for Aranesp(R)| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 5, 2008--Amgen
(NASDAQ: AMGN) today announced that the European Commission reached
its final decision to amend the prescribing information for Aranesp(R)
(darbepoetin alfa) based on the positive opinion from the European
Committee for Medicinal Products for Human Use (CHMP) in January 2008.
The CHMP granted positive opinions for all centrally-authorized
Erythropoiesis Stimulating Agents (ESAs) in the European Union (EU),
each of which will... |
| | | 03/04/08 | KRAS Biomarker Analysis from Pivotal Vectibix(TM) Trial Published| Manuscript Data Delineate Potential Role of KRAS Oncogene in Patient Selection for Vectibix Treatment
THOUSAND OAKS, Calif., Mar 04, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ: AMGN) today announced that the results from a
biomarker analysis of the pivotal "408" trial were published in the
Journal of Clinical Oncology (JCO). The analysis showed that KRAS
mutations could be used to identify patients who may not respond to
treatment with Vectibix(TM) (panitumumab) monotherapy, the first fully
... |
| | | 02/04/08 | Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates| Amgen to Receive $200 Million Upfront Payment, $702 Million in Multi-year Global R&D Expense Sharing and Success-based Milestones, and Double Digit Royalties on Japan Sales; Takeda Will Receive Exclusive Rights to Develop and Commercialize Select Molecules in Japan Deal
Includes Global Partnership for Motesanib Diphosphate, which Provides Amgen with an Additional $100 Million Upfront Payment, $175 Million in Success- based Milestones for First 2 Indications, Double Digit Royalties on Japan ... |
| | | 02/01/08 | New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque Psoriasis| SAN ANTONIO, Texas--(BUSINESS WIRE)--Feb. 1, 2008--Amgen (NASDAQ:
AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE),
today announced findings from a retrospective analysis, which
demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of
inflammation, in patients with moderate to severe plaque psoriasis
following 12 weeks of treatment. Median reduction in CRP levels was 10
times greater in the ENBREL treated group compared to the placebo
treated group. These... |
| | | 01/31/08 | Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in The Lancet| THOUSAND OAKS, Calif., Jan 31, 2008 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ: AMGN) today announced data from two Phase 3
studies which evaluated the administration of Nplate(TM) (romiplostim)
on increasing and sustaining platelet counts in both splenectomized
(spleen removed) and non-splenectomized patients with chronic Immune
Thrombocytopenic Purpura (ITP). The data will be published in the Feb.
2, 2008, issue of The Lancet.
"Adult ITP is a serious chronic autoimmune disorder characterized
... |
| | | 01/28/08 | Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 28, 2008--Amgen
(NASDAQ:AMGN) issued the following statement on the publication of an
Aranesp(R) (darbepoetin alfa) manuscript in the January 28, 2008,
online issue of the Journal of Clinical Oncology. Amgen anticipates
this manuscript will be available in the March 1, 2008, print edition.
"The '103 Anemia of Cancer' study, a Phase 3 trial designed to
test whether anemic patients with active cancer not receiving
concurrent chemotherapy ... |
| | | 01/27/08 | Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy|
Emerging Data From Two Phase 3 Trials Exploring Vectibix in
Earlier Lines of Colorectal Cancer Treatment
ABSTRACT NUMBERS: 335, 443, 462
ORLANDO, Fla.--(BUSINESS WIRE)--Jan. 27, 2008--Amgen (NASDAQ:
AMGN) today announced interim pooled, blinded safety data from two
Phase 3 trials examining Vectibix(TM) (panitumumab) in combination
with chemotherapy in first- and second-lines of metastatic colorectal
cancer (mCRC) treatment. The respective independent Da... |
| | | 01/24/08 | Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))| THOUSAND OAKS, Calif., Jan 24, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced findings from a head-to-head,
double-blind study comparing the effects of twice-yearly subcutaneous
injections of denosumab versus weekly oral doses of alendronate
(FOSAMAX(R)) on bone mineral density (BMD) in postmenopausal women
with low bone mineral density. The study met primary and all secondary
endpoints.
In this one-year, non-pivotal study, denosumab treatment achieved
significantly greater B... |
| | | 01/24/08 | Amgen's Fourth Quarter 2007 Adjusted Earnings Per Share (EPS) Increased 11 Percent to $1.00; Full Year 2007 Adjusted EPS Increased 10 Percent to $4.29| Fourth Quarter 2007 Revenue Decreased 2 Percent to $3.7 Billion; Full Year 2007 Revenue Increased 4 Percent to $14.8 Billion
Fourth Quarter 2007 GAAP EPS Increased 7 Percent to $0.76; Full Year 2007 GAAP EPS Increased 14 Percent to $2.82
2008 Total Revenue Expected to be in the Range of $14.2 to $14.6 Billion
2008 Adjusted EPS Expected to be in the Range of $4.00 to $4.30
THOUSAND OAKS, Calif., Jan 24, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) reported adjusted EPS, excluding stock op... |
| | | 01/24/08 | KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients| Data Presented at ASCO GI Further Validate KRAS as a Potential Patient Selection Biomarker for Vectibix Monotherapy ABSTRACT NUMBER: 278ORLANDO, Fla., Jan 24, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ: AMGN) today announced the results of a biomarker
analysis which indicated that in metastatic colorectal cancer (mCRC)
patients who have failed all other chemotherapeutic regimens, the
efficacy of Vectibix(TM) (panitumumab) monotherapy is confined to
patients with non-mutated (wild-type) KRAS tumor... |
| | | 01/17/08 | Amgen Commences Registered Exchange Offer for Its Senior Floating Rate Notes Due 2008, 5.85 Percent Senior Notes Due 2017 and 6.375 Percent Senior Notes Due 2037| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 17, 2008--Amgen
(NASDAQ:AMGN) today announced offers to exchange (1) any and all of
its $2,000,000,000 Senior Floating Rate Notes due 2008 for an equal
amount of new Senior Floating Rate Notes due 2008, (2) any and all of
its $1,100,000,000 5.85 percent Senior Notes due 2017 for an equal
amount of new 5.85 percent Senior Notes due 2017, and (3) any and all
of its $900,000,000 6.375 percent Senior Notes due 2037 for an equal
amount of new 6.... |
| | | 01/16/08 | New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents| Study Published in The New England Journal of MedicineTHOUSAND OAKS, Calif. & COLLEGEVILLE, Pa., Jan 16, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE), today announced data from a Phase 3 study which
showed that children and adolescents with moderate to severe plaque
psoriasis who received treatment with ENBREL experienced significant
improvements in the signs and symptoms of their disease. This study
will be published in the Jan. 17... |
| | | 01/16/08 | Amgen Announces Webcast of 2007 Fourth Quarter and Full Year Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 16, 2008--Amgen
(NASDAQ:AMGN) today announced that it plans to report its fourth
quarter and full year financial results on Thursday, Jan. 24, 2008
after the close of the financial markets. The announcement will be
followed by a conference call with the investment community at 2 p.m.
Pacific Time. Participating in the call from Amgen will be Kevin
Sharer, chairman and chief executive officer, and other members of
Amgen's senior management t... |
| | | 01/10/08 | Breakaway from Cancer Public Service Announcement Spreads Support and Hope|
Patrick Dempsey Delivers Inspirational Message
THOUSAND OAKS, CA (January 10, 2008) -- In an ongoing effort to raise awareness and support for free services and programs that help people affected by cancer, Amgen today announced television and film actor Patrick Dempsey appears in a public service announcement supporting the Breakaway from Cancer(TM) initiative.
Amgen created Breakaway from Cancer in 2005 as a complementary component to its sponsorship of the Amgen Tour of Califor... |
| | | 01/08/08 | Amgen Updates 2007 Adjusted EPS Guidance and Outlines 2008 Expense Outlook at the JP Morgan Healthcare Conference| THOUSAND OAKS, Calif., Jan 08, 2008 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) Chairman and Chief Executive Officer Kevin
Sharer in a presentation to investors at today's JP Morgan Healthcare
Conference, said that, despite regulatory and reimbursement changes
affecting sales of Erythropoiesis Stimulating Agent (ESA) products,
the Company expects 2007 adjusted earnings per share (EPS) to be above
its previously announced (Oct. 24, 2007) guidance range of $4.13 -
$4.23, and close to the low end ... |
| | | 01/04/08 | Amgen to Present at the 26th Annual JP Morgan Healthcare Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 4, 2008--Amgen
(NASDAQ:AMGN) will participate in the 26th Annual JP Morgan Global
Healthcare Conference on Tuesday, Jan. 8, 2008, at the Westin St.
Francis in San Francisco, Calif., beginning at 7:30 a.m. Pacific Time.
Amgen Chairman and CEO Kevin Sharer will present at the conference.
Live audio of the presentation will be available over the Internet and
can be accessed from Amgen's Web site, www.amgen.com, under Investors.
Information... |
| | | 12/14/07 | Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy| A Study Evaluating Twice Yearly Dosing with Denosumab Met All
Primary and Secondary Endpoints
SAN ANTONIO--(BUSINESS WIRE)--Dec. 14, 2007--Amgen (NASDAQ:AMGN)
today announced results of the first Phase 3 pivotal study to complete
in the denosumab oncology development program. The study evaluated
denosumab's effect on bone density across the skeleton in women with
non-metastatic breast cancer who were receiving adjuvant Aromatase
Inhibitor (AI) Therapy. These r... |
| | | 12/10/07 | Pivotal Phase 3 Nplate(TM) Study in Non-Splenectomized Patients Met Primary Endpoints| Data Also Shows Potential of Nplate as a Long-term Treatment
Option for Chronic Adult Immune Thrombocytopenia Purpura
ATLANTA--(BUSINESS WIRE)--Dec. 10, 2007--Amgen Inc. (NASDAQ:AMGN)
today announced results from a second randomized, pivotal Phase 3
study where Nplate(TM) (romiplostim) increased and sustained platelet
counts in non-splenectomized (spleen not removed) adult patients with
chronic Immune Thrombocytopenic Purpura (ITP). Additionally,
Nplate-treated patients takin... |
| | | 12/08/07 | Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints| Data Show Romiplostim Increased and Sustained Platelet Counts in Splenectomized Adult Patients with Immune Thrombocytopenic Purpura
ATLANTA--(BUSINESS WIRE)--Dec. 8, 2007--Amgen Inc. (NASDAQ:AMGN)
today announced results from a randomized, pivotal Phase 3 study that
showed romiplostim (AMG 531) increased and sustained platelet counts
in splenectomized (spleen removed) adult patients with chronic Immune
Thrombocytopenic Purpura (ITP). Additionally, romiplostim-treated
patients takin... |
| | | 12/06/07 | Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs| Revised ESA Labeling to be Based on New Data from PREPARE and GOG
Studies
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 6, 2007--Amgen Inc.
(NASDAQ:AMGN) today announced the company is in discussions with the
U.S. Food and Drug Administration (FDA) with the goal of updating
safety information in all erythropoiesis-stimulating agents (ESAs)
labeling based on safety data from the recently announced PREPARE
interim study results in neoadjuvant breast cancer and... |
| | | 12/05/07 | Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer| Clinically Relevant Biomarker Provides Physicians With the Ability
to Predict the Patients Most Likely to Respond to Vectibix Treatment
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 5, 2007--Amgen
(NASDAQ: AMGN) today announced that the European Commission has
granted a conditional marketing authorization for Vectibix(R)
(panitumumab) as monotherapy for the treatment of patients with
epidermal growth factor receptor (EGFr) expressing metastatic
colorectal cancer (mCRC) with non-mu... |
| | | 12/04/07 | Amgen Foundation and Leading Universities Invite College Students to Apply for Amgen Scholars Program |
Hands-On Science Program Places Students in the Lab With Faculty Members for Intensive Research Experience
THOUSAND OAKS, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Amgen Scholars Program, a partnership of the Amgen Foundation, Massachusetts Institute of Technology (MIT) and premier universities around the country, is now accepting applications for the summer of 2008. The annual Amgen Scholars Program provides undergraduates the opportunity for hands-on research at 10 of the... |
| | | 11/30/07 | Amgen Announces Interim Results of Aranesp(R) ''PREPARE'' Study in Breast Cancer Patients| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 30, 2007--Amgen, Inc.
(NASDAQ: AMGN) today announced that it had received interim results
from the independent investigator-sponsored "PREPARE" study, an
open-label, randomized, multicenter Phase 3 study of Aranesp(R)
(darbepoetin alfa) in 733 neoadjuvant breast cancer patients receiving
dose-dense, dose-intense preoperative chemotherapy compared to a
standard preoperative chemotherapy regimen.
Initiated in 2002, the PREPARE study was d... |
| | | 11/15/07 | Amgen Announces ``My Cancer Coach'' Contest Winners at the College Hoops Classic| College Hoops Classic Benefits Coaches vs. Cancer, an Initiative
Supporting Cancer Patients
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 15, 2007--Amgen
(NASDAQ:AMGN) today announced the results of a contest designed for
cancer survivors to honor and thank their "cancer coach" -- the
spouse, family member or friend who played a crucial role in helping
them with the battle through cancer treatment. The contest, supported
by Amgen Oncology, in which applicants nom... |
| | | 11/08/07 | Amgen to Provide New Evidence as Part of a Formal Reconsideration of CMS' National Coverage Determination on ESAs| Revised Class Labeling and Data on Increased Transfusions are Part
of the Growing New Evidence to Revise the Policy
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 8, 2007--Amgen
(NASDAQ:AMGN) today announced its intention to submit new evidence to
the Centers for Medicare and Medicaid Services (CMS) to support a
reconsideration of the agency's National Coverage Determination (NCD)
on Erythropoiesis Stimulating Agents (ESAs). The Company plans to file
its request shortly.... |
| | | 11/08/07 | Amgen Announces Updates to the U.S. Prescribing Information for ESAs|
Revised Class Labeling Based on Data Discussed at the May 2007
ODAC and September 2007 CRDAC Meetings
Six Additional Studies Added to Current Pharmacovigilance Program
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 8, 2007--Amgen
(NASDAQ:AMGN) today announced that it has updated the Aranesp(R)
(darbepoetin alfa) and EPOGEN(R)/PROCRIT(R) (Epoetin alfa) package
inserts in collaboration with the U.S. Food and Drug Administration
(FDA) and Johnson and Jo... |
| | | 11/07/07 | New Data Show That Half of Patients with Active Early Rheumatoid Arthritis Achieved Clinical Remission at One Year When Treated with Enbrel(R) (etanercept) Plus Methotrexate| Clinical Trial Data Demonstrate Benefits of Early Treatment in
Patients with Moderate to Severe Rheumatoid Arthritis
BOSTON--(BUSINESS WIRE)--Nov. 7, 2007--Amgen (NASDAQ:AMGN) and
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today announced
that data from a multicenter, randomized, double-blind trial of ENBREL
plus methotrexate showed that 50 percent of patients with active early
rheumatoid arthritis achieved clinical remission at one year. In
contrast, 28 percent... |
| | | 11/01/07 | Call for Applications: The Amgen Award for Science Teaching Excellence| 32 Outstanding Teachers Will Be Recognized in Communities Where
Amgen Operates
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 1, 2007--Amgen
(NASDAQ:AMGN) today announced that it now invites applications for its
17th annual Amgen Award for Science Teaching Excellence. This award is
designed to recognize and honor extraordinary science teachers at the
K-12 level, who significantly impact their students through exemplary
science teaching and who achieve dem... |
| | | 10/25/07 | Amgen Foundation Donates $500,000 To Aid In Southern California Wildfire Relief Efforts|
THOUSAND OAKS, Calif. (Oct. 25, 2007) -The Amgen Foundation today announced that it is providing cash contributions totaling $500,000 to support those affected by the devastating fires throughout Southern California and has established a company-wide disaster relief program.
The After-the-Fires Fund at the San Diego Foundation and the Southern California Wildfire Relief Fund at the California Community Foundation will each receive $150,000. Direct Relief International and the American ... |
| | | 10/24/07 | Amgen's Third Quarter 2007 Adjusted Earnings Per Share Increased 4 Percent to $1.08|
Third Quarter 2007 Revenue Remained Unchanged at $3.6 Billion;
Anemia Franchise Product Sales Decreased 16 Percent
Third Quarter 2007 GAAP Earnings Per Share of $0.18 Reflect $1.0
Billion in Charges Primarily Related to the Write-Off of In-Process
R&D from the Alantos and Ilypsa Acquisitions and Restructuring
Activities
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 24, 2007--Amgen
(NASDAQ:AMGN) reported adjusted earnin... |
| | | 10/23/07 | Jury Rules Roche Infringes Amgen's EPO Patents| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 23, 2007--Amgen
(NASDAQ:AMGN) announced today that a jury in the U.S. Federal District
Court in Boston ruled that Roche's pegylated-erythropoietin (peg-EPO)
product MIRCERA infringes 11 Amgen EPO patent claims.
Amgen is pleased with the jury's verdict and will now seek an
injunction to prevent Roche from commercializing its peg-EPO product
in the United States in violation of Amgen's affirmed patent rights.
The injunction hearing is sch... |
| | | 10/16/07 | Amgen Announces Webcast of 2007 Third Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 16, 2007--Amgen
(NASDAQ:AMGN) today announced that it plans to report its third
quarter financial results on Wednesday, Oct. 24, 2007 after the close
of the financial markets. The announcement will be followed by a
conference call with the investment community at 2 p.m. Pacific Time.
Participating in the call from Amgen will be Kevin Sharer, chairman
and chief executive officer, and other members of Amgen's senior
management team.
Live... |
| | | 10/04/07 | Amgen and Dompe Biotec to Combine Commercial Operations in Italy| Single Company for Amgen Products in New Arrangement
ZUG, Switzerland. (Oct. 4, 2007) -- Amgen, the world's largest biotechnology company and Dompe Biotec, S.p.A., its co-marketing partner in Italy, announced today that they have agreed to combine their current commercial operations with respect to Amgen products under a single company to be called Amgen-Dompe S.p.A.
Based in Milan, Amgen-Dompe will be organised as an Amgen affiliate and comprise current Amgen and Dompe staff plus curre... |
| | | 10/03/07 | Amgen to Postpone Indefinitely Its Plans for a Manufacturing Facility in Ireland| CORK, IRELAND (Oct. 3, 2007) Amgen today announced that following an updated review of its business plans, concurrent with an evolving business environment, the company has decided to postpone indefinitely its planned design and build-out of a bulk manufacturing facility in County Cork. Amgen expects to maintain ownership of the site property in cooperation with Irish authorities.
Amgen will cease all current activities on the site in cooperation with the Irish Government and its agenc... |
| | | 10/02/07 | Amgen Appoints Vance D. Coffman to the Company's Board of Directors| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 2, 2007--Amgen
(NASDAQ:AMGN) announced today that its Board of Directors has
appointed Vance D. Coffman to the Company's Board. Coffman, 63, is the
former chairman and chief executive officer of Lockheed Martin
Corporation. The addition of Coffman brings the number of Amgen Board
members to 11.
Coffman was elected chairman of Lockheed in April 1998, having
served as CEO and vice chairman since August 1997. Previously, he
served in a nu... |
| | | 09/28/07 | Amgen Provides Update on Late-Stage and Early-Stage Pipeline at UBS Global Life Sciences Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 28, 2007--Amgen
(NASDAQ:AMGN), provided investors with an update on the company's
late-stage and early-stage pipeline during the previously webcast UBS
Global Life Sciences Conference in New York on Sept. 27, 2007. Roger
M. Perlmutter, M.D., Ph.D., executive vice president of Research and
Development, represented Amgen for the first time at a major investor
conference this year; his presentation coincided with the publication
of key Amgen ... |
| | | 09/28/07 | Aranesp(R) (darbepoetin alfa) Approved for Use in All European Paediatric Patients with Chronic Renal Failure Anaemia| European Commission Expands Aranesp Indication to Include All Paediatric Patients
ZUG, Switzerland (Sept. 28, 2007) - Amgen (Europe) GmbH today announced that the European Commission has approved Aranesp(R) (darbepoetin alfa) for the treatment of anaemia associated with chronic renal failure (CRF), also known as chronic kidney disease (CKD), in all European paediatric patients on dialysis or not on dialysis. For patients with CRF, Aranesp was previously indicated for the treatment of adults ... |
| | | 09/27/07 | Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R)| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 27, 2007--Amgen
(NASDAQ:AMGN) today announced that the European Medicines Agency's
(EMEA) Committee for Medicinal Products for Human Use (CHMP) has
communicated to Marketing Authorization Holders (MAHs) of epoetins a
proposal for amending prescribing information for Erythropoiesis
Stimulating Agents (ESAs) in the European Union, including Aranesp(R)
(darbepoetin alfa).
The CHMP's proposal includes:
-- Amending the Summar... |
| | | 09/26/07 | Phase 2 Study Suggests That Extended Dosing of Aranesp(R) is as Efficacious as Weekly Dosing| Aranesp Combined Patient Level Analyses Provide Additional
Evidence of Efficacy and Safety
BARCELONA, Spain--(BUSINESS WIRE)--Sept. 26, 2007--Amgen
(NASDAQ:AMGN) today announced data from a Phase 2, randomized,
multicenter, open-label study that suggest extended dosing of
Aranesp(R) (darbepoetin alfa) paired with chemotherapy treatment
(every two or every three weeks depending on chemotherapy regimen)
appeared to be efficacious with respect to changes in hemoglobin (Hb),
with n... |
| | | 09/26/07 | New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice| BARCELONA, Spain--(BUSINESS WIRE)--Sept. 26, 2007--Amgen
(NASDAQ:AMGN) today announced results from an integrated analysis
showing primary prophylactic use of Neulasta(R) (pegfilgrastim), a
granulocyte colony stimulating factor (G-CSF), with unique
neutrophil-mediated clearance, decreased febrile-neutropenia (FN)
hospitalizations by more than half (4 percent vs. 10 percent) when
compared to current practice neutropenia management and reduced
chemotherapy dose reductions by nearly two-... |
| | | 09/25/07 | New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response| Biomarker Analysis from Randomized, Controlled Trial Represents an
Advance in the Science of Anti-EGFR Therapy in Metastatic Colorectal Cancer
BARCELONA, Spain--(BUSINESS WIRE)--Sept. 25, 2007--Amgen (NASDAQ:
AMGN) today announced the results of a biomarker analysis that
supports KRAS as a predictive clinical biomarker that could be used to
select patients who are more likely to respond to treatment with
Vectibix(TM) (panitumumab) monotherapy.
These da... |
| | | 09/25/07 | Aranesp(R) DAHANCA 10 Study Results Presented at ECCO Annual Meeting| BARCELONA, Spain--(BUSINESS WIRE)--Sept. 25, 2007--Amgen
(NASDAQ:AMGN) today announced the analysis of the Aranesp(R)
(darbepoetin alfa) Danish Head and Neck Cancer (DAHANCA) 10 study
presented by investigators from the DAHANCA study group in the
Presidential Session at the 14th European Cancer Conference (ECCO) in
Barcelona, Spain. As previously communicated, the trial was stopped on
Nov. 28, 2006, due to futility following an interim analysis, which
showed low likelihood that the Ar... |
| | | 09/21/07 | Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union| Opinion Based on Positive Benefit / Risk Assessment in Patients
with Metastatic Colorectal Cancer with Non-Mutated KRAS
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 21, 2007--Amgen
(NASDAQ:AMGN) today announced that the European Committee for
Medicinal Products for Human Use (CHMP) has issued a positive opinion
recommending a conditional marketing authorization for Vectibix(TM)
(panitumumab) in the European Union (EU) for patients with refractory
metastatic colorectal canc... |
| | | 09/21/07 | Amgen Oncology Highlights Upcoming Data Presentations at the 2007 European Conference on Clinical Oncology| New Data on Targeted and Supportive Care Cancer Therapies
Underscores Amgen's Commitment to Patients
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 21, 2007--Amgen
(NASDAQ:AMGN), today announced several presentations of interest
featuring its portfolio of supportive care, and therapeutic agents
being highlighted at the 14th European Conference on Clinical Oncology
(ECCO) to be held in Barcelona, Spain, between Sept. 23 - 27, 2007.
Clinical data from an extended do... |
| | | 09/11/07 | Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee| Company Recommends Hemoglobin Target of 10-12 g/dL as Risk Management Approach
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 11, 2007--Amgen
(NASDAQ:AMGN) is presenting data today on the appropriate use of
Erythropoiesis Stimulating Agents (ESAs) in Chronic Renal Failure
(CRF) patients to a joint meeting of U.S. Food and Drug Administration
(FDA) advisory committees.
Amgen's presentation reviews data demonstrating that ESAs are safe
when used appropriately and explains the critica... |
| | | 09/06/07 | Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer| Amgen Oncology Presents New Lung Cancer Data for AMG 706 in
Combination with Chemotherapy and Vectibix(TM)
SEOUL, Korea--(BUSINESS WIRE)--Sept. 6, 2007--Amgen (NASDAQ:AMGN)
presented the results from a randomized, double-blind,
placebo-controlled Phase 3 study evaluating the efficacy and safety of
Aranesp(R) (darbepoetin alfa) in previously untreated patients with
extensive-stage small-cell lung cancer (SCLC) receiving chemotherapy
("the 145 study") on Monday, Sept. 3 at... |
| | | 09/05/07 | Amgen Foundation Awards Grant to Mentor LA to Help Improve Public High School Education in Los Angeles| LOS ANGELES and THOUSAND OAKS, Calif. - September 5, 2007 - Mentor LA (MLA) and the Amgen Foundation today announced the launch of a three-year partnership to improve education in South Los Angeles. The Amgen Foundation grant of $4 million over three years will assist MLA in advancing a new model of high performance public schooling, one where the public and private sector work together through a shared leadership structure to create successful high schools.
"We believe that we can leverag... |
| | | 08/28/07 | Court Rules That Roche Infringes One of Amgen's Erythropoietin Patents| Summary Judgment of Infringement Granted on Amgen '422 Patent; Court Also Rules in Amgen's Favor on Certain Defenses Raised by Roche Case Proceeds to Trial on Remaining Issues September 4, 2007 THOUSAND OAKS, Calif., Aug 28, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced that the U.S. Federal District
Court in Boston granted Amgen's motion for summary judgment and ruled
that Roche's pegylated-erythropoietin ("peg-EPO") product will
infringe Amgen's EPO pharmaceutical composit... |
| | | 08/15/07 | Amgen Restructures Due to Lower Aranesp(R) Revenues While Continuing to Invest in Innovation and Future Growth|
Expects to Reduce Staff by 12-14 Percent
Pre-Tax Restructuring Charges of $600 Million - $700 Million
Anticipated
Changes Adjusted Earnings Guidance for 2007 from $4.28 to a Range
of $4.13 - $4.23 Per Share
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 15, 2007--Amgen
(NASDAQ: AMGN) today announced initiatives that will reduce company
staff by 12-14 percent and deliver other operational efficiencies
w... |
| | | 08/15/07 | Amgen to Hold Conference Call Today after the Close of Financial Markets| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 15, 2007--Amgen
(NASDAQ:AMGN) will hold a conference call with the investment
community at 2 p.m. Pacific Time today, Aug. 15, 2007. Participating
in the call from Amgen will be Kevin Sharer, chairman and chief
executive officer, and other members of Amgen's senior management
team.
Live audio of the conference call will be simultaneously broadcast
over the Internet and will be available to members of the news media,
investors and the g... |
| | | 08/07/07 | First Year Amgen Scholars and Leading Scientists Attend Symposium to Explore Drug Discovery & Development| Symposium is a Component of a Rigorous Research Program Providing Hands-On Science Experience
THOUSAND OAKS, Calif. and CAMBRIDGE, Mass. - Aug. 7, 2007 - The Amgen Foundation in collaboration with Massachusetts Institute of Technology (MIT) recently hosted the first Amgen Scholars Program National Symposium in Lake Tahoe, Calif. The Amgen Scholars program, a $25 million, eight-year initiative, provides undergraduates from across the country the opportunity for hands-on research at 10 of the ... |
| | | 08/01/07 | Dennis Fenton, Executive Vice President of Operations, Elects to Retire after 25 Years with Amgen|
One of the First Staff Members, Fenton Helped Build the World's
Most Reliable and Efficient Biotechnology Manufacturing Operation
Fabrizio Bonanni, Senior Vice President of Manufacturing, Has Been
Selected to Succeed Fenton
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 1, 2007--Amgen
(NASDAQ: AMGN) today announced that Dennis Fenton, executive vice
president of Operations, has elected to retire at the end of 2007,
after 25 years with the co... |
| | | 07/31/07 | Amgen Responds to Final CMS National Coverage Determination on Use of Erythropoiesis-Stimulating Agents in Oncology| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 31, 2007--Amgen
(NASDAQ:AMGN) today announced its response to the Centers for Medicare
and Medicaid Services' (CMS) final National Coverage Determination
(NCD) on the use of erythropoiesis-stimulating agents (ESAs) in cancer
and related neoplastic conditions. Based on Amgen's preliminary
review, it appears that CMS has adopted a policy that will limit the
availability of these vital medicines to Medicare beneficiaries with
cancer. While the... |
| | | 07/26/07 | Amgen's Second Quarter 2007 Adjusted Earnings Per Share Increased 7 Percent to $1.12|
Second Quarter 2007 Revenue Increased 3 Percent to $3.7 Billion;
Anemia Franchise Product Sales Decreased 6 Percent
Denosumab Meets All Endpoints in a Pivotal Phase 3 Trial
Second Quarter 2007 GAAP Earnings Per Share Increased to $0.90
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 26, 2007--Amgen
(NASDAQ: AMGN) reported adjusted earnings per share (EPS), excluding
stock option expense and certain other expenses, of $1.12 for the
second quarter of 2007, ... |
| | | 07/18/07 | Amgen Completes Acquisition of Ilypsa| Acquisition of Late-Stage Selective Phosphate Binder
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 18, 2007--Amgen
(NASDAQ:AMGN) announced today the completion of its acquisition of
Ilypsa, a private company developing non-absorbed drugs for renal
disorders. The transaction provides Amgen with a late-stage phosphate
binder for the treatment of hyperphosphatemia in chronic kidney
disease (CKD) patients on hemodialysis. The acquisition was originally
announced June 4.
About Amge... |
| | | 07/16/07 | Amgen Completes Acquisition of Alantos| Acquisition of Dipeptidyl Peptidase IV Inhibitor for Treatment of Type II Diabetes and Matrix Metalloproteinases Platform for OsteoarthritisTHOUSAND OAKS, Calif., Jul 16, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced the completion of its
acquisition of Alantos, a private company developing drugs for the
treatment of diabetes and inflammatory diseases. The transaction
provides Amgen with Alantos's DPP-IV inhibitor in clinical development
(Phase 2a) for the treatment of type II ... |
| | | 07/12/07 | Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 12, 2007--Amgen
(NASDAQ:AMGN) today announced that its board of directors has
authorized additional repurchases of up to $5 billion in Amgen common
stock. The company currently has $1.5 billion remaining under its
previous stock repurchase authorization. This new authorization
reflects Amgen's confidence in its long-term prospects.
About Amgen
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pio... |
| | | 07/11/07 | Amgen and Daiichi Sankyo Announce Agreement for Denosumab in Japan| Amgen Grants Daiichi Sankyo Exclusive Rights to Develop and
Commercialize Denosumab in Japan
THOUSAND OAKS, Calif. & TOKYO--(BUSINESS WIRE)--July 11,
2007--Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited
(TOKYO:4568) today announced a collaboration and license agreement for
the development and commercialization of denosumab in Japan. Denosumab
is a fully human monoclonal antibody that targets RANK Ligand (an
essential mediator of cells that break down bone) ... |
| | | 07/11/07 | Amgen Announces Webcast of 2007 Second Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 11, 2007--Amgen
(NASDAQ:AMGN) today announced that it plans to report its second
quarter financial results on Thursday, July 26, 2007 after the close
of the financial markets. The announcement will be followed by a
conference call with the investment community at 2 p.m. Pacific Time.
Participating in the call from Amgen will be Kevin Sharer, chairman
and CEO, and other members of Amgen's senior management team.
Live audio of the confere... |
| | | 06/28/07 | Ralph Lauren Center for Cancer Care and Prevention Receives $2.5 Million from the Amgen Foundation to Launch National Patient Navigation Training Institute | New Institute Will Provide Training for Patient Navigators Across the Country to Help Ensure Cancer Patients Receive Access to Quality Healthcare
NEW YORK & THOUSAND OAKS, Calif.--(BUSINESS WIRE)--The Ralph Lauren Center for Cancer Care and Prevention and the Amgen Foundation today announced the launch of the Harold P. Freeman Patient Navigation Training Institute. Made possible by a generous $2.5 million leadership grant over three years from the Amgen Foundation, the Institute will provid... |
| | | 06/26/07 | Amgen Submits Testimony to House Ways & Means Committee|
Amgen Cites Evidence that Majority of EPOGEN(R) Use Has Been
Appropriate Over Time and Shares New Data Showing More Conservative
Dosing in Response to Updated CMS Policy and Product Labeling
Company Says Data Shows No Compelling Rationale for Congress to
Mandate Untested Changes to Payment System
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 26, 2007--Amgen
(NASDAQ:AMGN) today submitted testimony for the record of the House
Ways & Means Subcommittee... |
| | | 06/13/07 | ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR| THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--June
13, 2007--Amgen (NASDAQ:AMGN) and Wyeth Pharmaceuticals, a division of
Wyeth (NYSE:WYE), today announced the presentation of additional data
that showed that the safety profile of Enbrel(R) (etanercept) was
maintained with long-term use in patients with moderate-to-severe
juvenile rheumatoid arthritis (JRA) who completed up to eight years of
therapy. JRA is a chronic autoimmune disease of childhood that is
sometimes diff... |
| | | 06/06/07 | Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts|
Acquisition Will Provide Amgen with a Clinical Stage Dipeptidyl
Peptidase IV Inhibitor for the Treatment of Type II Diabetes and a
Matrix Metalloproteinases Platform for Osteoarthritis
THOUSAND OAKS, Calif., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--June
6, 2007--Amgen (NASDAQ:AMGN) announced today that it has agreed to
acquire Alantos, a private company developing drugs for the treatment
of diabetes and inflammatory diseases. Alantos' lead drug candidate,
ALS 2-0426, is... |
| | | 06/04/07 | Amgen to Acquire Ilypsa, a Private San Francisco Bay Area Biotechnology Company Focused on Kidney Disease Care| Acquisition Provides Nephrology Leader Amgen With A Late-Stage
Selective Phosphate Binder For The Treatment of Hyperphosphatemia in
Chronic Kidney Disease Patients
THOUSAND OAKS, Calif. & SANTA CLARA, Calif.--(BUSINESS WIRE)--June
4, 2007--Amgen (NASDAQ:AMGN) announced today that it has agreed to
acquire Ilypsa, a private company developing non-absorbed drugs for
renal disorders. Ilypsa's lead drug candidate, ILY101, is a phosphate
binder for the treatment of hype... |
| | | 06/02/07 | Amgen Submits Comments in Response to CMS' Proposed National Coverage Decision| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 2, 2007--Amgen
(NASDAQ:AMGN) today posted to its corporate Web site comments in
response to the Center for Medicare and Medicaid Services' (CMS)
Proposed Decision Memorandum (PDM) for Erythropoiesis Stimulating
Agents (ESAs) for Non-Renal Disease Indications released on May 14,
2007. CMS has stated that a public comment period on the proposed
National Coverage Determination (NCD) will end on June 13, 2007 with a
final policy expected to be ... |
| | | 05/29/07 | Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting| Clinical Data to be Presented on Seven Investigational Targeted and Supportive Care Cancer Therapies from Oncology Pipeline
THOUSAND OAKS, Calif., May 29, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), today announced upcoming data presentations
of interest at the 43rd Annual American Society of Clinical Oncology
(ASCO) Meeting in Chicago.
Clinical data will be presented on seven investigational
therapies: AMG 531 in thrombocytopenic patients with myelodysplastic
syndrome (MDS), motesanib... |
| | | 05/25/07 | Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab)| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 25, 2007--Amgen
(NASDAQ:AMGN) today issued the following statement:
Amgen has received notice from the European Medicines Agency
(EMEA) that the European Committee for Medicinal Products for Human
Use (CHMP) has adopted a negative opinion for Amgen's marketing
authorization application (MAA) for Vectibix(TM) (panitumumab) for
patients with metastatic colorectal cancer (mCRC) who have failed
chemotherapy.
In accordance with European ... |
| | | 05/24/07 | Amgen Prices $4 Billion of Senior Notes in Three Series; Company to Purchase Approximately $3 Billion in Common Stock| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 24, 2007--Amgen
(NASDAQ:AMGN) today announced the pricing of $1.1 billion principal
amount of 5.85 percent Senior Notes due 2017, $900 million principal
amount of 6.375 percent Senior Notes due 2037, and $2 billion
principal amount of 18 month floating rate Senior Notes, for an
aggregate transaction size of $4 billion. The eighteen month floating
rate Senior Notes will bear interest at a rate equal to the three
month LIBOR plus 0.08 percent ... |
| | | 05/23/07 | Amgen to Offer $4 Billion in Three Series of Senior Notes; Company to Purchase Approximately $3 Billion in Common Stock| THOUSAND OAKS, Calif., May 23, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced its intention to offer,
subject to market and other conditions, Senior Notes due 2017, Senior
Notes due 2037, and Senior Floating Rate Notes due 2008 through
offerings pursuant to Rule 144A and Regulation S under the Securities
Act of 1933, as amended (the "Securities Act"). The interest rate and
other terms are to be determined by negotiations between Amgen and the
initial purchasers of the notes.
... |
| | | 05/22/07 | Amgen Names David Lacey, M.D., Senior Vice President, Head of Research| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 22, 2007--Amgen
(NASDAQ:AMGN) today announced that David Lacey, M.D., has been named
senior vice president, head of Research, effective immediately. Over
the past year, Lacey acted as the interim head of Research -- in
addition to his role as Amgen South San Francisco site leader -- and
demonstrated his ability to effectively manage Amgen's global Research
organization, encompassing the company's Oncology/Hematology,
Inflammation, Metabolic ... |
| | | 05/18/07 | Amgen Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 18, 2007--Amgen
(NASDAQ:AMGN) has been notified of an unsolicited "mini-tender offer"
by TRC Capital Corporation (TRC) to purchase up to 1,500,000 shares of
its common stock, representing less than 0.13 percent of Amgen's
outstanding shares, at a price of $53.75 per share.
Amgen does not endorse TRC's unsolicited mini-tender offer and
recommends that stockholders not tender their shares in response to
this mini-tender offer. Amgen wants ... |
| | | 05/09/07 | Amgen Announces Voting Results of Annual Meeting of Stockholders| PROVIDENCE, R.I.--(BUSINESS WIRE)--May 9, 2007--Amgen
(NASDAQ:AMGN) today announced results of voting at the company's
Annual Meeting of Stockholders, held at the Westin Providence hotel in
Providence, R.I. Approximately 86.9 percent of outstanding shares were
represented at the meeting.
The director nominees, Frank J. Biondi, Jr., Jerry D. Choate,
Frank C. Herringer and Gilbert S. Omenn, were each reelected to
Amgen's Board of Directors, receiving at least 96.5 percent of 'For'
... |
| | | 04/30/07 | Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 30, 2007--Amgen
(NASDAQ:AMGN), today announced final results from a pivotal Phase 3
trial which showed that Vectibix(TM) (panitumumab), a fully human
monoclonal antibody directed against the epidermal growth factor
receptor (EGFr), prolonged progression-free survival (PFS) compared to
best supportive care (BSC) in metastatic colorectal cancer patients
who had failed fluoropyrimidine, irinotecan, and oxaliplatin
containing chemotherapy regi... |
| | | 04/23/07 | Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 Billion| Amgen's First Quarter 2007 Adjusted Earnings Per Share (EPS) Increased 19 Percent To $1.08
First Quarter 2007 GAAP EPS Increased 15 Percent to $0.94
Amgen Affirms Low End of EPS Guidance Range
THOUSAND OAKS, Calif., Apr 23, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS),
excluding stock option expense and certain other expenses, of $1.08
for the first quarter of 2007, an increase of 19 percent compared to
$0.91 during the first quarter o... |
| | | 04/19/07 | Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 19, 2007--Amgen
(NASDAQ: AMGN) today announced the results of the "145 study", a
randomized, double-blind, placebo-controlled, multicenter Phase 3
study of Aranesp(R) (darbepoetin alfa) in 600 previously untreated
patients with extensive-stage small-cell lung cancer (SCLC) receiving
platinum-containing chemotherapy. The study demonstrated no
statistically significant difference in risk of death (overall
survival Aranesp compared to placebo... |
| | | 04/18/07 | 2007 Recipients of Amgen Award for Science Teaching Excellence Announced| 30 Outstanding Science Teachers and Their Schools Recognized in Amgen Communities Across the U.S. and Puerto RicoTHOUSAND OAKS, Calif., Apr 18, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced the 30 science teachers across
the United States and Puerto Rico who are this year's recipients of
the Amgen Award for Science Teaching Excellence. Each of the
individuals honored has demonstrated an outstanding ability to inspire
their students and produce results in science education. The ... |
| | | 04/16/07 | Aranesp(R) Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 16, 2007--Amgen
(Nasdaq:AMGN) today presented the results from a randomized,
double-blind, placebo-controlled Phase 3 study evaluating the efficacy
and safety of Aranesp(R) (darbepoetin alfa) for the treatment of
anemia in patients with active cancer not receiving chemotherapy or
radiotherapy ("the 103 study"). Aranesp is not approved for use by the
FDA or EMEA in these patients. These results were presented in an oral
session at the 2007 ... |
| | | 04/11/07 | Amgen Announces Webcast of 2007 First Quarter Financial Results| THOUSAND OAKS, Calif., Apr 11, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced that it plans to report its
first quarter financial results on Monday, April 23, 2007 after the
close of the financial markets. The announcement will be followed by a
conference call with the investment community at 2 p.m. Pacific Time.
Participating in the call from Amgen will be Kevin Sharer, chairman
and chief executive officer, and other members of Amgen's senior
management team.
The Company ini... |
| | | 04/10/07 | Amgen Names Robert Bradway Executive Vice President and Chief Financial Officer| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 10, 2007--Amgen
(NASDAQ: AMGN) today announced the appointment of Robert Bradway as
executive vice president and chief financial officer. He will be
responsible for Amgen's finance, strategy and investor relations
operations. Bradway replaces Richard Nanula, who is leaving the
company to pursue other opportunities.
Bradway, 44, joined Amgen in 2006 as vice president, Operations
Strategy. Prior to joining the company, he spent 18 years ... |
| | | 03/22/07 | Amgen Discontinues Vectibix(TM) Treatment In PACCE Trial Evaluating Vectibix(TM) As Part Of Triple Combination Regimen| Preliminary Pre-Planned Interim Analysis Shows Negative Effect on Progression-Free Survival
THOUSAND OAKS, Calif. (March 22, 2007) - Amgen (NASDAQ: AMGN) today announced that it has discontinued Vectibix(TM) (panitumumab) treatment in the PACCE trial evaluating the addition of Vectibix to standard chemotherapy and Avastin(R)(bevacizumab) for the treatment of first-line metastatic colorectal cancer (mCRC). The PACCE trial investigated a treatment regimen that used dual biologics combined wit... |
| | | 03/19/07 | Amgen to Present at the Lehman Brothers Tenth Annual Global Healthcare Conference| THOUSAND OAKS, Calif., Mar 19, 2007 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) will participate in the Lehman Brothers Tenth
Annual Global Healthcare Conference on Tuesday, March 20, 2007, at the
Loews Miami Beach Hotel in Miami Beach, Fla., beginning at 10:15 a.m.
Eastern Time. George Morrow, executive vice president of Global
Commercial Operations for Amgen, will present at the conference. Live
audio of the presentation will be available over the Internet and can
be accessed from Amgen's Web... |
| | | 03/12/07 | Amgen to Present at the 27th Annual Cowen & Company Health Care Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 12, 2007--Amgen
(NASDAQ:AMGN) will participate in the 27th Annual Cowen & Company
Health Care Conference on Tuesday, March 13th, at the Boston Marriott,
beginning at 9:30 a.m. Eastern Time. Arvind Sood, vice president of
Investor Relations, will represent Amgen at the conference. Live audio
of the presentation will be available over the Internet and can be
accessed from Amgen's Web site, www.amgen.com, under Investors.
Information rega... |
| | | 03/09/07 | Amgen Announces Update To U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)| New Boxed Warning Applies to Oncology and Nephrology Indications for the Class of Approved ESAs
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 9, 2007--Amgen
(NASDAQ:AMGN) today announced the U.S. Food and Drug Administration
(FDA) has approved updated safety information, including a boxed
warning in the prescribing information for the class of drugs known as
Erythropoiesis-stimulating Agents (ESAs), including Aranesp(R)
(darbepoetin alfa) and EPOGEN(R) (Epoetin alfa).
"Patient... |
| | | 03/02/07 | Prime Minister Tony Blair Opens Major Amgen Development Centre in London|
Amgen's Largest R&D Investment Outside the U.S. to Support a Major
International Clinical Trial Programme Encompassing Nearly 41,000
Patients with Serious Illness
UXBRIDGE, England--(BUSINESS WIRE)--March 2, 2007--Amgen
(NASDAQ:AMGN) announced today that the Prime Minister Rt Hon Tony
Blair MP opened Amgen's new European Development Centre in Uxbridge,
London. The centre can accommodate more than 300 new staff and forms a
key part of a significant Resea... |
| | | 02/28/07 | Amgen to Participate in Oncologic Drugs Advisory Committee in May| Company is in Discussions with FDA About U.S. Prescribing
Information for Erythropoiesis-Stimulating Agents
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 28, 2007--Amgen
(NASDAQ: AMGN) today announced that the U.S. Food and Drug
Administration (FDA) has invited the Company to participate at an
upcoming meeting of the Oncologic Drugs Advisory Committee (ODAC). The
Company's understanding is that the ODAC will review progress made by
Amgen and other sponsors in delineating th... |
| | | 02/28/07 | Amgen to Participate in Goldman Sachs 'In Your Office' Call| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 28, 2007--Amgen
(NASDAQ:AMGN) announced today that Kevin Sharer, chairman and chief
executive officer, and George Morrow, executive vice president, global
commercial operations, will participate in a Goldman Sachs
Biotechnology "In Your Office" call on Thursday, March 1, 2007
beginning at 8 a.m. Pacific Time. Live audio of the call will be
available over the Internet and can be accessed from Amgen's Web site,
www.amgen.com, under Investors.... |
| | | 02/16/07 | Amgen to Hold Analyst Call to Discuss Danish Head and Neck Cancer (DAHANCA) 10 Study| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 16, 2007--Amgen
(NASDAQ:AMGN) will hold an analyst call at 1 p.m. Pacific Time today,
Feb. 16, 2007, to address inquiries following publication of the
interim results of the Danish Head and Neck Cancer (DAHANCA) 10 study.
Live audio of the conference call will be simultaneously broadcast
over the Internet as a webcast and will be available to members of the
news media, investors and the general public.
The webcast of the conference, as ... |
| | | 02/15/07 | Amgen Announces Proposals to Declassify Board to Be Presented at 2007 Annual Meeting and Adopts Majority Vote Bylaw| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 15, 2007--Amgen
(NASDAQ:AMGN) announced today that its Board unanimously voted to
approve corporate governance initiatives to declassify the Board of
Directors and adopt a majority vote standard for the election of
Directors in uncontested elections.
The Board unanimously voted to submit proposals to amend Amgen's
certificate of incorporation and bylaws to eliminate the
classification of the Board to stockholders at the 2007 annual
mee... |
| | | 02/06/07 | Amgen CEO Kevin Sharer to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 6, 2007--Amgen
(NASDAQ:AMGN) Chairman and CEO Kevin Sharer will present at the
Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device
Conference on Thursday, Feb. 8, 2007 beginning at 9:20 a.m. Eastern
Time. Live audio of the presentation will be available over the
Internet and can be accessed from Amgen's Web site, www.amgen.com,
under Investors.
Information regarding presentation time, webcast availability, and
webcast l... |
| | | 02/02/07 | Survey Indicates People with Chronic Moderate to Severe Plaque Psoriasis May Be Under-Treated| Severe Psoriasis Associated with Lower Income
WASHINGTON--(BUSINESS WIRE)--Feb. 2, 2007--The National Psoriasis
Foundation and Amgen (NASDAQ:AMGN), today announced survey findings
which show that nearly 40 percent of 1,142 patients surveyed with
chronic moderate or severe psoriasis are not currently receiving any
treatment. These results were presented at the American Academy of
Dermatology (AAD) Scientific Meeting in Washington, D.C.
According to AAD therapy guidelines, pati... |
| | | 01/31/07 | Amgen Announces Put Option for Liquid Yield Option Notes Due 2032 and Zero Coupon Convertible Notes Due 2032| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 31, 2007--Amgen
(NASDAQ:AMGN) today announced that holders of Amgen's Liquid Yield
Option(TM) Notes due 2032 (Zero Coupon--Senior) and Zero Coupon
Convertible Notes due 2032 (Zero Coupon--Senior) (collectively, the
"Securities") have the right to surrender their Securities for
purchase by Amgen pursuant to the terms of the indentures for the
Securities (the "Put Options"). The Put Options expire on March 1,
2007.
The Put Options entitl... |
| | | 01/25/07 | Amgen's Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 Billion| Amgen's Fourth Quarter 2006 Adjusted Earnings Per Share (EPS)
Increased 20 Percent to $0.90; Full Year 2006 Adjusted EPS Increased
22 Percent to $3.90
Fourth Quarter 2006 GAAP EPS Increased 8 Percent to $0.71 and Full
Year 2006 GAAP EPS Decreased 15 Percent to $2.48 Reflecting Write-Offs
of Acquired In-Process R&D
2007 Total Revenue Expected to Be in the Range of $15.4 to $16.0
Billion
2007 Adj... |
| | | 01/16/07 | Amgen Launches 2007 Breakaway from Cancer Initiative| Patrick Dempsey Joins Team Breakaway; Survey Findings Reveal
Impact of Cancer on Careers
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 16, 2007--In an
ongoing effort to raise awareness of and funds to support free
services and programs to help people affected by cancer, Amgen
(NASDAQ:AMGN) today announced one of TV's biggest stars - Patrick
Dempsey - will serve as a spokesperson for the Breakaway from
Cancer (TM) initiative. In addition, Amgen, in collaboratio... |
| | | 01/11/07 | Amgen Announces Webcast of 2006 Fourth Quarter and Full Year Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 11, 2007--Amgen
(NASDAQ:AMGN) today announced that it plans to report its fourth
quarter and full year financial results on Thursday, January 25, 2007
after the close of the financial markets. The announcement will be
followed by a conference call with the investment community at 2 p.m.
Pacific Time.
Participating in the call from Amgen will be Kevin Sharer,
chairman and chief executive officer, and other members of Amgen's
senior mana... |
| | | 01/03/07 | Cytokinetics and Amgen Announce Strategic Alliance in Heart Failure|
Collaboration Focused on Discovery, Development and
Commercialization of Cardiac Myosin Activators
Amgen Obtains Option on Cytokinetics' Drug Candidate CK-1827452
SOUTH SAN FRANCISCO & THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan.
3, 2007--Cytokinetics Incorporated (NASDAQ:CYTK) and Amgen
(NASDAQ:AMGN) today announced a strategic collaboration to discover,
develop and commercialize novel small-molecule therapeutics that
activate cardiac muscle contractility fo... |
| | | 12/13/06 | Amgen Announces $5 Billion Stock Repurchase Plan| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 13, 2006--Amgen
(NASDAQ:AMGN) today announced that its board of directors has
authorized additional repurchases of up to $5 billion in Amgen common
stock. The company currently has $1.5 billion remaining under its
previous stock repurchase authorization. This new authorization
reflects Amgen's confidence in its long-term prospects.
About Amgen
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pio... |
| | | 12/11/06 | Updated Interim Long-Term Follow-up Data Reported AMG 531 Dosed Once Weekly Increased and Sustained Platelet Counts in Patients with Immune Platelet Disorder| ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 11, 2006--Amgen (NASDAQ:
AMGN) today announced interim results from an open-label extension
study showing that long-term administration (up to 48 weeks) of its
investigational therapy AMG 531 stimulated platelet production and was
generally well-tolerated in adult patients with immune
thrombocytopenic purpura (ITP). These updated interim data were
presented in an oral session at the American Society of Hematology
(ASH) 48th Annual Meeting in Orland... |
| | | 12/10/06 | Final Phase 2 Data Continue to Show Promising Results after One Year of Aranesp(R) Treatment for Anemia in Patients with Myelodysplastic Syndromes (MDS)| Aranesp Treatment Appears to Improve Hemoglobin Levels in One of
the Largest MDS Studies to Date
ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 10, 2006--Amgen (NASDAQ:
AMGN) today announced that after 53/55 weeks of treatment with
Aranesp(R) (darbepoetin alfa) administered every three weeks, 74
percent of anemic patients with low- or intermediate-risk
myelodysplastic syndromes who had not previously received an
erythropoiesis-stimulating agent (ESA) had an erythroid respo... |
| | | 12/09/06 | Data Show Efficacy of Extended Dosing of Aranesp(R) in the Treatment of Chemotherapy-Induced Anemia| Aranesp with Supplemental Iron More Effective in Boosting
Hemoglobin Levels and Reducing Incidence of Transfusions
ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 9, 2006--Amgen (NASDAQ: AMGN)
today announced data from two studies showing that extended dosing of
Aranesp(R) (darbepoetin alfa) is effective in increasing hemoglobin
levels to the target level of 11 to 12 g/dL and reducing the need for
red blood cell transfusions in patients with chemotherapy-induced
anemia. These data were ... |
| | | 12/09/06 | New Phase 2 Data Show Promise of Aranesp(R) Treatment for Anemia of Cancer| Monthly Aranesp Treatment Improved Hematopoietic Response In
Cancer Patients Not Receiving Chemotherapy or Radiation Therapy
ORLANDO, Fla.--(BUSINESS WIRE)--Dec. 9, 2006--Amgen (NASDAQ:AMGN)
today announced final results of a 17-week randomized, double-blind,
placebo-controlled, Phase 2 study evaluating Aranesp(R) (darbepoetin
alfa) administered every four weeks for the treatment of anemia in
cancer patients not undergoing chemotherapy and/or myelosuppressive
radiotherapy, a c... |
| | | 12/06/06 | Amgen Submits Testimony to House Ways & Means Committee|
Given the State of Evidence and Current Regulatory Policy, Amgen
Questions the Justification for Congress to Legislate Medical
Practice, and Addresses Significant Risks to Patient Quality and
Access
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 6, 2006--Amgen
(NASDAQ:AMGN), today submitted testimony for the record of the
Committee on Ways & Means hearing on "Patient Safety and Quality
Issues in End Stage Renal Disease Treatment." In its t... |
| | | 12/04/06 | Amgen Responds to Reports About Use and Safety of EPOGEN and Aranesp in CKD Anemia Therapy| THOUSAND OAKS, Calif., Dec 04, 2006 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), today posted to its corporate web site
documents intended to clarify Amgen's position on the use of EPOGEN(R)
(Epoetin alfa) and Aranesp(R) (darbepoetin alfa) and to correct what
the company believes are misleading and inaccurate news reports
regarding the use of its drugs. Amgen's mission is to serve patients
and the company is committed to ensuring the highest standards of
patient safety.
Documents supporting ... |
| | | 12/01/06 | Amgen Names Yuji Orihara President, Amgen KK| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 1, 2006--Amgen
(NASDAQ:AMGN), today announced the appointment of Yuji Orihara to the
position of president and representative director, Amgen KK, effective
immediately. Amgen KK was formed in 1992 in Japan as a wholly owned
subsidiary of Amgen Inc. Orihara will be responsible for all aspects
of Amgen's commercial efforts in Japan and will be based at the Amgen
KK headquarters in Tokyo.
Amgen is building Amgen KK to become a full commerc... |
| | | 11/29/06 | Colorectal Patients Offered New Resource to Help Navigate Treatment Process| - Patient Advocate Foundation and Amgen Oncology Launch Colorectal CareLine -NEWPORT NEWS, Va. & THOUSAND OAKS, Calif., Nov 29, 2006 (BUSINESS WIRE) -- The Patient Advocate Foundation (PAF), with support from Amgen
(Nasdaq:AMGN), is pleased to announce the launch of the Colorectal
CareLine (CCL). The national toll free telephone hotline is designed
to offer assistance to all colorectal cancer patients and healthcare
providers seeking educational resources, direct assistance with access
to c... |
| | | 11/22/06 | District Court Judge Denies Preliminary Injunction in Ortho v. Amgen Suit| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 22, 2006--Amgen
(NASDAQ:AMGN), today announced that United States District Court Judge
Stanley R. Chesler has denied Ortho Biotech's request for a
preliminary injunction against the 2006 Amgen Portfolio Contract. The
lawsuit involves Amgen sales discounts on Aranesp(R) (darbepoetin
alfa) to its best customers.
"We believe that Amgen does not engage in anti-competitive
practices in the sale of Aranesp," said David Scott, Amgen's senior
... |
| | | 11/20/06 | Fashion Designer and Cancer Survivor Carmen Marc Valvo Offers Support| One-hundred percent of purchase price from sales of limited edition t-shirts
to support national Breakaway from Cancer initiative
New YORK (November 20, 2006) The same distinguished artistic talent that makes American fashion designer Carmen Marc Valvo a favorite among Hollywood's elite has been channeled into the creation of limited edition t-shirts that will help support a cause close to Valvo's heart. As a colorectal cancer survivor with a zeal not only for design, but also for life... |
| | | 11/16/06 | Amgen Launches ChemoCoach.com and ``My Cancer Coach'' Contest in Conjunction with Sponsorship of College Hoops Classic Benefiting Coaches vs. Cancer| Contest Provides Cancer Survivors an Opportunity to Say Thank You
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 16, 2006--Cancer
survivors now have a unique opportunity to thank their cancer coach --
the spouse, family member or friend who played a crucial role in
helping them through the battle -- through a contest sponsored by
Amgen Oncology. Starting today, cancer patients can nominate their
"cancer coach" at www.ChemoCoach.com by completing and submitting a
short essay.
Am... |
| | | 11/13/06 | Data Shows ENBREL Provides Sustained Clinical Improvements for People with Ankylosing Spondylitis for up to Three Years| Data Show Sustained Improvements in Clinical Measures for up to
Three Years
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 13, 2006--Amgen
(NASDAQ:AMGN), today announced that data from an ongoing open-label,
multinational, phase 4 extension study showed that patients with
ankylosing spondylitis (AS) who received treatment with Enbrel(R)
(etanercept) experienced sustained improvement in signs and symptoms,
spinal mobility and physical function over 148 t... |
| | | 11/12/06 | ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 12, 2006--Amgen
(NASDAQ:AMGN) today announced that Enbrel(R) (etanercept) is the first
biologic with published data to show improvements in multiple measures
of efficacy that were sustained in rheumatoid arthritis (RA) patients
completing up to nine years of therapy. These new data are being
presented at the American College of Rheumatology (ACR) Scientific
Meeting in Washington, D.C.
"The current data in Rheumatoid Arthritis suggest th... |
| | | 11/04/06 | AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors| Broad Clinical Development Program for AMG 706 Under Way
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 4, 2006--Amgen
(NASDAQ:AMGN) today announced results from a multicenter, single-arm,
Phase 2 study of AMG 706, an investigational oral targeted VEGF
receptor inhibitor. In this study, AMG 706 showed encouraging clinical
activity in patients with advanced high-dose imatinib-resistant
gastrointestinal stromal tumors (GIST). These data were presented in
an oral session at the Connect... |
| | | 11/02/06 | Nominations Open for the Amgen Award for Science Teaching Excellence| 30 Outstanding Teachers Will Be Recognized in Communities Where
Amgen Operates
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 2, 2006--Amgen
(NASDAQ:AMGN), today announced a call for nominations for its 16th
annual Amgen Award for Science Teaching Excellence. This award is
designed to recognize and honor extraordinary science teachers at the
K-12 level, who significantly impact their students through exemplary
science teaching and who achieve demonstrated... |
| | | 10/24/06 | Amgen Completes Acquisition of Avidia| Acquisition Of A Clinical Stage IL-6 Compound And Novel Avimer(TM) Protein Platform
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 24, 2006--Amgen
(NASDAQ:AMGN), today announced the completion of the acquisition of
Avidia, a privately held biopharmaceutical company that discovers and
develops a new class of human therapeutic known as Avimer(TM)
proteins. The transaction provides Amgen with Avidia's lead product
candidate, an inhibitor of interleukin 6 (IL-6) for the treatment of
in... |
| | | 10/23/06 | Amgen's Third Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 22 Percent to $1.04| GAAP Earnings Per Share Increased 22 Percent to $0.94 Full Year Adjusted Earnings Per Share Guidance Excluding Stock Option Expense Raised to $3.85 - $3.95 Revenues Grew 15 Percent to $3.6 BillionTHOUSAND OAKS, Calif., Oct 23, 2006 (BUSINESS WIRE) -- Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS),
excluding stock option expense and certain other expenses, of $1.04
for the third quarter of 2006, an increase of 22 percent compared to
85 cents during the third quarter of 2005. A... |
| | | 10/20/06 | U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit| Court Will Proceed on the Merits of Amgen's Claim That Roche's peg-EPO Infringes Amgen's EPO Patents
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 20, 2006--Amgen
(NASDAQ:AMGN) announced that a U.S. Federal District Court in Boston
today denied Roche's motion to dismiss Amgen's patent infringement
lawsuit against Roche. The court today also denied a motion by Ortho
Biotech to intervene as a co-plaintiff in the case.
"The judicial process can now move forward towards resolution of... |
| | | 10/19/06 | Amgen Foundation Launches $25 Million Undergraduate Research Program| Amgen Scholars Will Provide Hands-on Science Research Experience at 10 of the Nation's Premier Universities
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 19, 2006--As part of
its mission to advance science education, the Amgen Foundation today
announced its partnership with 10 of the nation's leading universities
to provide hundreds of selected undergraduate students an opportunity
to engage in a fully funded, hands-on research experience each summer.
Amgen Scholars is a $25 mil... |
| | | 10/13/06 | Amgen Receives Complete Response Letter for Extended Dosing of Aranesp(R) for Patients with Chronic Kidney Disease and Anemia| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 13, 2006--Amgen
(NASDAQ:AMGN) today announced that the U.S. Food and Drug
Administration (FDA) has issued a complete response letter, commonly
referred to as an "approvable" letter, for Aranesp(R) (darbepoetin
alfa) de novo once every-two-week and maintenance once-monthly dosing
regimens for chronic kidney disease (CKD) patients with anemia not on
dialysis.
In December 2005, Amgen submitted a biologics license supplement
to the FDA for... |
| | | 10/09/06 | Amgen Announces Webcast of Third Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 9, 2006--Amgen
(Nasdaq:AMGN) today announced that it plans to report its third
quarter financial results on Monday, October 23, 2006 after the close
of the financial markets. The announcement will be followed by a
conference call with the investment community at 2 p.m. Pacific
Daylight Time.
Participating in the call from Amgen will be Kevin Sharer,
chairman and chief executive officer, and other members of Amgen's
senior management te... |
| | | 09/29/06 | Amgen to Acquire Avidia, a Privately Held Biopharmaceutical Company in the San Francisco Bay Area| Acquisition of a Clinical Stage IL-6 Compound and Novel Avimer(TM) Protein PlatformTHOUSAND OAKS & MOUNTAIN VIEW, Calif., Sep 29, 2006 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced that it has entered into a
definitive merger agreement under which Amgen has agreed to acquire
Avidia, a privately held biopharmaceutical company that discovers and
develops a new class of human therapeutic known as Avimer(TM)
proteins. The transaction provides Amgen with Avidia's lead product
candidate,... |
| | | 09/27/06 | Amgen Introduces Comprehensive Financial Assistance Programs for Cancer Patients| Business Editors/Health/Medical Writers
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 27, 2006--Amgen
(NASDAQ:AMGN) today announced Amgen(TM) Oncology Assistance (AOA), a
comprehensive, multi-faceted financial assistance program that will
include a "cap" on out-of-pocket co-payments for cancer patients
receiving Vectibix(TM) (panitumumab). Through AOA, patients who are
uninsured, underinsured, or unable to afford their insurance
co-payments will receive help obtaining financial ... |
| | | 09/27/06 | FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer| Business Editors
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 27, 2006--Amgen
(NASDAQ:AMGN) today announced that the U.S. Food and Drug
Administration (FDA) has approved Vectibix(TM) (panitumumab) following
priority review. Vectibix is the first entirely human monoclonal
antibody for the treatment of patients with epidermal growth factor
receptor- (EGFr) expressing metastatic colorectal cancer after disease
progression on, or following fluoropyrimidine-, oxaliplatin-, and
irin... |
| | | 09/20/06 | Amgen Names Thomas Flanagan Senior Vice President and Chief Information Officer| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 20, 2006--Amgen
(NASDAQ:AMGN), the world's leading biotechnology company, today
announced the appointment of Thomas Flanagan as senior vice president
and chief information officer (CIO). Flanagan replaces Hassan Dayem,
who is retiring.
Flanagan joined Amgen in June 2004 as vice president, Information
Systems, and has been leading Amgen's global enterprise resource
planning program (ERP) since February 2005. Prior to joining Amgen,
Fla... |
| | | 09/19/06 | Amgen Announces License Agreement with Yeda Research and Development Company Ltd.; License Agreement Accords Amgen Freedom to Operate Under '866 Patent| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 19, 2006--Amgen
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced that it has entered into an agreement with Yeda Research and
Development Company Ltd., the commercial arm of the Weizmann Institute
of Science. Under the terms of the agreement Amgen obtained a license
under Yeda's rights in U.S. Patent No. 6,217,866 (the "'866 Patent").
Yesterday, Yeda was awarded sole ownership of the '866 Patent in an
opinion and o... |
| | | 09/19/06 | Amgen Presents Denosumab and Sclerostin Antibody Data at American Society for Bone and Mineral Research Annual Meeting; Data Suggest the Potential for Targeting the Key Proteins, RANK Ligand and Sclerostin, for Bone Loss Conditions| PHILADELPHIA--(BUSINESS WIRE)--Sept. 19, 2006--Amgen
(NASDAQ:AMGN), the world's largest biotechnology company, announced
today the presentation of data at the American Society for Bone and
Mineral Research (ASBMR) Annual Meeting highlighting its expertise in
bone biology research and commitment to developing therapies that
address the burden of bone disease. The studies evaluated denosumab
and a sclerostin antibody, two of the company's investigational
therapies. These antibodies targ... |
| | | 09/07/06 | Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated with Chemotherapy and Chronic Kidney Disease|
New Autoinjector Offers Secure and Simple Way
to Administer Anemia Treatment
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 7, 2006--
Amgen (NASDAQ:AMGN) today announced the launch of the Aranesp(R)
(darbepoetin alfa) prefilled SureClick(TM) autoinjector for patients
with chemotherapy-induced anemia and anemia associated with chronic
kidney disease (CKD) in the United States.
"With the availability of the Aranesp prefilled SureClick
... |
| | | 08/03/06 | Amgen Wins TKT Appeal| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 3, 2006--Amgen
(NASDAQ:AMGN) today issued the following statement:
The Court of Appeals for the Federal Circuit today affirmed the
District Court's decision that Transkaryotic Therapies Inc. (TKT) and
Aventis Pharmaceuticals Inc. infringe Amgen's erythropoietin (EPO)
patent estate.
Today's ruling reaffirms Amgen's confidence in the strength of its
intellectual property portfolio. The court's decision upheld the
validity of two of A... |
| | | 07/20/06 | Amgen's Second Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 19 Percent to $1.05; GAAP Earnings Per Share of 1 Cent Reflects $1.1 Billion One-Time Write-Off of In-Process R&D Related to Abgenix Acquisition| Full Year Adjusted EPS Guidance Excluding Stock Option Expense
Raised 15 Cents to $3.75 - $3.85; Revenues Grow 14 Percent to $3.6
Billion; International Sales up 18 Percent Excluding FX Impact
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 20, 2006--Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS),excluding stock option expense and certain other expenses, of $1.05 for the second quarter of 2006, an increase of 19 percent compared to
88 cents during the second quart... |
| | | 07/18/06 | Amgen Update on Presentation Materials for Webcast of Second Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 18, 2006--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, announced
that as part of its efforts to continuously improve its investor
communications, it intends to provide a slide presentation with its
upcoming second quarter financial results conference call, scheduled
for Thursday, July 20, 2006 at 2 p.m. Pacific Daylight Time. The slide
presentation will be posted in the Investor section of the company's
Web site (www.amge... |
| | | 07/16/06 | Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis|
GLASGOW, Scotland--(BUSINESS WIRE)--July 16, 2006--
-- New Data Showed Earlier Intervention With Sensipar/Mimpara
Improved Ability to Achieve K/DOQI(TM) Secondary HPT Treatment
Guidelines in Dialysis Patients --
Amgen (Nasdaq:AMGN), the world's largest biotechnology company,
announced today the initiation of the largest prospective, randomized
clinical trial planned to date in patients with stage five chronic
kidney disease (CKD). EVOLVE (EValuation Of C... |
| | | 07/11/06 | Amgen Announces Termination of Poison Pill Effective July 31, 2006| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 11, 2006--Amgen
(NASDAQ:AMGN) announced today that the company's board of directors
has voted unanimously to terminate the company's stockholder rights
plan, commonly referred to as a "poison pill." Originally scheduled to
expire on December 12, 2010, the plan has been amended to accelerate
the expiration date to July 31, 2006, effectively terminating the plan
as of that date.
Amgen's board has also established a policy providing for
s... |
| | | 07/07/06 | ITC Judge Grants Summary Determination That Roche's Activities Are Covered by Clinical Trial Exemption | Judge's Decision Does Not Address the Merits of Roche's Infringement of Amgen's Patents; Amgen Can Re-file Complaint Closer to a Potential Commercial Launch
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 7, 2006-- Amgen (NASDAQ:AMGN), today issued the following statement: An Administrative Law Judge (ALJ) at the U.S. International Trade Commission (ITC) in Washington, D.C. issued a summary determination that Roche's importation and use of peg-EPO in the United States to date are subject to... |
| | | 07/06/06 | Amgen Announces Webcast of Second Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 6, 2006--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it plans to report its second quarter financial results
on Thursday, July 20, 2006 after the close of the financial markets.
The announcement will be followed by a conference call with the
investment community at 2 p.m. Pacific Daylight Time.
Participating in the call from Amgen will be Kevin Sharer,
chairman and chief executive officer, and ot... |
| | | 06/19/06 | Final Results of Phase 2 Clinical Trial Program Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Decrease Risk of Hospitalization and All-Cause Mortality in Heart Failure Patients with Anemia, Based on a Prespecified Pooled Analysis| Results Validate Amgen's Phase 3 RED-HF(TM)
Trial to Address Unmet Medical Need
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 19, 2006--
Amgen (Nasdaq:AMGN), the world's largest biotechnology company,
announced results at the 2006 European Society of Cardiology-Heart
Failure (ESC-HF) Congress from a Phase 2 study showing that, in
patients with symptomatic heart failure and anemia, Aranesp(R)
(darbepoetin alfa) was well tolerated and effectively raised
hemoglobin (Hb... |
| | | 06/12/06 | FDA Grants Priority Review of Panitumumab for Treatment of Patients with Metastatic Colorectal Cancer| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 12, 2006--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that the U.S. Food and Drug Administration (FDA) has
accepted the Biologic License Application (BLA) for panitumumab, an
investigational fully human monoclonal antibody that targets the
epidermal growth factor receptor (EGFr) and has granted Priority
Review. The BLA was submitted for the treatment of metastatic
colorectal cancer patients who have faile... |
| | | 06/04/06 | Phase 2 Interim Data Show Denosumab Decreased Bone Turnover in Advanced Cancer Patients with Bone Metastases| Denosumab, a Fully Human Monoclonal Antibody that Inhibits
RANK Ligand, Showed Activity in Patients Naive to and on
Established IV Bisphosphonate Therapy
ATLANTA--(BUSINESS WIRE)--June 4, 2006--
Amgen (NASDAQ:AMGN), the world's largest biotechnology company,
announced interim data from two Phase 2 clinical studies of denosumab,
an investigational fully human monoclonal antibody that inhibits RANK
Ligand. As reported at the 42nd Annual Meeting of the Ameri... |
| | | 06/03/06 | Interim Data Suggest Potential Benefits of Aranesp(R) Dosed Every Three Weeks with Intravenous Iron for Chemotherapy-Induced Anemia; 94 Percent of Patients Achieved Target Hemoglobin Level| ATLANTA--(BUSINESS WIRE)--June 3, 2006--Amgen (NASDAQ:AMGN), the
world's largest biotechnology company, today announced interim Phase 3
data suggesting Aranesp(R) (darbepoetin alfa) administered every three
weeks with intravenous (IV) iron has the potential to further enhance
the effectiveness of increasing patient hemoglobin levels to the
recommended target of greater than or equal to 11 g/dL and reducing
the need for red blood cell transfusions in cancer patients with
chemotherapy-i... |
| | | 06/03/06 | Interim Phase 2 Aranesp(R) Data Suggest Major Response after 27/28 Weeks of Treatment for Anemia in Patients with Myelodysplastic Syndromes (MDS)| Results of One of the Largest MDS Studies to Date Show Both Previously Treated and ESA-Naive Patients Responded to Aranesp TreatmentATLANTA, Jun 03, 2006 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), the world's largest biotechnology company,
today announced that after 27/28 weeks of treatment with Aranesp(R)
(darbepoetin alfa) administered every three weeks, patients with
low-risk myelodysplastic syndromes who had not previously received an
erythropoiesis-stimulating agent (ESA) showed a major re... |
| | | 06/03/06 | New Interim Phase 2 Data Suggest the Antitumor Activity of Panitumumab in Metastatic Colorectal Cancer| Panitumumab Antitumor Response Observed in Patients with Either Low or Negative Levels of EGFr Staining; Additional Phase 1 Data Suggest AMG 706 Monotherapy Shows Promise for Advanced Thyroid CancerATLANTA, Jun 03, 2006 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), the world's largest biotechnology company,
today announced interim results from two Phase 2 studies of
panitumumab, an investigational fully human monoclonal antibody that
targets the epidermal growth factor receptor (EGFr). Results from... |
| | | 05/31/06 | Amgen Oncology Highlights Upcoming Data Presentations at the American Society of Clinical Oncology Annual Meeting; Clinical Data to be Presented on Four Investigational Targeted Cancer Therapies| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 31, 2006--Amgen
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced upcoming data presentations at the 42nd Annual Meeting of
the American Society of Clinical Oncology (ASCO) in Atlanta. Clinical
results will be presented on four investigational cancer therapies:
panitumumab in metastatic colorectal cancer patients, denosumab in
breast cancer patients with bone metastases, AMG 706 in advanced
thyroid cancer patients, an... |
| | | 05/18/06 | Large Head-to-Head Study of Aranesp(R) Dosed Every Two Weeks versus Epoetin Alfa Dosed Weekly Published in the Journal of Clinical Oncology| Randomized, Open-label, Multicenter Study Including More Than
1,200 Cancer Patients with Chemotherapy-Induced Anemia Shows
Comparability in Transfusion Rates and Achievement of Target
Hemoglobin THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 18, 2006--Amgen
(NASDAQ:AMGN)--Amgen (NASDAQ:AMGN), the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, open-label head-to-head study evaluating 200 mcg of Aranesp(R) (darbepoet... |
| | | 05/09/06 | ITC Accepts Amgen's Complaint to Investigate Roche's Importation of Peg-EPO| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 9, 2006--Amgen
(NASDAQ:AMGN), today issued the following statement:
In response to Amgen's April 11, 2006 filing with the U.S.
International Trade Commission (ITC) in Washington, D.C., the ITC has
decided to institute an investigation of Roche's importation of
pegylated recombinant human erythropoietin (peg-EPO) into the United
States. Amgen is asking the ITC to issue a permanent exclusion order
that would prohibit importation of peg-EPO... |
| | | 04/24/06 | Alcon and Amgen Sign Collaboration Agreement to Develop and Commercialize Innovative Therapies in Ophthalmology| FORT WORTH, Texas & THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April
24, 2006--Alcon, Inc. (NYSE:ACL), the world's leading eye care company
and Amgen (Nasdaq:AMGN), the world's largest biotechnology company,
today announced a broad, multi-target collaboration to jointly
research, develop, and commercialize therapeutics for the treatment of
eye diseases. The agreement encompasses multiple biological targets
and disease areas within the field of ophthalmology.
Under the terms of the ag... |
| | | 04/18/06 | Amgen's First Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 26 Percent to 91 Cents; First Quarter 2006 GAAP Earnings Per Share Increased 22 Percent to 82 Cents|
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 18, 2006--
Adjusted EPS Guidance Raised to $3.60 - $3.70 Including Dilution
From the Abgenix Acquisition, and Excluding Stock Option Expense;
Total Revenue Increased 14 Percent
Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS),
excluding stock option expense, of 91 cents for the first quarter of
2006, an increase of 26 percent compared to 72 cents during the first
quarter of 2005. Adjusted net... |
| | | 04/11/06 | Amgen Files with ITC Against Roche's Importation of peg-EPO| THOUSAND OAKS, Calif., Apr 11, 2006 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), the world's largest biotechnology
company, today issued the following statement:
Amgen filed a complaint with the U.S. International Trade
Commission (ITC) in Washington, D.C. requesting that the ITC institute
an investigation of Roche's importation of pegylated recombinant human
erythropoietin (peg-EPO) into the U.S. Amgen believes that importation
of peg-EPO is unlawful because peg-EPO, and the method of its
m... |
| | | 04/10/06 | 2006 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Amgen Communities Across the U.S. and Puerto Rico| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 10, 2006--Amgen
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced the 19 science teachers across the United States and Puerto
Rico who are this year's recipients of the Amgen Award for Science
Teaching Excellence. Each of the individuals honored have demonstrated
an outstanding ability to inspire their students and produce results
in science education. The program was designed to recognize teachers
in the K-12 grade... |
| | | 04/04/06 | Amgen Announces Webcast of First Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 4, 2006--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced plans to report its first quarter financial results on
Tuesday, April 18, 2006 after the close of the financial markets. The
announcement will be followed by a live conference with the investment
community at 2 p.m. Pacific Daylight Time.
Participating in the event from Amgen will be Kevin Sharer,
chairman and chief executive officer, and other mem... |
| | | 04/03/06 | Randomized Phase 3 Trial Shows Panitumumab Significantly Improved Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2006--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced pivotal Phase 3 results demonstrating that panitumumab
significantly improved progression-free survival and disease control
(response rate and stable disease) compared to best supportive care
(BSC) in metastatic colorectal cancer patients who had failed standard
chemotherapy. The results were presented in a Clinical Plenary Session
at the 97th Annual M... |
| | | 04/03/06 | Amgen Completes Acquisition of Abgenix; Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2006--Amgen
(NASDAQ: AMGN), the world's largest biotechnology company, today
announced the completion of the acquisition of Abgenix, Inc., a
company specializing in the discovery, development and manufacture of
human therapeutic antibodies. Final regulatory approvals were received
in January and Abgenix stockholders overwhelmingly approved Amgen's
acquisition of the company during a special meeting held on March 29,
2006.
"Our supp... |
| | | 03/30/06 | Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab| THOUSAND OAKS, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--March
30, 2006--Amgen (Nasdaq: AMGN) and Abgenix, Inc. (Nasdaq: ABGX) today
announced that Amgen has completed the Biologic License Application
(BLA) submission with the U.S. Food and Drug Administration (FDA) for
panitumumab. The potential indication is for the treatment of
metastatic colorectal cancer in patients who have failed prior
chemotherapy, including oxaliplatin and/or irinotecan containing
regimens. The rolling BLA s... |
| | | 03/27/06 | FDA Approves Extended Dosing of Aranesp(R) to Treat Chemotherapy-Induced Anemia; Every-Three-Week Dosing Can Provide Added Convenience, Potentially Reducing Number of Clinic Visits and Injections for Anemia Treatment| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 27, 2006--Amgen
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced the U.S. Food and Drug Administration (FDA) has approved
every-three-week dosing of Aranesp(R) (darbepoetin alfa) for the
treatment of chemotherapy-induced anemia (low red blood cell count) in
patients with non-myeloid malignancies. Aranesp is the only
erythropoiesis-stimulating agent approved by the FDA for
every-three-week administration.
"Amge... |
| | | 03/13/06 | New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Provide Clinical Benefits in Heart Failure Patients|
ATLANTA--(BUSINESS WIRE)--March 13, 2006--
Amgen's Phase 3 RED-HF(TM) Trial Will Evaluate the Clinical Effect
of Treating Anemia in Patients with Symptomatic Heart Failure
Amgen (Nasdaq:AMGN), the world's largest biotechnology company,
announced results from a Phase 2 study that showed that treating
anemia with Aranesp(R) (darbepoetin alfa) in patients with symptomatic
heart failure was well-tolerated, effectively raised hemoglobin and
improved patients' symptoms as m... |
| | | 02/26/06 | Amgen Donates $1.1 Million to The Wellness Community as Part of of ``Breakaway from Cancer'' Initiative and Title Sponsorship of Amgen Tour of California| REDONDO BEACH, Calif.--(BUSINESS WIRE)--Feb. 26, 2006--As part of the Breakaway from Cancer(TM) initiative, a national education campaign to support services and programs that help people who are living with cancer, Amgen today announced a donation totaling $1.1 million to The Wellness Community(R). The Wellness Community is an international, nonprofit organization dedicated to providing support, education and hope for people affected by cancer at no cost.
The presentation was made in Redo... |
| | | 02/25/06 | Hundreds of Local Residents Participate in Breakaway from Cancer Charity Ride to Benefit The Wellness Community; Bruce Jenner Kicks-off Twenty-Five Mile Ride That Coincides with Stage Six of Amgen Tour of California |
More than 500 local residents and Amgen staff and their families took part in the Breakaway from Cancer(TM) charity ride on Saturday, February 25 -- the same day that stage six of the inaugural Amgen Tour of California rolled into Thousand Oaks from Santa Barbara. And Bruce Jenner, 1976 decathlon Olympic gold medalist, kicked-off the charity ride.
The charity ride began at 8:30 a.m. and encompassed a moderate 25-mile route suitable to all levels of experienced riders. Participant... |
| | | 02/22/06 | Investigational Therapy Denosumab Increased Bone Mineral Density with Twice-Yearly Dosing; One Year Data Published in New England Journal of Medicine| THOUSAND OAKS, Calif., Feb 22, 2006 (BUSINESS WIRE) -- Amgen (NASDAQ: AMGN), the world's largest biotechnology
company, announced today the publication of Phase 2 data demonstrating
twice-yearly injections of denosumab (previously referred to as AMG
162), a RANK Ligand inhibitor, significantly increased bone mineral
density (BMD) in the total hip, lumbar spine, distal 1/3 radius and
total body compared to placebo. The results of this one-year study
appeared in the Feb. 23, 2006 issue of th... |
| | | 02/14/06 | Amgen Prices $5.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 14, 2006--Amgen
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced the pricing of $2.5 billion principal amount of Convertible
Senior Notes due 2011 and $2.5 billion principal amount of Convertible
Senior Notes due 2013, for an aggregate transaction size of $5
billion. This represents an increase of $1.0 billion from the
aggregate transaction size announced Feb. 13, 2006. The notes are
being sold in a private placemen... |
| | | 02/13/06 | Amgen to Offer $4.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 13, 2006--Amgen
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced its intention to offer, subject to market and other
conditions, approximately $2.0 billion principal amount of Convertible
Senior Notes due 2011 and approximately $2.0 billion principal amount
of Convertible Senior Notes due 2013 through offerings to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of
1933, as amended (the ... |
| | | 02/13/06 | Amgen and Biovitrum Expand Existing License Agreement for Innovative Treatment of Type 2 Diabetes and Other Metabolic Disorders| THOUSAND OAKS, Calif. & STOCKHOLM, Sweden--(BUSINESS WIRE)--Feb.
13, 2006---Amgen (NASDAQ:AMGN) and Biovitrum AB today announced that
they have expanded their existing agreement under which Amgen will now
receive exclusive worldwide rights to develop and commercialize
Biovitrum's small molecule 11beta-HSD1 enzyme inhibitors for the
treatment of metabolic diseases and certain other medical disorders.
The most advanced compound in this collaboration is currently in early
clinical develo... |
| | | 02/02/06 | Amgen Continues Manufacturing Expansion with Additional $1 Billion Investment in Puerto Rico| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 2, 2006--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it expects to invest $1 billion over the next four
years to expand its manufacturing capacity in Puerto Rico to meet
rising global demand for the company's products.
Fabrizio Bonanni, senior vice president, Manufacturing, said the
investment will include expansion of existing facilities in the
company's manufacturing complex in Juncos, Puerto R... |
| | | 01/31/06 | Amgen Announces Put Option for Liquid Yield Option Notes Due 2032 and Zero Coupon Convertible Notes Due 2032| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 31, 2006--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that holders of Amgen's Liquid Yield Option(TM) Notes due
2032 (Zero Coupon--Senior) and Zero Coupon Convertible Notes due 2032
(Zero Coupon--Senior) (collectively, the "Securities") have the right
to surrender their Securities for purchase by Amgen pursuant to the
terms of the indentures for the Securities (the "Put Options"). The
Put Options expire o... |
| | | 01/26/06 | Amgen's Fourth Quarter 2005 Adjusted Earnings Per Share Increased 29 Percent to 75 Cents; Full Year 2005 Adjusted Earnings Per Share Increased 33 Percent to $3.20| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 26, 2006--Amgen
(NASDAQ:AMGN):
Fourth Quarter 2005 GAAP Earnings Per Share Increased to 66
Cents from 53 Cents; Full Year 2005 GAAP Earnings Per Share of
$2.93
2006 Total Revenue Expected to be in the Range of $13.9 to
$14.4 Billion
2006 Adjusted Earnings Per Share Expected to be In the Range
of $3.55 to $3.70
Adjusted R&D Investment Expected to Grow 30 to 40 Percent in
2006
Amgen (NAS... |
| | | 01/26/06 | Amgen and Genentech Sign License Agreements For Antibody Patents| THOUSAND OAKS, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS
WIRE)--Jan. 26, 2006--Amgen (NASDAQ:AMGN) and Genentech Inc.
(NYSE:DNA) today announced that they have entered into license
agreements granting licenses to each other under multiple patents
relating to the manufacture and use of antibodies and related
technology. These agreements include a grant by Genentech to Amgen of
a license for multiple antibodies under the Cabilly patent family
(U.S. Patent No. 6,331,415 et al.) rel... |
| | | 01/24/06 | Amgen to Make Significant Investment in Manufacturing, R&D and Commercial Operations Expansion| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 24, 2006--Amgen
(Nasdaq: AMGN), the world's largest biotechnology company, today
announced that it anticipates significant investment in additional
manufacturing and R&D operations in the United States and Europe and
expansion of its commercial operations into new markets.
In Cork, Ireland, Amgen intends to invest more than $1 billion in
new process development, bulk manufacturing and fill and finish
facilities that will give the compan... |
| | | 01/09/06 | Amgen Announces Webcast of 2005 Fourth Quarter and Full Year Financial Results| THOUSAND OAKS, Calif., Jan 09, 2006 (BUSINESS WIRE) -- Amgen (Nasdaq:AMGN), the world's largest biotechnology
company, today announced plans to report 2005 fourth quarter and full
year financial results on Thursday, January 26, 2006, before the
opening of the financial markets. The announcement will be followed by
a live conference with the investment community at 8 a.m. Eastern
Standard Time.
Participating in the event from Amgen will be Kevin Sharer,
chairman and chief executive offic... |
| | | 12/14/05 | Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty|
THOUSAND OAKS, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--Dec. 14,
2005--
$0.05 to $0.10 Dilution of Adjusted Earnings Per Share
in 2006 and 2007 and Accretive Thereafter
Amgen (Nasdaq: AMGN), the world's largest biotechnology company,
and Abgenix, Inc. (Nasdaq: ABGX), a company specializing in the
discovery, development and manufacture of human therapeutic
antibodies, today announced that they have signed a definitive merger
agreement under which Amg... |
| | | 12/12/05 | New Phase 3 Data Show Potential Benefits of Aranesp(R) Dosed Every Three Weeks for Chemotherapy-Induced Anemia; Aranesp Treatment Achieved and Maintained Target Hemoglobin Levels and Reduced Incidence of Red Blood Cell Transfusions| ATLANTA--(BUSINESS WIRE)--Dec. 12, 2005--Amgen (NASDAQ: AMGN), the
world's largest biotechnology company, today announced results
from the first multi-center, randomized, double-blind,
placebo-controlled, Phase 3 trial of Aranesp(R) (darbepoetin alfa)
administered every three weeks in cancer patients with
chemotherapy-induced anemia. The study revealed that Aranesp increased
and maintained patient hemoglobin levels to the target level of
greater than or equal to 11 grams per deciliter... |
| | | 12/12/05 | Interim Long-Term Follow-up Data Show AMG 531 Increases Platelets in Patients with Immune Thrombocytopenic Purpura; Results Suggest Once-Weekly Dosing of AMG 531 Results in Sustained Platelet Response| ATLANTA--(BUSINESS WIRE)--Dec. 12, 2005--Amgen (NASDAQ:AMGN), the
world's largest biotechnology company, today announced interim results
from an open-label study showing that long-term administration (up to
48 weeks) of its investigational therapy AMG 531 was generally
well-tolerated and stimulated platelet production in patients with
immune thrombocytopenic purpura (ITP). Overall, 85 percent of patients
in the study (29 of 34) achieved a platelet response, defined as
doubling of the ... |
| | | 12/11/05 | Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in Anemic Patients with Myelodysplastic Syndrome (MDS); Patients with Bone Marrow Disorder Also Showed Improvements in Hemoglobin Levels and Fatigue| ATLANTA, Dec 11, 2005 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), the world's largest biotechnology
company, today announced updated interim data from a Phase 2 study
evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa)
administered every three weeks to treat anemia in patients with a bone
marrow disorder known as myelodysplastic syndrome (MDS). Low-risk MDS
patients receiving Aranesp every three weeks, who had no prior
erythropoietic therapy, exhibited an overall response of 70 perc... |
| | | 12/08/05 | The Wellness Community and Amgen Partner with Professional Cyclist George Hincapie to Launch 'Breakaway from Cancer' Initiative| WASHINGTON & THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 8,
2005--
Public can learn more by visiting www.breakawayfromcancer.com
The Wellness Community(R)(TWC) and Amgen (NASDAQ:AMGN) today
joined Discovery Channel(R) professional cycling team member and
10-time Tour de France veteran George Hincapie in launching Breakaway
from Cancer(TM), a national education campaign to raise awareness and
funds to support valuable services and programs that help people
affected by cancer... |
| | | 12/07/05 | Amgen Announces $5 Billion Stock Repurchase Plan| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 7, 2005--Amgen
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced that its board of directors has authorized additional
repurchases of up to $5 billion in Amgen common stock. The company
currently has $2 billion remaining under its previous stock repurchase
program. This new authorization reflects Amgen's confidence in its
long-term prospects.
About Amgen
Amgen discovers, develops and delivers innovative huma... |
| | | 11/15/05 | Amgen Foundation Donates $500,000 to South Asia Earthquake Relief Efforts| Foundation Encourages Other Corporations, Philanthropies to Contribute
THOUSAND OAKS, CA. (November 15, 2005) - The Amgen Foundation today announced
that it will provide $500,000 in cash donations to aid victims of the October
8 South Asia earthquake.
The Foundation will donate $250,000 to Oxfam International to help provide appropriate
winter shelter and clothing for earthquake survivors throughout Pakistan and India.
The Foundation will also give $250,000 to Direct Relie... |
| | | 11/13/05 | Two-Year Trial Results of Amgen Investigational Therapy for Bone Loss, Denosumab, Show Increased Bone Mineral Density with Twice-Yearly Dosing| Phase 2 Trial Results of a Pre-Planned Exploratory Analysis in Postmenopausal Women Released at American College of Rheumatology Annual Scientific MeetingSAN DIEGO, Nov 13, 2005 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), the world's largest biotechnology company,
today announced that twice-yearly subcutaneous injections of denosumab
(60 mg) (previously referred to as AMG 162) increased bone mineral
density (BMD) in the lumbar spine, total hip, distal 1/3 radius and
total body compared to placeb... |
| | | 11/13/05 | Treatment Has Demonstrated Improvement in Physical Function and Kept Joint Damage from Progressing at Three Years| ENBREL Plus Methotrexate: First Treatment Regimen to Demonstrate Ability to Inhibit Radiographic Progression of Joint Damage for Three Consecutive Years
THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa., Nov 13, 2005 (BUSINESS WIRE) --
Amgen (Nasdaq:AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE),
today announced data from a long-term blinded study of anti-TNF agent in patients
with rheumatoid arthritis (RA) demonstrated that more than three quarters of
patients treated ... |
| | | 11/12/05 | Data Show Aranesp(R) (Darbepoetin Alfa) Administered Once Monthly Maintains Hemoglobin Levels in Chronic Kidney Disease Patients with Anemia| Results Presented at the American Society of Nephrology 2005 Annual Meeting Add to the Growing Body of Evidence Examining Administration of Aranesp at Extended Dosing IntervalsPHILADELPHIA, Nov 12, 2005 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), the world's largest biotechnology company,
today announced results from a study by Silver et al. that indicates
Aranesp(R) (darbepoetin alfa) administered once-monthly (QM)
maintained stable hemoglobin control in chronic kidney disease (CKD)
patients wi... |
| | | 11/10/05 | Nominations Open for the Amgen Award for Science Teaching Excellence; 19 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates| THOUSAND OAKS, Calif., Nov 10, 2005 (BUSINESS WIRE) -- Amgen (Nasdaq:AMGN), the world's largest biotechnology
company, today announced a call for nominations for its 15th annual
Amgen Award for Science Teaching Excellence. This award is designed to
recognize and honor extraordinary science teachers, grades K-12 in
communities where Amgen operates, who significantly impact their
students through exemplary science teaching and who achieve
demonstrated results in student learning.
A longst... |
| | | 11/09/05 | Amgen Files Lawsuit Against Roche for Patent Infringement| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 9, 2005--Amgen
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced that it filed a lawsuit in the United States District Court
in Boston, Massachusetts against F. Hoffmann-LaRoche Ltd., Roche
Diagnostics GmbH, and Hoffmann-LaRoche, Inc., seeking a declaration by
the Court that defendants' importation, use, sale or offer to sell a
pegylated version of recombinant human erythropoietin infringe Amgen's
patents. Amgen alle... |
| | | 11/03/05 | Panitumumab Significantly Improves Progression-Free Survival in Phase 3 Randomized Metastatic Colorectal Cancer Study| First EGFr Inhibitor to Demonstrate Improvement in Progression-Free Survival as Monotherapy for Metastatic Colorectal CancerTHOUSAND OAKS & FREMONT, Calif., Nov 03, 2005 (BUSINESS WIRE) -- Amgen (Nasdaq:AMGN) and Abgenix, Inc. (Nasdaq:ABGX) today
announced that a pivotal Phase 3 study of panitumumab met the primary
endpoint of improving progression-free survival in patients with
metastatic colorectal cancer (mCRC) who had failed standard
chemotherapy. In this randomized Phase 3 trial involvi... |
| | | 11/03/05 | Media Notification/Webcast Notification - Amgen and Abgenix to Conduct Conference Call and Webcast Regarding Panitumumab Pivotal Study Results - November 3, 2005, 8:00 am PT| THOUSAND OAKS & FREMONT, Calif.--(BUSINESS WIRE)--Nov. 3,
2005--Amgen (Nasdaq:AMGN) and Abgenix, Inc. (Nasdaq:ABGX) will host a
joint conference call on November 3 at 8:00 a.m. Pacific Time to
discuss the top-line results of a recently completed pivotal study of
panitumumab. A separate press release announcing these results is
being issued this morning.
Live audio of the conference call will be simultaneously broadcast
over the Internet and will be available to members of the news... |
| | | 11/02/05 | Amgen Announces Sponsorship of World-Class Cycling Event; Company to Join with the Wellness Community to Raise Awareness and Funds to Help People Fight Cancer| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 2, 2005--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced its title sponsorship of the Amgen Tour of California, an
approximately 700-mile cycling event featuring world-class
professional teams battling it out in some of the most picturesque
locales in the state from February 19 - 26, 2006.
"For 25 years, Amgen has tapped the power of pioneering science
and innovation to fight serious illness and improve p... |
| | | 10/28/05 | European Commission Approves Kepivance(TM) (Palifermin) for Oral Mucositis in Cancer Patients Undergoing Blood and Bone Marrow Transplant| THOUSAND OAKS, Calif., Oct 28, 2005 (BUSINESS WIRE) -- Amgen (Nasdaq:AMGN), the world's largest biotechnology
company, today announced that Kepivance(TM) (palifermin) has received
regulatory approval in the European Union (EU). Palifermin is now
authorized in the EU to decrease the incidence, duration and severity
of oral mucositis (mouth sores) in patients with hematologic (blood)
cancers undergoing myeloablative therapy associated with a high
incidence of severe oral mucositis, and requi... |
| | | 10/19/05 | Amgen's Third Quarter 2005 Adjusted Earnings Per Share Increased 33 Percent to 85 Cents; Third Quarter 2005 GAAP Earnings Per Share Increased to 77 Cents from 18 Cents| Third Quarter Product Sales Growth of 19 Percent Driven by Sales of Aranesp, Neulasta and EnbrelTHOUSAND OAKS, Calif., Oct 19, 2005 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS) of
85 cents for the third quarter of 2005, an increase of 33 percent
compared to 64 cents during the third quarter of 2004. Adjusted net
income rose 27 percent to $1.1 billion compared to $839 million in the
third quarter of 2004.
During the third quarter, total product sales in... |
| | | 10/03/05 | Amgen Announces Webcast of Third Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 3, 2005--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it plans to report its third quarter financial results
on Wednesday, October 19, 2005 after the close of the financial
markets. The announcement will be followed by a conference call with
the investment community at 2 p.m. Pacific Daylight Time.
Participating in the call from Amgen will be Kevin Sharer,
chairman and chief executive officer, and... |
| | | 09/15/05 | FDA Expands Neulasta(R) Label; New Label Extends First-Cycle Protection From Infection To Cancer Patients Receiving Moderately Myelosuppressive Chemotherapy| THOUSAND OAKS, Calif., Sep 15, 2005 (BUSINESS WIRE) -- Amgen (Nasdaq: AMGN), the world's largest biotechnology
company, today announced that the U.S. Food and Drug Administration
(FDA) approved an update to the Neulasta(R) (pegfilgrastim)
prescribing information to include data from a landmark Phase 3 study
demonstrating the white blood cell booster helps protect patients with
most types of cancer undergoing moderately myelosuppressive
chemotherapy from infection, as manifested by febrile ... |
| | | 09/06/05 | Amgen Announces FDA Licensure of Two New Manufacturing Facilities; Company Continues to Meet Increased Demand for Its Novel Therapeutics| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 6, 2005--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced the U.S. Food and Drug Administration (FDA) has approved the
company's new manufacturing facilities in West Greenwich, Rhode
Island, and Juncos, Puerto Rico for the production of Amgen's
therapeutics.
The new manufacturing plant at Amgen's Rhode Island facility has
received FDA approval for the production of Enbrel® (etanercept),
the company's leadi... |
| | | 09/02/05 | Amgen Names Phyllis Piano Vice President, Corporate Communications and Philanthropy| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 2, 2005--Amgen
(Nasdaq:AMGN) today announced the appointment of Phyllis Piano to the
position of vice president, Corporate Communications and Philanthropy.
Piano will be responsible for the company's strategic communications
platform, including internal and external communications, public
relations, communications issues management, master brand management,
web communications and Amgen's philanthropy efforts.
Piano joins Amgen after serv... |
| | | 09/02/05 | Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia with Darbepoetin Alfa in Patients with Heart Failure to Reduce Mortality and Hospitalization| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 2, 2005--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it will initiate a Phase 3 randomized,
placebo-controlled, double-blind, multicenter, multi-national trial to
evaluate the effect of anemia treatment with darbepoetin alfa on
morbidity and mortality in patients with heart failure.
"Numerous epidemiological studies have consistently demonstrated
that lower hemoglobin values, reflecting a conditio... |
| | | 09/01/05 | Amgen Donates $2.5 Million to Hurricane Katrina Relief Efforts| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 1, 2005--Amgen
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it is providing an initial cash contribution of $2.5
million and establishing a company-wide Hurricane Katrina Relief
Program in support of humanitarian aid, with a special focus on access
to health care. A portion of Amgen's contribution will go to the
American Red Cross for general aid to the region and the balance will
support organizations that ca... |
| | | 08/10/05 | Amgen Names Michael Kelly as Chief Accounting Officer| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 10, 2005--Amgen
(NASDAQ:AMGN), a leading human therapeutics company in the
biotechnology industry, today announced the appointment of Michael
Kelly as vice president, Corporate Planning and Control, and chief
accounting officer. Kelly, formerly vice president, Finance for
Process Development, Operations and Quality at Amgen, will report to
Richard Nanula, executive vice president and chief financial officer.
Kelly replaces Timothy Martin as Amg... |
| | | 08/04/05 | Amgen Strengthens Focus on Oncology Pipeline, Names David R. Parkinson to New Role in Research and Development Organization| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 4, 2005--Amgen
(NASDAQ:AMGN), a leading human therapeutics company in the
biotechnology industry, today announced that David R. Parkinson, M.D.,
formerly vice president and head of Global Clinical Oncology, will
assume a new role as vice president, Oncology Development and
Commercialization.
In this new position, Parkinson will join Amgen's most senior
executives as a member of the Pipeline Steering Committee, and will
develop strategi... |
| | | 08/02/05 | Amgen Adopts ``Guiding Principles'' for Direct-to-Consumer Advertising| THOUSAND OAKS, Calif., Aug 02, 2005 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN) today announced that it has become a
signatory to the pharmaceutical industry's "Guiding Principles" on
direct-to-consumer (DTC) advertising. The Pharmaceutical Research and
Manufacturers of America (PhRMA) approved the Guiding Principles on
Friday, July 29, 2005 and they will go into effect in January 2006.
Amgen's guidelines will go into effect by January 1, 2006.
These voluntary principles recognize the role ... |
| | | 08/01/05 | Abgenix and Amgen Announce FDA Grants Panitumumab Fast Track Designation for Metastatic Colorectal Cancer| THOUSAND OAKS, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--Aug. 1,
2005--Amgen (Nasdaq:AMGN) and Abgenix, Inc. (Nasdaq:ABGX) today
announced that the U.S. Food and Drug Administration (FDA) has granted
fast track designation for panitumumab, an experimental fully human
monoclonal antibody directed against the epidermal growth factor
receptor (EGFr), for patients with metastatic colorectal cancer who
have failed standard chemotherapy treatment.
"We are advancing the development of... |
| | | 07/28/05 | Kepivance(TM) (palifermin) Receives Positive Regulatory Opinion for Approval in Europe| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 28, 2005--Amgen
(Nasdaq:AMGN) today announced that the European Committee for
Medicinal Products for Human Use (CHMP), which is the scientific
advisory panel to the European Medicines Agency (EMEA), has issued a
positive opinion to approve marketing authorization for Kepivance(TM)
(palifermin) in the European Union (EU). The CHMP opinion recommends
authorization of palifermin to decrease the incidence, duration and
severity of oral mucositis (m... |
| | | 07/19/05 | Amgen's Second Quarter 2005 Adjusted Earnings Per Share Increased 42 Percent to 88 Cents| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 19, 2005--Amgen Inc.
(NASDAQ:AMGN):
Second Quarter 2005 GAAP Earnings Per Share Increased 44
percent to 82 Cents
2005 Revenue Growth Guidance Raised to Mid-to-High Teens
2005 Adjusted Earnings Per Share Guidance Increased to a Range
of $3.10 to $3.20, a Growth Rate of 29 to 33 Percent
Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS) for
the second quarter of 2005 of 88 cents, an incre... |
| | | 07/06/05 | Interim Data Suggest Major Response with Aranesp(R) in Anemic Patients with Myelodysplastic Syndromes (MDS)| THOUSAND OAKS, Calif., Jul 06, 2005 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ:AMGN), the world's largest
biotechnology company, today announced new interim data from a Phase 2
study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa)
every three weeks to treat anemia in patients with a bone marrow
disorder known as myelodysplastic syndromes (MDS). The data were
presented at the 17th International Symposium of the Multinational
Association of Supportive Care in Cancer (MASCC) in Gene... |
| | | 06/23/05 | Amgen Announces Webcast of Second Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 23, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it plans to report its second quarter financial results
on Tuesday, July 19, 2005 after the close of the financial markets.
The announcement will be followed by a conference call with the
investment community at 2 p.m. Pacific Daylight Time.
Participating in the call from Amgen will be Kevin Sharer,
chairman and chief executive officer, and... |
| | | 06/01/05 | FDA Expands ENBREL Psoriatic Arthritis Indication -- ENBREL Approved as First and Only Treatment to Improve Physical Function in These Patients|
Label Also Updated with ENBREL Data Demonstrating Inhibition of
Joint Destruction among Most Psoriatic Arthritis Patients Treated
Continuously for Two Years
THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--June
1, 2005-- Amgen Inc. (NASDAQ:AMGN) and Wyeth Pharmaceuticals, a division of
Wyeth (NYSE:WYE), today announced that the U.S. Food and Drug
Administration (FDA) approved an expanded indication for Enbrel(R)
(etanercept) to improve phy... |
| | | 05/19/05 | 2005 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Communities Across U.S. and Puerto Rico| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 19, 2005--Amgen Inc.
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced the 19 science teachers who are this year's recipients of
the 14th annual Amgen Award for Science Teaching Excellence. This
award is designed to recognize and honor extraordinary science
teachers in K-12 public and private schools in communities where Amgen
operates. Those selected are teachers whose exemplary science teaching
has had demonstrated resu... |
| | | 05/17/05 | Amgen Names Jim Daly, Senior Vice President, North America Commercial Operations| THOUSAND OAKS, Calif., May 17, 2005 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ:AMGN), the world's largest
biotechnology company, today announced the appointment of Jim Daly to
the new position of senior vice president, North America Commercial
Operations. Daly, formerly vice president and general manager of the
U.S. Oncology Business Unit at Amgen, will be responsible for leading
the company's commercial activities in the United States and Canada.
Daly will report to George Morrow, executive vi... |
| | | 05/17/05 | Further Phase 2 Data Confirm Panitumumab Single-Agent Antitumor Activity in Patients with Metastatic Colorectal Cancer| ORLANDO, Fla., May 17, 2005 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ:AMGN), the world's largest
biotechnology company, and Abgenix, Inc. (NASDAQ:ABGX), a leading
antibody development company, today announced updated results from an
ongoing Phase 2 study of panitumumab, a fully human monoclonal
antibody directed against the epidermal growth factor receptor (EGFr).
The results demonstrate that panitumumab has antitumor activity when
administered as a single-agent treatment to patients with meta... |
| | | 05/15/05 | Aranesp Dosed Every Three Weeks Achieved and Maintained Target Hemoglobin Levels in Patients with Chemotherapy-Induced Anemia| ORLANDO, Fla.--(BUSINESS WIRE)--May 15, 2005--Amgen Inc.,
(NASDAQ:AMGN) the world's largest biotechnology company, today
announced that new interim data from a single-arm, open label study of
1,225 cancer patients receiving chemotherapy demonstrated that
Aranesp(R) (darbepoetin alfa) administered every three weeks was
effective in increasing and maintaining patient hemoglobin levels to
the recommended target of greater than or equal to 11 g/dL. Further,
treatment with Aranesp reduced the ... |
| | | 05/15/05 | Final Results of Phase 3 Head-to-Head Study Demonstrate Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Weekly in Cancer Patients with Chemotherapy-Induced Anemia| ORLANDO, Fla.--(BUSINESS WIRE)--May 15, 2005--Amgen Inc.
(NASDAQ:AMGN):
Randomized Head-to-Head Study of Anemia Treatments Shows
Comparability in Transfusion Rates and Achievement of Target
Hemoglobin in More Than 1,200 Patients with
Chemotherapy-Induced Anemia
Amgen Inc., (NASDAQ:AMGN) the world's largest biotechnology
company, today announced that final results of a Phase 3 randomized,
head-to-head study demonstrated that 200 mcg of Aranesp... |
| | | 05/15/05 | Large Community-Based Clinical Trial in Older Cancer Patients Suggests Benefits of Neulasta in First and Subsequent Cycles Of Chemotherapy| ORLANDO, Fla.--(BUSINESS WIRE)--May 15, 2005--Amgen Inc.,
(NASDAQ:AMGN) the world's largest biotechnology company, today
announced that an initial report from a study of 701 older cancer
patients with solid tumors demonstrates Neulasta(R) (pegfilgrastim)
administered beginning in the first cycle of myelosuppressive
chemotherapy resulted in reductions in febrile neutropenia (low white
blood cell count with fever) and related complications, compared to
those who received Neulasta in later c... |
| | | 05/06/05 | Amgen Submits Supplemental Biologics License Application for Aranesp Extended Dosing; Phase 3 Study Evaluated Aranesp Dosed Once Every Three Weeks in Patients with Chemotherapy-Induced Anemia| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 6, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced the submission of a supplemental Biologics License
Application (sBLA) to the U.S. Food and Drug Administration (FDA) for
Aranesp(R) (darbepoetin alfa). The sBLA is based on Phase 3 data that
Amgen believes will demonstrate Aranesp administered every three weeks
is safe and effective in the treatment of chemotherapy-induced anemia
in patients with non-my... |
| | | 05/05/05 | Amgen Announces Expiration and Results of its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 5, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, announced
today that it has completed its previously announced offer to exchange
up to $2,359,102,000 aggregate principal amount at maturity of its
outstanding Liquid Yield Option Notes due 2032 (the "Old Notes") for
an equal amount of its Zero Coupon Convertible Notes due 2032 (the
"New Notes"). The exchange offer expired at 5:00 p.m., EDT, on May 5,
2005 (the "Expira... |
| | | 05/04/05 | Amgen Announces One-Day Extension of Its Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 4, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it has extended its pending exchange offer under which
Amgen is offering to exchange new Zero Coupon Convertible Notes due
2032 (the "New Notes") for all of its $2,359,102,000 principal amount
at maturity of currently outstanding Liquid Yield Option Notes due
2032 (the "Old Notes"). The expiration date for the exchange offer has
been extended to 5:... |
| | | 05/03/05 | Amgen Announces Plans to Webcast Selected Management Presentations| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 3, 2005--Amgen Inc.
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced that it plans to webcast selected presentations regarding
developments in Amgen's business given by management at certain
investor and medical conferences. Information regarding presentation
times and webcast availability will be noted in advance on Amgen's
Investor Relations Calendar of Events at www.amgen.com. The live
webcasts for these presentations... |
| | | 04/26/05 | Phase 3 Clinical Trial Initiated to Evaluate the Use of Panitumumab Therapy for First-Line Treatment of Metastatic Colorectal Cancer; Study Evaluates Panitumumab Administered With Bevacizumab and Chemotherapy| THOUSAND OAKS & FREMONT, Calif.--(BUSINESS WIRE)--April 26,
2005--Amgen Inc. (Nasdaq:AMGN) and Abgenix, Inc. (Nasdaq:ABGX) today
announced the initiation of a Phase 3 clinical study to evaluate the
potential benefits of adding panitumumab, an experimental fully human
monoclonal antibody, administered every other week to bevacizumab
(Avastin(TM), Genentech) and either oxaliplatin- (Eloxatin(R),
sanofi-aventis) or irinotecan-based (Camptosar(R), Pfizer)
chemotherapy for the first-line treat... |
| | | 04/21/05 | Amgen's First Quarter 2005 Adjusted Earnings Per Share Increased 26 Percent to 72 Cents| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 21, 2005--Amgen Inc.
(NASDAQ:AMGN):
First Quarter 2005 GAAP Earnings Per Share of 67 Cents
Total Product Sales Increased 24 Percent
2005 Guidance Increased for Total Revenue and Adjusted EPS
Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology
company, reported adjusted earnings per share for the first quarter of
2005 of 72 cents, an increase of 26 percent compared to 57 cents
during the first quarter ... |
| | | 04/11/05 | Multimedia Available: Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease| --(BUSINESS WIRE)--Most people with chronic kidney disease die
from cardiovascular problems before ever receiving dialysis or a
transplant. Now there's a new clinical trial called TREAT -- Trial To
Reduce Cardiovascular Events with Aranesp Therapy. The goal of the
trial is to determine if treating anemia will reduce cardiovascular
events in people with chronic kidney disease and Type 2 diabetes.
Radio News Feature
You can reach the story directly by going to:
http://www.ne... |
| | | 04/11/05 | Landmark Trial to Link Reduction in Cardiovascular Risk With Treatment of Anemia in Diabetics With Chronic Kidney Disease| Apr 11, 2005 (BUSINESS WIRE) -- Most people with chronic kidney disease die from
cardiovascular problems before ever receiving dialysis or a
transplant. Now there's a new clinical trial called TREAT -- Trial To
Reduce Cardiovascular Events with Aranesp Therapy. The goal of the
trial is to determine if treating anemia will reduce cardiovascular
events in people with chronic kidney disease and Type 2 diabetes.
Radio News Feature
You can reach the story directly by going to
http://www.n... |
| | | 04/06/05 | Amgen Commences Exchange Offer for Its Outstanding Liquid Yield Option Notes Due 2032| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 6, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it has commenced an exchange offer under which Amgen is
offering to exchange new Zero Coupon Convertible Notes due 2032 (the
"New Notes") for all of its $2,359,102,000 principal amount at
maturity of currently outstanding Liquid Yield Option Notes due 2032
(the "Old Notes"). As consideration for exchanging the Old Notes for
the New Notes, holders... |
| | | 04/04/05 | Amgen Announces Webcast of First Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 4, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it plans to report its first quarter financial results
on Thursday, April 21, 2005 after the close of the financial markets.
The announcement will be followed by a conference call with the
investment community at 2 p.m. Pacific Daylight Time.
Participating in the call from Amgen will be Kevin Sharer,
chairman and chief executive officer, an... |
| | | 03/28/05 | Landmark Trial Will Evaluate the Impact of Treating Anemia on Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes|
TREAT Study Highlighted in March American Heart Journal
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 28, 2005-- Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology
company, today announced that TREAT (Trial to Reduce Cardiovascular
Events with Aranesp(R) Therapy), an Amgen-sponsored trial, is featured
in the March 2005 issue of the American Heart Journal. TREAT is the
first randomized controlled trial specifically designed to determine
whether treating anemia ... |
| | | 03/02/05 | Amgen Announces Results of Its Repurchase of Tendered Liquid Yield Option Notes Due 2032| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 2, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced the results of its offer to purchase its Liquid Yield Option
Notes (Zero Coupon--Senior) due 2032 (the "LYONs") pursuant to the
terms thereof. The holders' option to surrender their LYONs for
repurchase expired at 5:00 pm EST on March 1, 2005.
Amgen has been advised by the paying agent, LaSalle Bank National
Association, that approximately $1.59... |
| | | 02/25/05 | Phase 3 Study Published in The Journal of Clinical Oncology Shows First-Cycle Administration of Neulasta Significantly Lowers Incidence of Neutropenia with Related Fever and Hospitalization| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 25, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that data from the largest randomized placebo-controlled
study to date for Neulasta(R) (pegfilgrastim) has been published in
the February 20 issue of The Journal of Clinical Oncology. The phase 3
study showed that administering Neulasta beginning in the first and
subsequent cycles of chemotherapy reduced the incidence of febrile
neutropenia (low white... |
| | | 02/22/05 | Amgen Announces One-Time Cash Payment and Additional Put Right for Liquid Yield Option Notes Due 2032| THOUSAND OAKS, Calif., Feb 22, 2005 (BUSINESS WIRE) -- Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced a one-time cash payment of $9.23 for every $1,000 aggregate
principal amount at maturity of Amgen's Liquid Yield Option(TM) Notes
due 2032 (Zero Coupon--Senior) (the "LYONs"). This payment is
approximately equal to 1.25 percent of each LYONs' accreted value and
0.923 percent of each LYONs' principal amount at maturity. Amgen will
make this payment to ... |
| | | 02/18/05 | Treatment with ENBREL Had a Positive Effect on Activities of Daily Living for Patients with Psoriasis| THOUSAND OAKS, Calif. & MADISON, N.J.--(BUSINESS WIRE)--Feb. 18,
2005--
Data Also Show Many ENBREL Patients Experienced Improvements in
Symptoms and the Impact of the Disease on Their Daily Life
At three months, nearly 30 percent of 311 patients with
moderate-to-severe psoriasis who were taking Enbrel(R) (etanercept)
reported that they were "not at all" bothered by their psoriasis, as
indicated by their achieving a "zero" score on the Dermatology Life
Quality Index (D... |
| | | 02/11/05 | Following Complete Review of Phase 2 Trial Data Amgen Confirms Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings, Patient Safety, Drove Decision| Company Confirms Commitment to Parkinson's Disease Research THOUSAND OAKS, Calif., Feb 11, 2005 (BUSINESS WIRE) -- Citing patient safety concerns and scientific findings, Amgen Inc.
(Nasdaq:AMGN) announced today that it has confirmed its previous
decision to halt clinical trials of the experimental drug GDNF
(Glial-cell-lined-derived neurotrophic factor). Amgen halted studies
of GDNF when scientific results indicated that allowing patients to
continue treatment could potentially cause perm... |
| | | 01/31/05 | Amgen Announces Put Option Notification for Liquid Yield Option Notes Due 2032| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 31, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it has notified holders of Amgen's Liquid Yield
Option(TM) Notes due 2032 (Zero Coupon--Senior) (the "LYONs") that
they have the right to surrender their LYONs for purchase by Amgen
pursuant to the terms of the Indenture for the LYONs (the "Put
Option"). The Put Option expires on March 1, 2005.
As required by law, Amgen will file a Tender O... |
| | | 01/27/05 | Amgen's Fourth Quarter 2004 Adjusted Earnings Per Share Increased 26 Percent to 58 Cents; Full Year 2004 Adjusted Earnings Per Share Increased 26 Percent to $2.40| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 27, 2005--Amgen Inc.
(Nasdaq:AMGN):
Fourth Quarter 2004 GAAP Earnings Per Share of 53 Cents; Full
Year 2004 GAAP Earnings Per Share of $1.81
2005 Total Revenue Growth Expected to be in the High
Single-Digits to Low Teens Range
2005 Adjusted Earnings Per Share Expected to be in the Range
of $2.70 to $2.85
Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology
compan... |
| | | 01/21/05 | Amgen Announces Webcast of 2004 Fourth Quarter and Full Year Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 21, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it plans to report its 2004 fourth quarter and full
year financial results on Thursday, January 27, 2005 before the
opening of the financial markets. The announcement will be followed by
a live conference with the investment community at 8 a.m. Eastern
Standard Time.
Participating in the event from Amgen will be Kevin Sharer,
chairman an... |
| | | 01/11/05 | Amgen Significantly Expands Support of Patient Assistance Programs; Financial Support To Help Ensure Patients Have Access To Innovative Therapies Critical To Care| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 11, 2005--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced a significant increase in its funding to
foundation-sponsored patient assistance programs for 2005. These
programs are designed to ensure access for patients with cancer or
kidney disease who cannot afford the co-payments for prescription drug
therapies critical to their overall treatment. Amgen is increasing the
level of this patient assistance to an... |
| | | 01/03/05 | Amgen Donates $1 Million and Establishes Tsunami Relief Program; Staff Donations, Company Contributions To Help South Asia Victims| THOUSAND OAKS, Calif., Jan 3, 2005 (BUSINESS WIRE) -- Amgen Inc.
(Nasdaq:AMGN) today announced that it has established a company-wide
South Asia Tsunami Relief Program and provided an initial cash
contribution of $1 million in support of humanitarian aid to the
International Federation of Red Cross and Red Crescent Societies.
Amgen has also launched an internal Web site to facilitate
individual staff donations. Amgen staff contributions for tsunami
relief efforts will be matched dolla... |
| | | 12/15/04 | FDA Approves Kepivance for Severe Oral Mucositis in Cancer Patients Undergoing Bone Marrow Transplant; Pivotal Phase 3 Study Published in This Week's New England Journal of Medicine| THOUSAND OAKS, Calif., Dec 15, 2004 (BUSINESS WIRE) -- Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that following priority review, the U.S. Food and Drug
Administration (FDA) has approved Kepivance(TM) (palifermin), the
first and only therapy to decrease the incidence and duration of
severe oral mucositis (mouth sores) in patients with hematologic
(blood) cancers undergoing high-dose chemotherapy, with or without
radiation, followed by a bone marro... |
| | | 12/14/04 | Amgen Names Willard Dere Senior Vice President, Global Development| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 14, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced the appointment of Willard Dere, M.D. to the position of
senior vice president, Global Development. In addition, Dere will also
be named Amgen's chief medical officer. Dere, formerly vice president
and head of General Medicine at Amgen, will be responsible for leading
Amgen's development organization, one of the strongest in the industry
with more tha... |
| | | 12/11/04 | Randomized Head-to-Head Trial Shows Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once a Week in Breast Cancer Patients| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 11, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that data from a head-to-head study show that 200 mcg of
Aranesp(R) (darbepoetin alfa) dosed once every two weeks has similar
efficacy to 40,000 U of Epoetin alfa dosed once every week in boosting
hemoglobin and reducing the need for blood transfusions in breast
cancer patients with chemotherapy-induced anemia. The results were
presented by one of the... |
| | | 12/10/04 | Phase 3 Study Shows Majority of Neutropenia with Related Fever and Hospitalization Occurs in First Treatment Cycle for Breast Cancer Patients Not Receiving Neulasta|
The Largest Randomized Placebo-Controlled Study to Date for
Neulasta Supports First and Subsequent Cycle Administration
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 10, 2004--
Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology
company, today announced that new data from a Phase 3 study show that
the majority of neutropenic complications occur in the first cycle of
chemotherapy treatment for breast cancer patients who are not
administered Neulasta(R) (p... |
| | | 12/07/04 | Amgen Announces $5 Billion Stock Repurchase Plan| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 7, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that its Board of Directors has authorized additional
repurchases of up to $5 billion in Amgen common stock. The company
currently has $968 million remaining under its previous stock
repurchase program. This new authorization reflects Amgen's confidence
in its long-term prospects.
About Amgen
Amgen is a global biotechnology company that di... |
| | | 12/06/04 | FDA Grants Fast Track Designation for Amgen's AMG 531 and AMG 706 Experimental Therapies to Potentially Treat Life-Threatening Conditions| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Dec. 6, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that the U.S. Food and Drug Administration (FDA) has granted
fast track designation for two of the company's experimental
therapies, AMG 531 and AMG 706. AMG 531 received orphan drug
designation in 2003.
"AMG 531 is Amgen's first peptibody and represents a new approach
to potentially treat immune thrombocytopenic purpura (ITP), an
autoimmune ble... |
| | | 11/29/04 | Nominations Open for the Amgen Award For Science Teaching Excellence; 19 Outstanding Teachers Will Be Recognized in Communities Where Amgen Operates| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 29, 2004--Amgen Inc.
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced a call for nominations for its 14th annual Amgen Award for
Science Teaching Excellence. This award is designed to recognize and
honor extraordinary science teachers, grades K-12 in communities where
Amgen operates, who significantly impact their students through
exemplary science teaching and who achieve demonstrated results in
student learning.
... |
| | | 11/29/04 | Nominations Open for the Amgen Award For Science Teaching Excellence| Four Outstanding Teachers Will Be Recognized in Puerto Rico
JUNCOS, Puerto Rico (November 29, 2004) – Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, announces a call for nominations for its 14th annual Amgen Award for Science Teaching Excellence. This award is designed to recognize and honor extraordinary science teachers, grades K-12 in communities where Amgen operates, who significantly impact their students through exemplary science teaching and who achieve demon... |
| | | 11/24/04 | Published Head-to-Head Data Show Aranesp Dosed Every Two Weeks is Comparable to Epoetin Alfa Dosed Once-a-Week|
Data Show Aranesp(R) Offers Patients Added Convenience and
Flexibility in the Treatment of Anemia
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 24, 2004-- Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology
company, today announced that data published online in the December
edition of The Oncologist from a study analyzing three identical
head-to-head trials show that 200 mcg of Aranesp(R) (darbepoetin alfa)
dosed once every two weeks is as effe... |
| | | 11/15/04 | Amgen Announces Offer of $2 Billion in Two Series of Senior Notes| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 15, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced the pricing of an offering of $1.0 billion principal amount
of 4% Senior Notes due 2009 and $1.0 billion principal amount of 4.85%
Senior Notes due 2014. The offering is being made pursuant to an
exemption from the registration requirements of the Securities Act of
1933, as amended (the "Securities Act"). The sale of the notes is
expected to close on ... |
| | | 11/11/04 | Amgen Announces the Formation of Amgen Ventures; Venture Capital Fund Designed to Provide Resources to Help Advance Early-Stage Biotechnology Companies and Human Therapeutics| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 11, 2004--Amgen Inc.
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced the formation of Amgen Ventures, a corporate venture capital
fund designed to provide emerging biotechnology companies with
resources to develop pioneering discoveries focused on human
therapeutics. Amgen Ventures reflects Amgen's commitment to helping
patients through cutting-edge science and is an important component of
Amgen's overall outreach stra... |
| | | 11/01/04 | Amgen Launches Landmark Trial to Evaluate the Impact of Treating Anemia on Cardiovascular Risks in Patients with Chronic Kidney Disease and Type 2 Diabetes| ST. LOUIS--(BUSINESS WIRE)--Nov. 1, 2004--
Sensipar(R) (cinacalcet HCl) Data Also Presented at American Society
of Nephrology Meeting Underscores Amgen's Commitment to Chronic Kidney
Disease Patients with Secondary Hyperparathyroidism
Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology
company, today announced that the company has initiated a landmark
trial to evaluate the impact of treating anemia on cardiovascular
outcomes in patients with chronic kidney dis... |
| | | 11/01/04 | Interim Phase 2 Data Suggest Activity of Panitumumab with Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer| VIENNA, Austria--(BUSINESS WIRE)--Nov. 1, 2004--Amgen Inc.
(Nasdaq:AMGN) and Abgenix (Nasdaq:ABGX) today announced interim data
from part one of an ongoing Phase 2 study suggesting panitumumab, the
first fully human monoclonal antibody that inhibits the epidermal
growth factor receptor (EGFr), has activity as a first-line treatment
with chemotherapy in patients with metastatic colorectal cancer
(mCRC). Results from part one of this two-part single-arm, open-label
phase 2 study were descri... |
| | | 10/28/04 | European Commission Approves Innovative First-in-Class Treatment for a Serious Complication of Chronic Kidney Disease|
Amgen Introduces Mimpara(R) Approved to Treat Secondary
Hyperparathyroidism in Chronic Kidney Disease Patients on Dialysis
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 28, 2004--
Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology
company, today announced that its first-in-class oral calcimimetic,
Mimpara(R) (cinacalcet), known as Sensipar(R) (cinacalcet HCl) in the
United States (U.S.), has received regulatory approval in the European
Union (EU... |
| | | 10/20/04 | Amgen's Third Quarter 2004 Adjusted Earnings Per Share Increased 21 Percent to 64 Cents| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 20, 2004--Amgen Inc.
(Nasdaq:AMGN):
Third Quarter GAAP Earnings Per Share of 18 Cents Includes a
$554 Million Acquired In-Process R&D Charge Related to Tularik
Acquisition
Total Product Sales Grew 23 Percent in the Third Quarter Led
by Aranesp(R) and Enbrel(R)
2004 Guidance Increased for Total Revenue and Adjusted
Earnings Per Share
Amgen Inc. (Nasdaq:AMGN), the world's... |
| | | 10/18/04 | New Two-Year Data Show That Most Rheumatoid Arthritis Patients Treated with ENBREL Plus Methotrexate Had No Progression of Joint Damage| Additional Data Demonstrated that Patients Treated with ENBREL
Plus Methotrexate had Greater Improvement in Physical Function Scores
After Two Years Compared to Methotrexate Alone
THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Oct.
18, 2004--
Nearly three quarters (74.2 percent) of rheumatoid arthritis (RA)
patients treated with ENBREL(R) (etanercept) plus methotrexate
combination therapy experienced no progression of joint damage over a
cont... |
| | | 10/15/04 | Court Rules in Amgen's Favor in TKT Litigation; Affirms Validity of EPO Patents| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 15, 2004--Amgen, Inc.
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced that Judge William G. Young of the U.S. District Court of
Massachusetts in Boston ruled in its favor in the patent litigation
suit against Transkaryotic Therapies Inc. ("TKT") and Aventis
Pharmaceuticals Inc. The Court found Amgen's patent claims valid and
infringed by TKT and Aventis.
Today's decision addressed the issues remanded to the Distr... |
| | | 10/13/04 | Amgen Names Rolf Hoffmann Senior Vice President, European Operations| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 13, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced the appointment of Rolf Hoffmann to the position of senior
vice president, Amgen Europe. Hoffmann will be responsible for setting
Amgen's commercial strategy in Europe and continuing to grow Amgen's
presence in Europe.
"Rolf brings to Amgen a wealth of international management
experience gained over nearly 20 years in the pharmaceutical
industr... |
| | | 10/12/04 | Amgen Announces Webcast of Third Quarter Financial Results| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 12, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that it plans to report its third quarter financial results
on Wednesday, October 20, 2004 after the close of the financial
markets. The announcement will be followed by a conference call with
the investment community at 2 p.m. Pacific Standard Time.
Participating in the call from Amgen will be Kevin Sharer,
chairman and chief executive officer,... |
| | | 10/03/04 | Amgen Investigational Therapy for Bone Loss, AMG 162, Increased Bone Mineral Density with Twice Yearly Injection|
Phase 2 One Year Trial Results in Postmenopausal Women Released at
American Society for Bone and Mineral Research Annual Meeting
SEATTLE--(BUSINESS WIRE)--Oct. 3, 2004--
Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology
company, today announced that at all doses studied, twice yearly
injections of AMG 162, the company's investigational therapy for bone
loss, significantly increased bone mineral density (BMD) at the total
hip compared with placebo at 12 m... |
| | | 09/28/04 | FDA Approves ENBREL to Induce Major Clinical Response in Patients With Rheumatoid Arthritis; Additional Data Demonstrates Increased Levels of Sustained Disease Control| THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Sept.
28, 2004--Enbrel(R) (etanercept) is the first and only biologic to
receive an indication by the U.S. Food and Drug Administration (FDA)
to induce a Major Clinical Response in patients with rheumatoid
arthritis (RA), Amgen Inc. (Nasdaq:AMGN) and Wyeth Pharmaceuticals, a
division of Wyeth (NYSE:WYE), announced today. In addition, the FDA
approved updated radiographic data in the ENBREL label, which
demonstrated that more ... |
| | | 09/28/04 | FDA Approves New and Easy Way to Take ENBREL; Benefits of ENBREL Delivered in Convenient Once-Weekly 50 mg/mL Prefilled Syringe| THOUSAND OAKS, Calif., & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Sept.
28, 2004--Amgen Inc. (NASDAQ:AMGN) and Wyeth Pharmaceuticals, a
division of Wyeth (NYSE:WYE), today announced that the new 50 mg/mL
prefilled syringe of Enbrel(R) (etanercept) has been approved by the
U.S. Food and Drug Administration (FDA) as the recommended dosing form
for treatment in all approved adult indications. The new prefilled
syringe, available for patient use in the fourth quarter 2004, will
eliminate the need ... |
| | | 09/27/04 | Amgen Announces Plans to Webcast Selected Management Presentations| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 27, 2004--Amgen Inc.
(NASDAQ:AMGN), the world's largest biotechnology company, today
announced that it plans to webcast selected presentations given by
management at certain investor and medical conferences. Information
regarding presentation times and webcast availability will be noted in
advance on Amgen's Investor Relations Calendar of Events at
www.amgen.com. The live webcasts for these presentations may be
accessed via the same link on th... |
| | | 09/21/04 | Aranesp Approved for Extended Dosing by European Commission|
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 20, 2004--
New Dosing Paradigm To Benefit Patients Across EU
Suffering From Anemia Associated With Cancer Chemotherapy
and Chronic Kidney Disease
Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology
company, today announced that the European Commission has approved
expanded marketing authorization for Aranesp(R) (darbepoetin alfa) in
the European Union (EU) following the positive o... |
| | | 09/16/04 | Amgen Names Arvind Sood Vice President, Investor Relations| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Sept. 16, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced the appointment of Arvind Sood to the position of vice
president, Investor Relations. Sood will be responsible for
developing, implementing and managing a comprehensive and strategic
global investor relations program.
"Arvind brings more than 20 years of domestic and international
pharmaceutical industry experience to Amgen," said Richard Nanul... |
| | | 08/13/04 | Amgen Completes Acquisition of Tularik; Acquisition Enhances Amgen's Strong Research Organization and Establishes Amgen in the San Francisco Bay Area| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 13, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced the completion of the acquisition of Tularik Inc., a pioneer
in drug discovery related to cell signaling and the control of gene
expression. Final regulatory approvals were received in June and
Tularik stockholders approved Amgen's acquisition of the company
during a special meeting held yesterday.
"The completion of this acquisition underscores... |
| | | 08/10/04 | First Patients Dosed with Amgen's AMG 162 In Phase 3 Studies for Postmenopausal Osteoporosis and Treatment-Induced Bone Loss| THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 10, 2004--Amgen Inc.
(Nasdaq:AMGN), the world's largest biotechnology company, today
announced that the first patients have been dosed in two pivotal Phase
3 trials of AMG 162, the company's fully human monoclonal anti |
|
|
